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 Flora and fauna from terrestrial and marine environments provide libraries of 
natural compounds for drug discovery. The last four decades have seen major advances 
in ocean exploration that have allowed chemists and biologists to explore previously 
inaccessible and rare marine organisms. To date, over 3,000 natural products have 
been reported from marine macroalgae, with properties of these compounds ranging 
from ecological roles to pharmacological activities. Chapter 2 contextualizes previous 
studies on marine macroalgal natural products, with particular attention to structurally-
diverse natural products with ecological relevance and pharmaceutical potential, 
highlighting biosynthetic implications from complex secondary metabolites. Preference 
was given to recently discovered natural products, as well as to compounds that are 
particularly promising for future development as drugs in pharmacological studies. 
 The study of under-explored marine organisms can result in the discovery of 
structurally novel and unusual natural products with drug potential. Prior to 2005, no 
natural products had been reported from the Fijian red macroalgae Callophycus serratus 
or Neurymenia fraxinifolia. As a result of the work described in this thesis and others in 
the same research group, 33 novel bioactive natural products have now been isolated 
and elucidated from C. serratus – six of which are fully described in Chapter 3 – and two 
new secondary metabolites were discovered from N. fraxinifolia (Chapter 5), enriching 
the natural product library for drug development. The absolute stereochemistry of 
callophycolide A (Chapter 3), a unique non-brominated macrolide from C. serratus, was 
determined using a combination of Mosher’s ester analysis, circular dichroism analysis 
with a dimolybdenum tetraacetate complex, and conformational analysis using NOEs. 
Several natural products isolated from C. serratus exhibited sub-micromolar inhibition 
against the human malaria parasite Plasmodium falciparum, including a drug-resistant 
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strain. The natural product neurymenolide A, isolated from N. fraxinifolia, and its 
hydrogenated semi-synthetic derivative inhibited the growth of the human pathogenic 
bacteria methicillin-resistant Staphylococcus aureus and was as potent as the antibiotic 
vancomycin. In addition, two known tocopherols, β-tocopherylhydroquinone and δ-
tocopherylhydroquinone, were isolated from the coralline red macroalga Amphiroa 
crassa, presented in Chapter 3. By oxidizing δ-tocopherylhydroquinone to the 
corresponding δ-tocopherylquinone, antimalarial activity was increased by more than 20-
fold.  
 Derivatization of the natural product bromophycolide A into fluorescent probes 
allowed the determination of a non-enzymatic mechanism of action against the human 
malaria parasite P. falciparum (Chapter 4). Through a combination of detailed SAR 
mapping, molecular fluorescent imaging of live cells, UV-VIS spectroscopic analyses, 
and protein affinity techniques, the mechanism of action of bromophycolide A against the 
human malaria parasite was determined to involve inhibition of heme crystallization. 
Heme crystallization inhibition prevents detoxification of heme to hemozoin in parasite 
food vacuoles and ultimately results in parasite death. The discovery and development 
of heme crystallization inhibitors is an excellent malaria drug target because heme 
crystallization is a physicochemical process rather than an enzymatic one that allows for 
facile evolution of resistance by the parasite. These studies identify a new class of 
natural products that target heme detoxification in both drug-sensitive and drug-resistant 
P. falciparum and suggest an avenue to circumvent drug resistance. 
 Natural products are not only excellent sources for drug discovery, but also as 
tools for the study of biological systems and chemical signaling. Steroids play 
fundamental roles regulating mammalian reproduction and development. While sex 
steroids and their receptors are well characterized in vertebrates and several arthropod 
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invertebrates, little is known about the hormones and receptors regulating reproduction 
in other invertebrate species. Evolutionary insights into ancient endocrine pathways can 
be gained by elucidating the hormones and receptors functioning in invertebrate 
reproduction. In collaboration with Professor Terry W. Snell and colleagues (Georgia 
Institute of Technology, School of Biology), a combination of genomic analyses, receptor 
imaging, ligand identification, target elucidation, and exploration of function through 
receptor knockdown, was used to illustrate that comparable progesterone 
chemoreception exists in the invertebrate monogonont rotifer Brachionus manjavacas 
(Chapter 6), suggesting an ancient origin of the signal transduction systems commonly 









 Natural products have traditionally played an important role in drug discovery and 
were the basis of most medicines dating back to ancient civilizations.1 Well-known 
natural product drugs include penicillin, morphine, and paclitaxel (TaxolTM), which are 
used for the treatment of bacterial infections, excessive pain, and cancer, respectively. 
The aforementioned drugs originated from terrestrial sources, and while these sources 
continue to play an important role in natural product drug discovery, the oceans 
represent a relatively untapped resource for the discovery of novel chemistry.2 Unique 
marine natural products possessing potent biological activities may have evolved as 
biochemical warfare between organisms in order to survive in an aggressive and 
demanding environment.3 Selection pressures such as predation, herbivory, disease, 
and competition for space on highly populated coral reefs may apply adaptive pressure 
that favors individuals with chemical defenses. Marine organisms produce natural 
products with structures notably different from those produced by terrestrial organisms, 
possibly the result of distinctive environmental factors including high salinity and a 
relatively constant temperature.2 For example, terpenoids from marine sponges often 
contain unusual functional groups, such as isocyanate, isonitrile, dichloroimines which 
are entirely unknown in terrestrial terpenoids. The hallmark of many marine natural 
products is high degree of halogenation, with about half of the known marine metabolites 
isolated to date containing bromine, chlorine and even iodine.2 Many marine natural 
products exhibit remarkable biological activities, some of which have become molecular 
probes used in biomedical research. 
 New drugs are constantly in demand; for example, to combat drug resistance 
against anti-infectives and for better selectivity in cancer chemotherapy.4 The first marine 
 2
anticancer drug, Yondelis®, an alkaloid from the sea squirt Ecteinascidia turbinata, was 
approved in 2007 for use against liposarcoma for which there were no prior superior 
treatments.5 Other antitumor marine natural products in the pipeline of preclinical and 
clinical trials6 include dolastatin-10,7 discodermolide,8 kahalalide F,9 and bryostatin 1,10 to 
name a few (Figure 1.1). 
 
 
Figure 1.1. Anticancer natural products in preclinical or clinical trials isolated from 
marine organisms. 
 
 Marine natural products have also begun to play a significant role in the 
discovery of novel anti-infectives, such as antibiotics and antiparasitic drugs. Over two-
thirds of current antibiotics are natural products or their derivatives, many of which were 
discovered from terrestrial soil bacteria such as the well studied actinomycetes.11Recent 
efforts to discover structurally novel antibiotics from soil microbes have led to the 
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overcome the constant evolving of drug resistance.12 The study of marine actinomycetes 
has dramatically increased in recent years, and marine microbes have been shown to 
produce a wide variety of unique antibacterial compounds that show promise as new 
drug leads (Figure 1.2).13 Furthermore, marine macroorganisms such as macroalgae 
(seaweeds) and sponges are exposed to a vast array of marine pathogenic microbes 
and show potential as excellent sources in the discovery of novel antibiotics.14 For 
example, the alkaloid manzamine A, discovered from the marine sponge Haliclona sp., 
has demonstrated activity against tuberculosis, HIV, and malaria and is currently in 
preclinical trials.15 The neurymenolides, isolated from the Fijian macroalga Neurymenia 
fraxinifolia, displayed low micromolar inhibition against both Gram-positive methicillin-
resistant Staphylococcus aureus and Gram-negative E. coli, thus has the potential to be 
developed as a broad-spectrum antibiotic (Chapter 5).14b 
 



















































 Malaria represents another disease deserving immediate attention in drug 
discovery, as over 500 million cases of malaria are reported annually, causing one- to 
three-million deaths worldwide and drug resistance to current treatments is on the rise.16 
Prophylactic drugs remain expensive and inadequate, making the need for new 
treatments an immediate concern. Current antimalarial drugs of terrestrial origin include 
the artemisinins and quinines, products of terpene and alkaloid biosynthesis, 
respectively (Figure 1.3). In recent years, several marine organisms have shown 
promise in the discovery of new antimalarial treatments,17 such as the manzamines as 
previously mentioned (Figure 1.2). Marine sources such as sponges, macroalgae, and 
microbes have potential as chemically-rich sources of compounds with antimalarial 
activity.17 For example, several brominated meroditerpenes from the Fijian macroalga 
Callophycus serratus were shown to possess sub-micromolar activity against the malaria 











Figure 1.3. Antimalarial natural products: quinine and artemisinin originate from 
terrestrial sources, and diisocyanoadociane, bromophycolide A, and aigialomycin D were 
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 A key aspect in advancing a bioactive natural product further along the drug 
discovery pipeline is to determine its mechanism of action towards its therapeutic target. 
Within therapeutic targets, thousands of biological macromolecules (especially proteins) 
represent potential targets for a bioactive compound. Two generalized approaches to 
identify a mechanism of action include 1) strategies in which specific molecular targets 
are screened and 2) “unbiased” methods such as proteomics, metabolomics, and affinity 
chromatography. The first approach includes target-based drug discovery, in which a 
natural product of interest or libraries of compounds are screened against a validated 
molecular target; for example, actin or tubulin binding in cancerous tumors. Natural 
products are well known for their ability to interact with both actin and tubulin, for 
example as tubulin polymerization inhibitors.19 Therefore, natural products capable of 
binding actin or interacting with tubulin are highly desired and are screened for these 
specific interactions. 
 The second generalized approach searches for unknown molecular targets. For 
example, Boone et al. have developed a mutant yeast deletion library approach, in which 
mutant genes from the yeast Saccharomyces cerevisiae have are utilized to determine 
the molecular target of natural products.20 This approach, however, requires that the 
natural product of interest possess moderate to potent activity against S. cerevisiae. 
Proteomic and metabolomic studies have seen major advances in recent years, and 
activity-based protein profiling (ABPP) has become a standard method.21 A major 
advantage of ABPP, which is based on chemical probes reacting with mechanistically-
related classes of enzymes, is the ability to examine the enzyme active site directly as 
opposed to being limited by protein abundance as with affinity-based methods. However, 
when applying ABPP to natural product mechanism of action studies, two major 
requirements exist; 1) the natural product must possess an intrinsic reactivity – or it 
should be plausible to synthetically introduce this reactivity – that allows for covalent 
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binding of the natural product to the protein target, and 2) the presence of a reporter 
group, such as a fluorescent tag.21 Affinity chromatography-based methods are often 
employed; however, these methods also have constraints. As with ABPP, affinity 
methods require derivatization of the natural product with a tag, such as biotin or another 
antigen. This derivatization requires the presence of a synthetically accessible and 
reactive functional group, and functionalized natural products often suffer from 
decreased bioactivity which can cause difficulties in interpreting results.22 Furthermore, 
affinity methods are dependent on natural product-protein affinity as well as protein 
abundance.  
 While affinity-based chromatographic methods have certain drawbacks, they can 
be employed successfully if the natural product of interest conforms to the required 
conditions. Biotin-avidin affinity is well established, and thus is commonly used in 
developing probes for protein affinity studies, although this system can result in 
problematic non-specific binding. As exploited in Chapters 4 and 6, a more specific 
affinity system utilizes a 7-dimethylamino-4-coumarin tag23 for which a selective 
monoclonal antibody against the coumarin tag is available.24 When fluorescent probes 
are developed from natural products, histological studies can also be performed to 
determine the intracellular localization of the probe, and thus natural product, to gain 
insight into potential mechanisms of action. 
 Natural products have evolved to encompass a broad range of chemical and 
functional diversity. This diversity enables small molecule natural products to target a 
sub-set of biomolecules in a highly selective fashion as a result of their structural and 
stereochemical complexity. These features make natural products not only excellent 
sources for drug discovery, but also tools for the study of biological systems and 
chemical signaling.22 For example, Schreiber et al. used the fungal natural product 
trapoxin as a chemical probe to study histone deacetylation.25 These studies revealed 
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the relationship between histone deacetylases, transcriptional regulation, and cell cycle 
progression, and thus led to the development of histone deacetylation inhibitors for 
cancer treatment.26 As discussed in Chapter 6, natural products can also be used as 
probes in the understanding of chemical signaling and regulation of important biological 
processes such as reproduction in non-model organisms. Evolutionary insights into 
endocrine pathways were gained by elucidating the hormones and receptors functioning 
in reproduction, such as in the ancient marine micro-invertebrate Brachionus 
manjavacas.27 These studies demonstrated that progesterone and its receptor exhibit a 
conservation of function over a broad expanse of animal phylogeny. Collectively, 
chemical probes are an essential component in the understanding of complex biological 
processes from a therapeutic and evolutionary perspective. 
 Reported herein is a collection of studies in which (1) underexplored tropical red 
macroalgae were investigated for unique bioactive natural products (Chapters 3 and 5); 
and (2) isolated bioactive natural products were derivatized to fluorescent probes for 
which (a) specific mechanisms of action in therapeutic targets were explored (Chapter 4) 
and (b) biological processes and chemical signaling were studied (Chapter 6). Efforts 
were focused on identifying natural products possessing antimalarial and antibacterial 
activities to address human diseases for which new drugs are urgently needed due to 
constantly evolving resistance to current medicines. A literature review on macroalgal 
natural products (Chapter 2) discusses the importance and impact of this field on both 
drug discovery and marine chemical ecology. 
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CHAPTER 2 
MARINE MACROALGAL NATURAL PRODUCTS 
 
Introduction 
 The ocean covers nearly 70% of the Earth and represents 90% of the biosphere, 
providing a home for over 30 phyla and 500,000 species of marine organisms.28 These 
organisms have evolved over millions of years to produce a vast diversity of unique 
chemical compounds that fulfill varied functions. Among these are molecules with potent 
biological activities that may have evolved as biochemical warfare between organisms in 
order to persist in an aggressive environment. Marine organisms produce secondary 
metabolites that are structurally distinct from those produced by terrestrial organisms, 
possibly due to factors unique to marine environments such as high salinity and 
pressure and a relatively constant temperature.2, 28 Unusual functional groups, such as 
isocyanate, isonitrile, dichloroimine, and halogenated functionalities occur predominantly 
in marine metabolites.2   
 Natural products from terrestrial plants and soil microbes have traditionally 
played an important role in drug discovery and were the basis of most early medicines.1 
The ocean, in contrast, was left virtually untapped of its vast resources until the early 
1970s. Over the last several decades, scientists have discovered many distinctive types 
of biologically active secondary metabolites with unusual and exciting carbon skeletons 
from Chlorophyta (green algae), Phaeophyta (brown algae), and Rhodophyta (red 
algae). Scientific reports of new natural products from marine macroalgae have steadily 
increased since the 1980’s (Figure 2.1). This chapter contextualizes studies on marine 
macroalgal natural products, with particular attention to structurally diverse natural 
products with ecological relevance and pharmaceutical potential, highlighting 
biosynthetic implications from structurally diverse metabolites. Preference is given to 
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recently discovered natural products, as well as to compounds that are particularly 
promising for future development as drugs in pharmacological studies. 
 A series of excellent reviews on marine natural product chemistry, organized 
phylogenetically, is published annually in Natural Product Reports.29 In addition, many 
recent review articles have explored particular marine natural products based upon their 
specific biological activities, such as antitumor and cytotoxic compounds,30 therapeutics 
for tuberculosis and malaria,31 and antifoulants.32 Furthermore, review articles are also 
available based on compound class, such as the review written by Gross & König on 
terpenoids from marine organisms with pharmacological activity.2 Other reviews of 






































Figure 2.1.  Reports of novel natural products from marine macroalgae since 1980. The 
search was conducted using Marinlit and ISI Web of Science, limiting output to chemistry 
journal research articles and notes, using a variety of keywords. Hits were verified to 
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ensure that natural products reported were new and discoveries were not double-
counted. This figure may under-represent the actual discovery rate, if natural products 
were reported in non-chemistry journals and/or if keywords were different from those 




 Marine macroalgae produce a wide variety of intriguing and diverse isoprenoid 
structures deriving from C5 isoprene units,33 and many reports have been published on 
the ecological roles of these metabolites.34 Marine terpenoids are frequently found with 
halogenated functionalities and one or more rings, which can have important 
implications for their biological activities. Isoprenoid metabolites are derived via the 
classical mevalonate pathway or the more recently discovered deoxyxylulose phosphate 
pathway.35 Isoprenoids are the dominant class of secondary metabolites known from 
macroalgae, representing 59% of the metabolites isolated to date from green algae, 46% 
from red algae, and 68% from brown algae.3 Due to the substantial representation of 
isoprenoids among macroalgae, approximately half of this review will focus on novel 
isoprenoid carbon connectivities, ecological roles, and isoprenoids that have gained 
pharmaceutical interest. 
 
Novel Connectivity and Cyclization Patterns 
  Due to the immense effort already applied to the discovery of isoprenoid natural 
products from macroalgae, uncovering novel carbon skeletons is now rare. However, 
several reports have recently been published on macroalgal isoprenoids that possess 




  Labdane-based diterpenes (Figure 2.2) have been isolated from tissues of fungi, 
insects, marine organisms, and from essential oils, resins, and tissues of higher plants, 




Figure 2.2.  Labdane carbon skeleton 
 
Two labdane-type brominated diterpenes (1-2) containing unprecedented seven- and 
eight- membered ether rings were isolated from the red alga Laurencia obtusa, collected 






Metabolites 1 and 2 were proposed to share a common decalin precursor, formed from 
geranyllinalool (3) via cyclization and bromination, and the relative stereochemistry was 
assigned using 1H-1H scalar couplings and NOESY experiments.37 Enzyme-catalyzed 
dehydration, followed by double-bond transposition, allylic chlorination, and epoxidation 
could give rise to the intermediate 4. Nucleophilic attack of the C-8 hydroxyl group on 





























Scheme 2.1.  Hypothesized biosynthetic pathway of 1-2.37  
  
  Laurencia paniculata, collected from Qatari, Arabian Gulf, was found to produce 
(-)-paniculatol (5), an unusual labdane with a tetrahydropyran ring, and absolute 
stereochemistry was determined by X-ray crystallography.38 More recently, two 
additional labdanes (6-7) with tetrahydropyran rings were indentified from an unknown 
Okinawan species of Laurencia, and absolute stereochemistry also established by a 
combination of 2D NMR spectral data and X-ray crystallographic data.39 While labdanes 
originating from macroalgae have intriguing structures, no biological tests were reported 




  Cyclization between C-6 and C-11 is an unusual skeletal characteristic for 
diterpenes (Figure 2.3), with only four marine species reported to utilize this pattern in 






















Figure 2.3.  Dactylomelane cyclization 
 
  Two dactylomelane metabolites were isolated from sea hares Aplysia 
dactylomela40 (dactylomelol, 8) and Aplysia punctata (puctatene acetate, 10),41 and more 
recently, similar metabolites were found from two red algal species, Sphaerococcus 
coronopifolius (sphaerolabdadiene-3,14-diol, 9)42 and  Laurencia sp.43 Laurencia sp. 
(Tenerife, Canary Islands) produced a number of novel and relatively unstable 
hydroperoxide metabolites, such as dactylohydroperoxide C (12), in addition to 8 and 
puctatene (11).43 Isolation of 8 and 11 from Laurencia suggests a macroalgal biogenesis 
for this class of diterpenes. The relative stereochemistries of 8-12 were established by 
analysis of NOE data. No biological activities were reported for these metabolites. 
 
Meroditerpenes 
  Novel metabolites of mixed biogenesis are more likely to contain novel carbon 
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hybrid metabolites from macroalgae seem likely to become front-runners for exciting 
natural product discovery. Uncovering novel skeletons for new scaffolds remains an 
integral part of drug discovery.   
  Since 2005, 33 novel bioactive metabolites (e.g., bromophycolides A-B (13-14), 
callophycoic acid C (15), and callophycol A (16)) representing eight new carbon 
skeletons derived from mixed isoprenoid-shikimate biosynthesis, have been isolated 
from the red alga Callophycus serratus (Fiji Islands).18, 44 The absolute configurations of 
13-14 were determined by X-ray crystallography, and absolute stereochemistries of 
subsequent bromophycolides were established by analysis of NOE data and from 
inferring a common biogenesis as 13-14. An X-ray crystal structure of callophycoic acid 
A (structure not shown) provided its configuration from which the absolute 
stereochemistries of other callophycolic acids were inferred, and relative stereochemistry 
of 16 was determined through analysis of NOESY data.18a Extracts yielding callophycoic 
acids and callophycols showed no signs of bromophycolides, which were found from 
collections at different sites, suggesting population-level variation in secondary 
metabolism leading to two chemotypes.18a The most cytotoxic secondary metabolite was 
13, with moderate in vitro cytotoxicity against a broad range of tumor types (mean IC50 = 
6.7 µM). The G1 phase of the cell cycle was arrested when human ovarian cells were 
exposed to 13, suggesting that apoptosis stemmed from cells arrested in G1.44a 
Interestingly, the callophycoic acids and callophycols were significantly less active in 
pharmacological assays than 13-14, suggesting the importance of the macrocyclic 
lactone functionality.18a Nevertheless, compounds of both chemotypes suppressed 
growth of the algal pathogen Lindra thalassiae at and below natural concentrations, 
suggesting a potent antifungal chemical defense.45   
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  An extract of the brown alga Cystoseira sp. (Montaña Clara Island, 
Mediterranean Sea) exposed to acetylation reaction conditions yielded two novel 
meroditerpenes, cystoseirone diacetate (17), with an unusual C-6 to C-12 ether linkage, 
and amentol chromane diacetate (18), and whose relative stereochemistry was 



















The biosynthesis of cystoseirone (the unacetylated, likely natural product) was 
hypothesized to arise from an oxidation of the enol-ether system found in 18, with 






























acid (MCPBA) in dichloromethane, which afforded two isomers, one of which was 
identical to 17 (Scheme 2.2). 
 




  Secondary metabolites have long been assumed to enhance the survival of 
macroalgae by providing defenses against consumers, competitors, or parasites.3 Many 
field and laboratory studies have tested antifeedant and antifouling effects of macroalgal 
metabolites.34a, 47 Fewer ecological studies have addressed antimicrobial or other 
antiparasitic defenses in macroalgae, despite the fact that marine organisms are 




































  Numerous reports and reviews focus on macroalgal-herbivore interactions and 
the mechanisms by which macroalgae tolerate or resist herbivory.48 Many algal species 
deter herbivores by morphological, structural, or chemical defenses49 or by associating 
with unpalatable algae or other benthic organisms.50 Due to the extensive literature 
available on these interactions, the aim of this section is to highlight specific 
antiherbivore terpenes from macroalgae.  
  Three new diterpenoids, acutilol A (19), acutilol A acetate (20), and acutilol B (21) 
from the brown alga Dictyota acutiloba, were found to be potent feeding deterrents 
against both temperate and tropical herbivorous fishes and sea urchins, and whose 
relative stereochemistry was determined by NOESY experiments.51 Common tropical 
and temperate herbivores were deterred by the acutilols at 20% of their natural 
concentrations, suggesting that these secondary metabolites provide an efficient 
chemical defense for D. acutiloba.52 These compounds are structurally related to the 
common pachydictyane carbon skeleton, but the ∆1,10 double bond is an unusual feature 
for this compound class.51 The pachydictyols and dictyols, first isolated in the 1970s, 
have also been shown to possess potent deterrent effects. Cruz-Rivera and Hay tested 
the antifeedant effects of dictyols against six mesograzers, and found that amphipods 
were deterred by dictyols, but the isopod Paracerceis caudata was not deterred.53   
 
   
 
 
   
  Halimeda spp. are well-studied green algae found in tropical areas characterized 
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halimedatetraacetate (22) and halimedatrial (23),55 which act as feeding deterrents and 
allow the alga to persist in areas of intense herbivory.56 Additional studies established 
that upon damage, levels of 22 decreased while the concentration of 23 increased, 
suggesting that upon wounding, the alga quickly converts 22 into the more deterrent 23 
via a putative enzyme-mediated pathway.57 One difficulty of working with activated 
defenses is that the use of extraction solvents may lead to spontaneous activation of 
reactive precursors, preventing assessment of the true “inactivated” state of defenses 
(Kubanek and Hay, unpublished). Nevertheless, activated defenses appear to be 
common among tropical macroalgae. Cetrulo and Hay found that upon wounding, 17% 




 In a more recent example of activated macroalgal chemical defenses, caulerpenyne 
(24) from the invasive green alga Caulerpa taxifolia, was suggested to rapidly transform 
into oxytoxin 2 (25) upon wounding.59 However, due to the labile nature of 25, the 
authors were unable to test the hypothesis that 25 is more deterrent than 24. Other 
studies testing the reactivity of 1,4-dialdehyde metabolites found in higher plants 
demonstrated that these compounds readily react with nucleophiles, making it difficult to 























  Solid surfaces exposed to seawater can undergo a series of changes leading to 
the accumulation of marine organisms, mainly consisting of microbial slimes, diatoms, 
barnacles, tunicates, bryozoans, and spores of marine algae.61 Macroalgae, being a 
prolific source of bioactive natural products, may produce secondary metabolites to 
inhibit this process of fouling.32 Since the 1970s, the antifouling effects of Laurencia spp. 
isoprenoids have been noted.62 These metabolites, however, are generally toxic to many 
marine organisms and so their commercial development is not feasible.63   
 
   
  
  
 Caulerpa prolifera, found in the shallow waters of Saronicos Gulf, Greece, is 
abundant and exhibits minimal fouling.64 Fifteen acetylene sesquiterpenoid esters (26a-i, 
27a-f) from this alga inhibited fouling in a manner similar to the biocide bis-(tributylin) 
oxide (TBTO).64 Similar to Laurencia antifouling metabolites, 26-27 and TBTO are 
generally toxic, thus limiting the further development of these compounds. 
  To date, no macroalgal terpenes have been utilized commercially as antifoulants. 
Macroalgal furanones, however, are currently in development to prevent fouling. 








26a, 27d R = CH3-(CH2)4-(CH=CH-CH2)2-(CH2)6CO-
26b, 27c R = CH3-(CH2)14CO-
26c R = CH3-CH2-(CH=CH-CH2)3-(CH2)6CO-
26d R = CH3-CH2-(CH=CH-CH2)5-(CH2)2CO-
26e R = CH3-(CH216CO-
26f R = CH3-(CH2)7-CH=CH-(CH2)9CO-
26g R = CH3-(CH2)4-(CH=CH-CH2)4-(CH2)2CO-
26h, 27e R = CH3-CH2-(CH=CH-CH2)3-(CH2)4CO-
26i R = CH3-CH2-(CH=CH-CH2)4-(CH2)3CO-
27a R = CH3-(CH2)12CO-
27b R = CH3-(CH2)5-CH=CH-(CH2)7CO-
27f R = CH3-(CH2)7-CH=CH-(CH2)7CO-
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  Despite a large body of literature describing the antimicrobial activities of 
macroalgal secondary metabolites, little evidence exists to date to support the 
hypothesis that algal secondary metabolites target marine pathogens at realistic natural 
concentrations.65 Only a handful of studies demonstrate the ability of macroalgal 
secondary metabolites to effectively deter or suppress ecologically-relevant pathogens. 
Two novel triterpene sulfate esters, capisterones A and B (28-29) from the green alga 
Penicillus capitatus, suppressed growth of the marine fungal pathogen Lindra thallasiae 
when tested at and below whole-tissue natural concentrations.66 Assignment of the 
relative stereochemistries of 28-29 relied on interpretation of 2D NMR spectral data. 
While work in this area of chemical ecology is progressing, the few studies reported thus 







Metabolites with Pharmacological Potential 
Halomon 
 Halogenated monoterpenes have been known from red algae since the mid-
1970s, but it wasn’t until the early 1990s that a metabolite with pharmaceutical potential 







28 R = OAc
29 R = H
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(30) was isolated from extracts of the red alga Portieria hornemannii (Batan Island, 
Philippines) and its X-ray crystal structure, absolute stereochemistry, and complete 1H 
and 13C NMR assignments were reported.67 Halomon (30) was associated with a novel 
cytotoxicity profile against diverse tumor types in the National Cancer Institute’s (NCI) 
primary screening panel.67 Several reports have been published on the total synthesis of 
30 to aid its progress and development through preclinical trials.68 Unfortunately, 
research and development of 30 as an anticancer agent has been limited to its failure to 







  Squalene-derived polyether triterpenes (e.g., 31-34) are a structurally-exciting 
group of marine algal natural products exhibiting a great diversity of ring sizes and 
intriguing biological activities. The first reported macroalgal polyether metabolite, 
thyrsiferol (31), from Laurencia thyrsifera, collected from New Zealand, was assigned the 
absolute structure 31 by X-ray crystallographic analyses based on thyrsiferol 18-acetate 
(32).70 Following this discovery, several other structurally-related polyether metabolites 
were reported from Laurencia spp., including dehydrothyrsiferol (33)71 and thyrsiferyl 23-
acetate (34).72 The latter exhibited superior activity against P-388 lymphoid neoplasm 
cells, with IC50 = 0.47 nM. Furthermore, 34 potently and selectively inhibited protein 
phosphatase 2A (PP2A), with no effect on protein phosphatases 1, 2B, 2C, or protein 
tyrosine phosphatase, making 34 a potential probe for identification of cellular processes 




   







The potent and selective effects of 34 propelled further studies with this compound 
class. After discovering many new analogs from Laurencia spp., structure-activity 
relationships were established based on a combination of isolated natural products and 
synthetic analogs.74 Fernandez et al. proposed that the spatial arrangement of the 
flexible chain affected metabolite bioactivity. From calculations of stable conformations 
of isolated polyethers using distance constraints established from NOE data, it was 
proposed that polyethers with C-15–C-19 chain turned downward were more potent than 
those with the side chain turned upward, as illustrated by comparing 33 (downward side 
chain, IC50 = 0.01 µg/ml) versus 35 (upward side chain, IC50 > 1 µg/ml) (Figure 2.4).74a 
The original structures and pharmacological activities drove synthetic efforts towards 
producing these compounds, and a thorough review of the total synthesis strategies is 


















31 R1 = R2 = H
32 R1 = H, R2 = Ac




Figure 2.4.  Stereoviews of proposed 3D structures of (a) 33 with downward side chain 
and (b) 35 with upward side chain, adapted from Fernandez et al. with permission.74a  
 
Dolabellanes 
  Dolabellanes (Figure 2.5) are constituents of mollusks, coelenterates, and brown 
algae, and they are also found in terrestrial mold, liverwort, and higher plant species.76 
Several dolabellanes have shown potential for pharmaceutical application, exhibiting 



































  Dolabellanes 36-39 from the brown alga Dictyota dichotoma in Cortadura (Cádiz, 
Spain) exhibited mild activity in vitro cytotoxicity assays against P-388 mouse 
lymphoma, A549 human lung carcinoma, HT-29 human colon cancer carcinoma, and 
MEL-28 human melanoma tumor cell lines.77 Dolabellane 37 exhibited IC50 = 1.2 µg/ml 
against P-388 and A549 tumor cell lines and IC50 =2.5 µg/ml against HT-29 and MEL-28 
tumor cell lines.77 Relative stereochemical assignments were made upon analysis of a 
series of NOE difference spectroscopy experiments.  
 
 
   
  From Dictyota dichotoma collected near Sicily, Italy, four dolabellanes (40-43) 
were isolated, displaying activity against Gram-positive and Gram-negative bacteria.78 
Moreover, 40 exhibited significant in vitro activity against influenza and adenoviruses.79 
As with 36-39, the relative stereochemistries of dolabellanes 40-43 were determined by 
NOE.   
 











3836 R1 = OH; R2 = H















  The diverse array of functionalities and stereocenters has made dolabellanes a 
challenge for synthetic chemists, who have helped to establish the absolute 
configurations of these natural products.76 Several distinct strategies have been tackled, 
with macrocyclization as the key reaction.76 Although macroalgal dolabellane diterpenes 
exhibit a range of pharmacologically relevant activities, no dolabellane metabolite has 
yet been pursued for further pharmaceutical development.   
 
Fatty Acid and Polyketide Metabolites 
  The condensation of C2 acetate units and their subsequent modification leads to 
a vast number of polyketide (acetogenin) and fatty acid-based metabolites. Complex 
structures are biosynthesized via reactions involving alkylation, phenolic oxidative 
coupling, oxidative cleavage of aromatic rings, cyclization, and the use of extension units 
other than acetate.35 These secondary metabolites constitute the second most abundant 
class found in macroalgae, accounting for 19% of green algal metabolites and 38% of 

















C15 Acetogenins   
  Although C15 acetogenins have been isolated from various algal species since 
the 1970s, novel derivatives are continually being reported, with mono-, di- and tri-, and 
tetra-cyclic structures possessing enyne and bromoallene functionalities. However, the 
discovery of acetogenins with new carbon skeletons is now rare. C15 acetogenin 
biological activities are generally weak to moderate.   
  The red alga Laurencia obtusa (Scanlon’s Island, Ireland) was found to contain 
scanlonenyne (44), a novel acetogenin with a ketone at C-7.80 No biological data were 
reported. A new brominated acetogenin, chinzallene (45), was isolated from an unknown 
species of Laurencia in Japanese waters (Chinzei, Saga, Prefecture) and is structurally-
related to okamurallene (46), which is known from Laurencia intricata.81 Relative 
stereochemistries of 44-46 were established by analysis of 1H-1H scalar couplings in 
combination with 2D NOE spectral data. 
 
 
  While acetogenins have frequently been isolated from Laurencia spp., it is 
unusual to see bromoallene and enyne metabolites co-occurring. Four novel 
acetogenins, laurendecumallenes A-B (47-48) and laurendecumenynes A-B (49-50), 


























China), suggesting that these functional groups share a common biosynthetic pathway 
(Figure 2.6).82 Stereochemical assignments are relative for 47-50, as established 















Figure 2.6.  Proposed biogenesis of bromoallene from terminal enyne adapted from Ji et 
al. with permission.82  
 
  While structurally diverse, these known macroalgal acetogenins do not possess 
exciting pharmacological activities. Moreover, the ecological relevance of this compound 
class has not been well documented. However, due to the large database of 
acetogenins isolated from various species of Laurencia, many studies have used these 





















































  Strong antifungal activity against the marine pathogen Lindra thalassiae led to 
the isolation of lobophorolide (51), a polyketide from the brown alga Lobophora 
variegata.83 Throughout the bioassay-guided fractionation, only 51 or fractions 
containing it inhibited fungal growth, suggesting that this compound accounts for all of 
the antifungal activity.83 Significant antifungal effects were also observed against the 
human pathogen Candida albicans (IC50 = 1.3 µg/ml) and against human colon cancer 
cells (IC50 = 0.03 µg/ml). The structural similarity of 51 to tolytoxin84 from cyanobacteria 
suggests that 51 is likely the product of a microbial symbiont; however, a putative 
symbiont has not been discovered to date. The relative and absolute stereochemistry of 
51 was proposed to share that of tolytoxin, with the exception of C-6, for which Kubanek 
et al. argued an R configuration, as opposed to the S configuration proposed by Carmeli 
et al. in tolytoxin. A putative microbial origin was also supported by the patchy 







  Several successive food poisonings reported from ingestion of the Hawaiian red 
alga Gracilaria coronopifolia (Waiehu, Maui) led to the identification of manauealides A-
C (52-54), aplysiatoxin (55), and debromoaplysiatoxin (56), with the latter two implicated 
as causative agents.85 To date, 51 and 52-56 are the only reports of macrocyclic 
polyketide metabolites isolated from macroalgae. The absolute configurations of 52-54 













whose absolute configuration was previously established.86 As with the case of 51, 
Nagai et al. suggested that cyanobacteria could be the true producer of these toxins, 
since 55 and 56 were previously reported from cyanobacteria and a sea hare known to 
feed on cyanobacteria, and that cyanobacteria were sometimes found growing on G. 














  Acetylenic functionalities, as in peyssonenynes A and B (57-58) from the red alga 
Peyssonnelia caulifera (Yanuca Island, Fiji)88 are rare for macroalgae, with only one 
previous report of lipid acetylenes, produced by the red alga Liagora farinosa.89 Both 57 
and 58 showed similar activity in a DNA methyltransferase (DNMT-1) enzyme inhibition 
assay, with an IC50 = 16 and 9 µM, respectively, but peyssopyrone (59), also from P. 




















52 R1 = Cl, R2 = H
54 R1 = H, R2 = COCH3
53 R1 = H, R2 = Br
55 R1 = Br, R2 = H















  Many in-depth ecological studies have been performed using the red alga 
Delisea pulchra, which is known to produce a series of structurally-related brominated 
furanones (60-63).90 These furanones inhibit fouling and bacterial attachment, acting as 
antagonists of bacterial communication normally mediated by acylated homoserine 
lactones, which regulate bacterial swarming and biofilm formation .91 Dworjanyn et al. 
demonstrated chemically-mediated antifouling effects of furanones using  surface 
extracts of D. pulchra, as well as pure furanones tested at natural surface 
concentrations.92 These metabolites are also strongly deterrent to many herbivores at 
natural concentrations.93 It seems reasonable to suggest that D. pulchra is able to 
compensate for the cost of producing these secondary metabolites by utilizing these 
furanones as a defense against multiple threats, such as biofouling, antimicrobial 













  Shikimic acid (64) is the biosynthetic precursor to an array of aromatic 
compounds, including benzoic and cinnamic acids.35 This pathway is utilized by 
microorganisms and plants, but not by animals, who obtain essential shikimate building 
blocks like phenylalanine from their diets.35 Red algae are known to be a prolific source 
of halogenated phenolic metabolites derived from shikimic acid, comprising 







  A number of bromophenols have been isolated from the genus Rhodomela, 
exhibiting various biological functions such as feeding deterrents.94 Antibacterial assays 
led to the isolation of two new (65-66) and three known (67-69) bromophenols from the 
red alga R. confervoides (Qingdao, China).95 Metabolite 69 exhibited moderate activity 








60 R1 = H, R2 = Br
61 R1 = H, R2 = H
62 R1 = OAc, R2 = H








  Three new (70-72) and three known (73-75) bromophenols from the red alga 
Polysiphonia urceolata (Qingdao, China), whose absolute configurations were 
determined by CD spectra, displayed significant radical scavenging activity when 
compared to known antioxidants, with IC50 values of 6-36 µM.96 The radical scavenging 
activities of 70-72 were 10-fold to 13-fold more active than the known synthetic 
antioxidant butylated hydroxytoluene (BHT), making these metabolites potential leads as 
































































Nonribosomal Peptide Metabolites 
  Many natural peptides are synthesized by a sequence of enzyme-controlled 
processes carried out by a multifunctional enzyme of modular arrangement, similar to 
some polyketide synthases.35 These nonribosomal peptide synthetases (NRPS) typically 
consist of an adenylation domain, a peptidyl carrier protein, and a condensation domain 
in order to carry out amide bond formation and some derivations of amino acid 
residues.35   
 
Depsipeptides 
  Depsipeptides are a class of nonribosomal peptides cyclized via an ester bond 
and often contain nonproteinogenic amino acids. Several bioactive depsipeptides, 
ranging from a C31 tripeptide to a C75 tridecapeptide, were isolated from a sacoglossan 





























73 74 R = OH
75 R = Br
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kahalalides, these peptides display a range of biological activity. Kahalalide A (76) 
displayed moderate antimalarial activity and has been noted for its in vitro effects against 
Mycobacterium tuberculosis, while kahalalide E (77) selectively inhibits Herpes simplex 
II virus (HSV II).97 Kahalalide F (78), whose absolute stereochemistry was determined by 
chemical degradation,98 exhibits activity against select solid tumors and some AIDS-
opportunistic infections, and is currently undergoing phase II clinical trials.5c, 9a Hill et al. 
reported strains of kahalalide-producing Vibrio sp. bacteria associated with Bryopsis sp. 
and E. rufescens, which suggests a microbial origin of these depsipeptides; however, 
natural product chemists await full description of this work in the peer-reviewed 
literature.99 
  Kahalalide G (79), the linear peptide form of 78, has so far been found to be 
inactive in all bioassays.97 To date, 17 kahalalides have been isolated and characterized 
from Bryopsis sp., but 78 remains the only kahalalide to advance to clinical trials for the 














































































































  Algal compounds are rarely nitrogenous, possibly because macroalgae are often 
nitrogen-limited.101 However, a handful of non-peptide, nitrogen-containing metabolites 
that possess interesting biological activity has been reported from macroalgae. 
 
Indole Metabolites 
  Red algae of the genus Chondria are known for the production of cyclic 
polysulfides and terpenoids.102 An unidentified species of Chondria (Buenos Aires, 
Argentina) was found to produce novel indolic metabolites, chondriamides A-B (80-81), 
with antiviral, antifungal and cytotoxic activities.103 Chondriamide A (80) exhibited 
antiviral activity against HSV II with IC50 = 1 µg/ml, while 81 displayed antifungal activity 
against Aspergillus oryzae and Trichonphyton mentagrophytes.103 Furthermore, 80-81 
displayed moderate cytotoxicity against KB cell lines, with IC50 values of 0.5 µg/ml and 
<1 µg/ml, respectively.104 Chondriamide C (82), from Chondria atropurpurea, exhibited in 
vitro anthelmintic activity against Nippostrongylus brasiliensis with EC80 of 90 µM.105 
Kuramochi et al. reported a total synthesis of 80 and 82 using a newly developed 
approach based on the Curtius rearrangement and acylation of alkenylcarbamate.106 
 














R 80 R = H










  Almazoles A-B (83-84) were isolated from an unknown red algal species of 
Haraldiophyllum (Dakar, Senegal) containing a rare 2,5-disubstituted oxazole ring.107 
After recollection of Haraldiophyllum sp. some years later, 83-84 were not observed, 
perhaps because of geographic variation or compound instability, but another novel 
indole bearing an oxazolone ring, almazolone (85), was discovered.108 Almazolone (85) 
was isolated as an 88:12 mixture of Z/E isomers, due to the photochemical and thermal 
instability of the compound. Guella et al. also synthesized 85 by condensation of indole-




83 R = CHO











  Gross et al. discovered two novel 2,7-naphthyridine metabolites, lophocladines A 
and B (86-87), from an unknown and understudied red alga species Lophocladia 
(Savusavu, Fiji Islands).109 The only other naturally-occurring representative of this 
compound class comes from the terrestrial plant Valeriana officinalis.110 Lophocladine B 
(87) exhibited moderate activity against lung and breast cancer cells, with IC50 values of 
64.6 and 3.1 µg/ml, respectively, whereas 86 was found to be inactive in all assays.109 
NCI-H460 lung cancer cells showed morphologic changes when treated with 87, 
depolymerizing 85% of the microtubules at 45 µM, but the potency of 87 is rather 












  Carbohydrates are one of the more common components of plants, animals, and 
microorganisms, with six-carbon sugars (hexoses) and five-carbon sugars (pentoses) 
being the most commonly encountered carbohydrate unit.35 Medicinally-important 
natural products are frequented with various sugar units to form a class of compounds 
known as glycosides.35 Macroalgae are known to produce a handful of biologically-active 
glycosides, representing another exciting class for pharmacological research.  
  The red alga Gracilaria asiatica (Indonesia) was found to produce gracilarioside 
(88) and gracilamides (89-90), possessing unusual cyclopropane-containing alkyl 
chains.111 This was the first report of naturally-occurring marine ceramides with a 
cyclopropane ring. Fatty acid chain lengths and cyclopropane ring positions were 
determined using microscale chemical degradation. Furthermore, absolute 
configurations of 88-90 were established through a combination of chemical degradation 
and CD spectral analyses. These metabolites exhibited weak activity against melanoma 










  Human intoxication resulting after ingestion of the red alga Polycavernosa tsudai 
(Tanguisson Beach, Guam, previously called Gracilaria edulis) led to the isolation of 
toxic glycosidic macrolides, polycavernosides (91-97), with polycavernoside A (91) 
reported as the illness-causing agent.112 The toxicity of 91 in mouse bioassays was 
established as 0.2-0.4 mg/kg, with human symptoms including diarrhea, vomiting, 
paresthesia, loss of consciousness, and in extreme cases, death.112a, 113 Total synthesis 
of 91 was reported by Fujiwara and Murai and thus the absolute configuration of 91 was 
determined by CD analysis.114 No reports have been published on the ecological role of 


























   










  A highly active antimitotic extract from the green alga Avrainvillea nigricans 
(Portsmouth, Dominica) yielded two novel glycolipids, nigricanosides A-B (98-99), 
representing a new class of ether-linked glycoglycerolipids.115 Nigricanoside A dimethyl 
ester (100) was found to arrest human breast cancer MCF-7 cells in mitosis with IC50 = 3 
nM, stimulating polymerization of tubulin.115 Hydrogenation of the alkenes significantly 
reduced activity against the MCF-7 cells, establishing their importance. The ability of the 
potent nigricanosides to promote tubulin polymerization is without precedent among 
previously known glycoglycerolipids, making these metabolites an exciting anticancer 




















91 R1 = H, R2 = Me, R3 = H
92 R1 = H, R2 = H, R3 = H
93 R1 = Me, R2 = Me, R3 = H
94 R1 = Me, R2 = Ac, R3 = H
95 R1 = Me, R2 = H, R3 = H
96 R1 = Me, R2 = Ac, R3 = Me













  Structurally-diverse, bioactive metabolites are continually being reported from 
macroalgae. The rate of new natural product discovery increased substantially in the 
1990’s and has continued to increase through the 2000’s, particularly from red 
macroalgae (Figure 2.1). However, it should be noted that most recent discoveries are 
featured in more specialized journals than in the early years and the discovery of new 
structural classes of secondary metabolites from macroalgae has become rare. 
Properties of macroalgal natural products range from pharmacological activities, such as 
antitumor, antimicrobial, and antiviral effects, to ecological roles such as herbivore 
deterrence and antimicrobial defenses. The large numbers of known isoprenoids and 
phenolic compounds lacking significant pharmacological activities make these structural 
classes less stimulating for future discoveries for pharmaceutical leads. However, rare 
and/or understudied macroalgal species could be promising for the discovery of new and 
exciting secondary metabolites, including compounds of mixed biogenesis. Some of the 
most structurally-complex and biologically-active molecules reported recently from 

















100 R1 = Me, R2 =
101 R1 = Me, R2 =
98 R1 = H, R2 =
99 R1 = H, R2 =
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source of chemical innovation. Continued research on bioactive macroalgal natural 
products could stimulate the identification of structurally novel compounds as well as 
intriguing syntheses of compounds for biological and pharmacological research.   
 43
CHAPTER 3 
UNUSUAL ANTIMALARIAL MERODITERPENES FROM FIJIAN RED 
MACROALGAE 
 
 Natural products have been the source of the most successful antimalarial drugs 
to date, including notably the quinines and artemisinins.11, 17 The design and 
development of many synthetic antimalarial drugs has largely been inspired by these 
and other antimalarial natural products.11 Thus, the discovery of novel chemistry from 
natural sources could provide new scaffolds for the development of much needed 
antimalarial treatments. 
 We previously discovered a structurally-novel class of brominated meroditerpene 
macrolides and non-macrocyclic metabolites, called bromophycolides and callophycoic 
acids, respectively, from the Fijian red macroalga Callophycus serratus.18, 44 Our efforts 
to uncover antimalarial natural products from understudied tropical red macroalgae led 
us to continue exploring metabolites responsible for the potent antimalarial activity from 
two red algae in our library, C. serratus and the coralline alga Amphiroa crassa. 
Bioassay-guided fractionation led to the identification of an unusual non-brominated 
macrolide we named callophycolide A (1)18c; additional bromophycolides L (2), N (3) and 
O (4)18b; and callophycoic acids C (5) and D (6)18a from C. serratus. Two known 
tocopherols, β-tocopherylhydroquinone (13) and δ-tocopherylhydroquinone (14) were 




Figure 3.1. Meroditerpenes isolated from Fijian red macroalgae. Callophycolide A (1), 
bromophycolides L (2), N (3), and O (4), callophycoic acid C (5) and D (6), 
bromophycolides A (7), B (8), D (9), E (10), K (11) and debromophycolide A (12) were 
isolated from Callophycus serratus.18, 44a, b β-Tocopherylhydroquinone (13) and δ-
tocopherylhydroquinone (14) were isolated from Amphiroa crassa. δ-tocopherylquinone 

















































































































































 Unlike previously isolated bromophycolides44a, b, callophycolide A (1) did not 
display a characteristic brominated isotopic pattern with HRESIMS, but showed an [M + 
H]+ m/z of 427.2825, appropriate for a formula of C27H38O4. The p-hydroxybenzoate 
segment common to all reported C. serratus secondary metabolites18a, b, 44 remained 
intact, apparent from the 13C and 1H NMR chemical shifts for positions 3 (δC 131.1; δH 
7.85), 21 (δC 129.6; δH 7.73), 22 (δC 114.8; δH 6.78), and 23 (δC 158.0; OH δH 5.83). 
HMBC correlations from H2-5 (δ 3.17, 3.49) to C-3, C-4 (δ 127.7), and C-23 connected 
the C-5 methylene to the p-hydroxybenzoate fragment, as in other bromophycolides, but 
surprisingly C-5 was not connected to a substituted cyclohexene. Instead, a linear 
isoprene unit was established through COSY correlations between both H2-5 protons 
and H-6 (δ 5.45), as well as HMBC correlations from Me-24 (δ 1.60) to C-6 (δ 122.7), C-
7 (δ 136.8), and C-8 (δ 39.3). COSY correlations failed to establish the vicinal 
relationship of H2-8 (δ 2.17, 2.27) and H2-9 (δ 2.15, 2.23) due to substantial chemical 
shift overlap; instead, HSQC-TOCSY correlations were used to connect well-resolved 
carbons at C-8 and C-9 (δ 23.8; Figure 3.2). COSY correlations between both H2-9 
protons and H-10 (δ 5.19) and HMBC correlations from Me-25 (δ 1.59) to C-10 (δ 123.5), 
C-11 (δ 135.2), and C-12 (δ 35.8) connected a second isoprene unit within 1. HMBC 
correlations from H-14 (δ 4.75) to C-1 (δ 169.2), C-12 (δ 35.8), C-13 (δ 29.2), C-15 (δ 
74.8), and Me-26 (δC 22.0) provided strong evidence in support of a macrocyclic lactone 
framework and accounted for a third isoprene fragment. Me-26 (δH 1.16) showed strong 
HMBC signals to C-14 (δ 82.1), C-15, and C-16 (δ 40.0), while vicinal COSY correlations 
established a C-16—C-17—C-18 connectivity. Allylic coupling was observed with weak 
COSY correlations between H-18 (δ 5.10) and both Me-20 (δ 1.66) and Me-27 (δ 1.60), 
establishing the diterpene head. This structural feature was further confirmed by HMBC 
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correlations from both Me-20 and Me-27 to C-18 (δ 124.3), C-19 (δ 131.8), and to each 
other, completing the planar connectivity of 1.  
 ROESY data were used to assign the configurations of the olefins within the 
macrocyclic ring of 1. NOEs observed between H-6 and both H2-8 protons and between 
Hb-5 (δ 3.49) and Me-24 (δ 1.60) supported an E configuration for ∆6,7. Similarly, ROESY 
correlations between H-10 (δ 5.19) and Ha-12 (δ 1.87) as well as between Hb-9 (δ 2.23) 






Figure 3.2. Key 2D NMR spectroscopic correlations establishing the connectivity of 
callophycolide A. (a) 1H-1H COSY (bold), HMBC (red single-headed arrows), and HSQC-
TOCSY (blue double-headed arrow) correlations; (b) ROESY (red double-headed 
arrows) correlations establishing configurations for macrocyclic olefins in 1. 
 
 Absolute configuration at C-14 was determined by analysis of Mosher ester 
data116 derived from the methanolysis product 16 (Figure 3.3). Methanolysis product 16 
was acylated with each of R-(−)- and S-(+)-α-methoxy-α-(trifluoromethyl)phenylacetyl 
chloride (MTPA-Cl) to produce the corresponding S- and R-MTPA esters 16a and 16b, 
respectively. Analysis of the 1H NMR and HSQC-TOCSY spectra obtained for both 
esters permitted the assignment of the proton chemical shifts in proximity of the 
esterified carbon. Calculation of the ∆δS-R values established the absolute configuration 






































Figure 3.3. Mosher’s ester analysis of callophycolide A (1). (a) methanolysis product 16; 
(b) and ∆δS-R values (ppm) for Mosher esters 16a and 16b from 16. 
 
 Solution of the configuration at C-15 proved to be challenging relative to other 
stereocenters in 1. Frelek et al. reported a circular dichroism (CD) spectroscopic method 
for determining the absolute configuration of restricted and flexible vicinal diols 
complexed with dimolybdenum tetraacetate.117 After ligation to Mo2, free-rotation about 
flexible diols is substantially reduced due to steric requirements of the transition metal 
complex. The energetically preferred conformation of a flexible diol ligated to Mo2 in a 
bidentate fashion is an antiperiplanar orientation of the O—C—C—R groups, with the 
bulky R-groups pointing away from the Mo2 complex and the vicinal diols in a gauche 
conformation.117b The CD spectrum of the in situ formed Mo2 complex with 16 showed a 
negative Cotton effect at 310 nm, which corresponded to a negative O—C—C—O 
dihedral angle (Figure 3.4a) as predicted by the helicity rule proposed by Frelek et al.117 
Molecular modeling of a 14S, 15S configuration in accordance with the lowest energy 
conformation predicted  a positive O—C—C—O dihedral angle, ruling out this 























16a: R = (S)-MTPA
















the dimolybdenum complex could have yielded either a positive or negative torsional 
angle. A stable conformation of 1 should involve intramolecular hydrogen bonding 
between the C-15 hydroxy and C-1 carbonyl. This places the C-15 hydroxy anti to H-14 
which is supported by NOEs observed between H-14 and both Hb-16 (δ 1.52) and Me-
26; however this conformation is feasible for both 15R and 15S. An NOE correlation 
from Hb-16 to Hb-13 (δ 2.03) could differentiate between a 15R or 15S configuration 
(Figure 3.4b), and inspection of 1D NOE spectra (irradiating Hb-16, acquired at -10 ºC) 
showed the presence of this correlation. Lack of NOEs between H2-13 protons and Me-
26 implied an anti conformation of these groups and further supported a 15R 
stereochemical assignment (Figure 3.4b). Overall, the combination of Mosher’s ester 
analysis, CD analysis with a dimolybdenum tetraacetate complex, and conformational 
analysis using NOEs argue strongly for an absolute stereochemistry of 14S, 15R for 1. 
 
 
Figure 3.4. Analysis of C-15 stereochemistry in 1. (a) CD spectrum of the in situ Mo2-
complex formed with methanolysis product 16; (b) Observed NOE correlations (ROESY 
= double-headed arrow; 1D NOE = single-headed arrow) used to establish the relative 
stereochemistry at C-15 as R in 1. NOEs that were not observed are indicated by an “x” 
through the arrow.  
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 High resolution mass spectral data indicated that bromophycolide L (2) differed 
from the previously identified bromophycolide K (11)18b by a loss of one H2O molecule, 
displaying an [M – H]- m/z of 501.1677, appropriate for a molecular formula of 
C27H35O4Br. HMBC correlations from Me-27 (δ 1.79) to C-14 (δ 74.9), C-15 (δ 140.7), 
and C-26 (δ 111.5) suggested an isopropenyl diterpene head identical with that of 
bromophycolide E (10)44b (Appendix A). Likewise, HMBC correlations from both H-26 
vinyl protons (δ 4.98, 5.07) to C-14, C-15, and C-27 (δ 19.5) confirmed this connectivity. 
Evaluation of 1H, COSY, and HMBC NMR spectral data of 2 to that of 11 indicated an 
additional difference within the terpene carbocyclic system. HMBC correlations from Me-
24 (δ 1.38) to C-7 (δ 49.0), C-21 (δ 122.5), and C-22 (δ 138.8) suggested that the 
rearranged terpene skeleton was present as in 11; however, the unsaturation was 
determined to be endocyclic at ∆21,22 through COSY correlations of olefinic H-21 (δ 4.81) 
with H-20b (δ 2.42) and a weak long range COSY correlation between H-21 and Me-24 
(Appendix A).   
 For 2, similar NOEs were observed as for 10, suggesting a 10R, 11S, 14S 
configuration.44b NOEs were present between H-7 (δ 3.41) and H-20b, located 1,4 
relative to each other across their six-membered ring, thus suggesting a pseudo-boat 
conformation of this ring. The lack of stereocenters near C-7 prevented stereochemical 
assignment at this position, given that an R or S configuration would be expected to 
result in NOEs between the axial protons H-7 and H-20b. 
 The mass spectrum of bromophycolide N (3), with [M – H]- m/z of 581.0907, 
suggested yet another regioisomer of 10, with a molecular formula of C27H36O4Br2. 
Comparison of 1H, COSY, and HMBC NMR spectral data of 3 with that of 10 suggested 
a difference in the cyclohexenyl double bond. HMBC correlations observed from Me-23 
(δ 1.50) to C-6 (δ 47.8), C-19 (δ 137.2), and C-20 (δ 120.3), along with COSY 
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correlations between both H-5 protons (δ 2.60, 2.83) and H-6 (δ 2.67), supported the 
∆19,20 assignment. Because similar NOEs were observed for 3 as for 10, 6R, 7S, 10R, 
11S, 14S, 22S stereochemistry was proposed for 3 (Appendix A). 
 Bromophycolide O (4) exhibited an [M – H]- m/z of 661.0182 with a tribrominated 
isotopic pattern, appropriate for a molecular formula of C27H37O4Br3 as seen with 
bromophycolides A (7), B (8), and D (9). Inspection of 1D and 2D NMR spectral data of 4 
suggested yet another 15-membered macrocyclic skeleton. As with 3, regioisomerization 
of the cyclohexenyl double bond to ∆19,20 was supported by observation of HMBC 
correlations from Me-23 (δ 1.65) to C-6 (δ 43.7), C-19 (δ 135.8), and C-20 (δ 119.4), as 
well as COSY correlations between H-5a (δ 2.82) and H-6 (δ 2.84) and a long-range 
COSY correlation between Me-23 and H-20 (δ 5.33). Similar NOEs were observed for 4 
as with 7 and 9, thus a 6R, 7S, 10R, 11S, 14S, 22S stereochemistry was inferred for 4. 
 Callophycoic acid C (5) gave a parent ion at m/z 581.0895, supporting a 
molecular formula of C27H36O4Br2. Callophycoic acids A18a and C (5) exhibited nearly 
identical 1H and 13C chemical shifts and 2D NMR correlations for C-1 through C-8 and C-
17 through C-25 (Appendix A), indicating these molecules shared a common tricyclic 
structure. However, substantial differences in chemical shifts and 2D NMR correlations 
were found in the diterpenoid head. Assessment of sites of unsaturation indicated that 
this group included one more ring system than callophycoic acid A. COSY correlations 
were observed between H-8 (δ 1.78, δ 2.16) and H-9 (δ 1.41, δ 1.46), establishing 
connectivity between these methylenes. Likewise, COSY correlations between H-9 and 
H-10 (δ 1.29) established connectivity between these carbons, an assignment further 
supported by an HMBC correlation from H-10 to C-9 (δ 20.8). This proton also exhibited 
HMBC correlations to quaternary C-11 (δ 73.0) and C-15 (δ 41.6), and methyl C-16 (δ 
30.8), establishing C-11—C-10—C-15—C-16 connectivity. In 5, the singlets Me-16 
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(δ 1.16) and Me-27 (δ 0.87) shared identical HMBC correlations to C-10 (δ 57.6), C-14 (δ 
68.9), and C-15, as well as to each other. These correlations were thus a starting point 
for establishing connectivity within spin systems of the cyclohexanol ring through COSY 
and additional HMBC correlations. Hydroxy and bromine groups were assigned at C-11 
and C-14, respectively, on the basis of carbon and proton chemical shift arguments.  
 NOEs for the tricyclic moiety of 5 matched closely those of callophycoic acid A 
for which X-ray crystallography established absolute configuration, leading us to predict 
6R, 7S, and 24S absolute configurations for 5. Relative stereochemistry within the 
cyclohexanol ring was then established based on observed NOEs. First, H-10 and H-14 
were assigned to diaxial positions on the same face of the ring, with NOEs observed 
between these protons. The diaxial orientation of these protons supported a chair 
conformation for the cyclohexanol ring, with the bulky alkyl substituent on C-10 and 
bromine on C-14 assigned equatorial positions. Me-16 was then assigned to an 
equatorial position on the same face as H-10 and H-14, based on NOEs between both of 
these protons and Me-16, an assignment further supported by the lack of NOEs between 
H-10 or H-14 and axial Me-27. Finally, Me-26 was assigned in an axial position on the 
opposite side of the ring to H-10 and H-14, based on an NOE between Me-26 and Me-
27, and supported by the absence of an NOE between Me-26 and H-10 or H-14.   
 With the relative stereochemistry of the cyclohexanol moiety of 5 elucidated, the 
absolute stereochemistry of this ring was determined with a series of NOEs that 
established the orientation of this ring relative to the 6R, 7S, 24S tricycle. First, the 
conformation of the bond between C-9 and C-10 was determined by NOEs between H-
9a and both Me-16 and Me-27, which supported H-9a pointing towards these two 
methyls. This assignment was further supported by the lack of an NOE between H-9a 
and Me-26. An NOE between H-9b and Me-26, but not between H-9b and Me-16 or Me-
27, analogously prompted placement of H-9b pointing towards Me-26, thus establishing 
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the dominant conformation of the C-9—C-10 bond. Next, NOEs were observed between 
H-9a and H-24 and between H-9b and H-6, supporting a conformational preference of H-
9a, Me-16, H-24, and Me-27 on one side of the molecule and H-9b, H-6, and Me-26 on 
the other side. Based on these correlations, a 10S, 11S, 14S stereochemistry was 
assigned for the cyclohexanol ring. The enantiomer (10R, 11R, 14R) should instead 
afford NOEs between H-9b and H-24 and between H-9a and H-6, but these correlations 
were not observed, thus confirming the cyclohexanol stereochemistry. 
 Callophycoic acid D (6) appeared structurally similar to 5, with an identical 
molecular formula (C27H36O4Br2 from [M-H]- m/z 581.0889). The major difference 
between 5 and 6 occurred in the tricyclic moiety. 1H and 13C chemical shifts, and HMBC 
and COSY correlations for this group closely matched those observed for callophycoic 
acid B,18a prompting assignment of a tricycle with ∆20,21, as opposed to the ∆21,22 
observed in 5. The stereochemistry of 6 was established as 6R, 7S, 10S, 11S, 14S, 24S 
and the ∆20,21 olefin was assigned a cis conformation on the basis of NOE arguments 
analogous to those for 5.    
 Previously reported bromophycolides and related non-macrocyclic callophycoic 
acids and callophycols18a, 44a, b exhibit antimalarial IC50 values ranging from 0.3 to >100 
µM, providing a detailed structure-activity relationship (SAR) analysis for this class of 
compounds (bioactivity of select compounds listed in Table 3.1).18b The identification of 1 
provides additional insight into the SAR for the 33 known C. serratus metabolites, in that 
1 retains moderate antimalarial activity (IC50 = 5.2 µM, Table 3.1) despite the complete 
absence of bromine atoms, similar to debromophycolide A (12), whose antimalarial IC50 
is > 100 µM. Furthermore, 1 has a carbon skeleton different than other bromophycolides, 
although its skeleton is not unprecedented and is shared with tocopherols.118 The 
lactonization pattern through C-14 in 1 is unique, and the absence of a substituted 
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cyclohexene ring (compared to 7, IC50 = 0.7 µM) suggests that this ring is not essential 
but can enhance antimalarial activity. Macrolides 3-4, 7-10, representing both 15- and 
16-membered lactone frameworks, exhibited potent antimalarial activity with IC50 values 
of 0.3-4.8 µM, suggesting that neither mode of lactonization confers an inherent 
bioactivity advantage. Furthermore, a macrolide motif appears to be essential for 
antimalarial activity, considering that non-macrocyclic metabolites 5-6 were less active 
against P. falciparum (IC50 values of 59 and 76 µM, respectively).  
 While all tested C. serratus metabolites exhibited moderate anticancer activity 
against a panel of 12 human tumor cell lines, only 3 displayed some cell line selectivity, 
with an IC50 of 1.5 µM against the breast tumor cell line DU4475, the most sensitive 
cancer tested (Table 3.2). Callophycolide A (1) and all tested bromophycolides inhibited 
bacterial growth in the low micromolar range but most were ineffective at deterring 
growth of human pathogenic fungi and Mycobacterium tuberculosis (Table 3.1).  
 




activity  antimicrobial MIC (µM) 
cmpd  IC50 (µM)  MRSAa VREFb M. tuberculosis ARCAc 
1  5.2  9.1 9.1 12 >250 
2  9.8  8.2 26 49 46 
3  1.4  13 13 >50 44 
4  1.4  13 25 NT >100 
5  59  NT NT >100 NT 
6  76  NT NT >100 NT 
7  0.7  5.9 5.9 11 49 
8  4.8  5.9 3.0 49 49 
9  0.3  NT NT 1.1 NT 
10  0.8  NT NT 95 NT 
11  44  NT NT NT NT 
12  >100  NT NT >100 >500 
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Table 3.1 continued 
 
13  190  >500 >500 NT NT 
14  220  >500 >500 >100 NT 
15  10  >500 >500 NT >500 
aMethicillin-resistant Staphylococcus aureus; bVancomycin-resistant Enterococcus 
faecium; cAmphotericin B-resistant Candida albicans; NT indicates not tested due to 
insufficient material 
  
Table 3.2. Anticancer activity of 1-15.18, 44a, b 
 
  anticancer activity IC50 (µM) 
cmpd  mean
a cell line selectivity (IC50 max/IC50 
min) 
1  16 3.0 
2  NT - 
3  8.6 15 
4  9.7 3.5 
5  21 1.7 
6  23 1.5 
7  6.7 4.8 
8  28 3.8 
9  9.0 2.3 
10  12 6.4 
11  31 3.6 
12  >76 - 
13  >25 - 
14  >25 - 
15  NT - 
  aMean of 12 cell lines; 
 
 Purified from extracts of A. crassa, tocopherylhydroquinones 13-14 were 
identified by a detailed analysis of their 1- and 2D NMR and MS spectral data and 
compared to related tocopherols previously reported.119 While 1H and 13C NMR spectral 
data are available in the literature for vitamin E and related tocopherols, complete 
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spectral data for 13-14 were lacking. Therefore, we provide full NMR spectral data for 
13-14 in the present study (Table 3.1 and Appendix A).  
 Tocopherols have been isolated and characterized from various brown algae 
including Sargassum fallax120 and Cystoseira stricta,119 but the identification of 13-14 
represents the first isolation of tocopherols from red algae. This class of molecules has 
been shown to have a variety of functions in terrestrial vascular plants, including 
scavenging lipid peroxy radicals and preventing propagation of lipid peroxidation in 
membranes; protecting lipids and other membrane components by quenching and 
reacting with singlet oxygen and thus providing photo-protection for chloroplasts; and 
increasing membrane rigidity.121 While a number of tocopherol derivatives have been 
isolated from brown macroalgae, their ecological functions are unclear. These 
compounds may function similarly as in vascular plants given the high exposure of many 
macroalgae to UV radiation, however this hypothesis has not been tested. 
 The biomedical potential of tocopherols and related compounds mainly relate to 
their antioxidant activities, as these compounds are well established in their radical 
scavenging activity.122 Hydroquinones 13-14 showed weak activity against P. falciparum 
(IC50 values of 190 and 220 µM for 13 and 14, respectfully (Table 3.2), but oxidation of 
14 to quinone 15 increased the antimalarial activity by more than 20-fold to an IC50 of 10 
µM, suggesting that the quinone functionality is essential for activity for tocopherol-
related compounds. Unfortunately, following bioassays we did not have enough 12 to 
oxidize to the corresponding β-tocopherylquinone. This is the first report of tocopherols 
in red macroalge and of antimalarial activity for tocopherols 13-15. Furthermore, 13-15 
displayed no activity in cancer and microbial assays, although 15 was not tested against 
human cancer cells due to insufficient material. These macroalgal natural products are 
unusual scaffolds when compared to current natural antimalarial treatments, such as the 
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quinines and artemisinins. These meroditerpenes could inspire the development of novel 
templates for future antimalarial drugs.  
 
Experimental Section 
Biological material. Callophycus serratus (family Solieriaceae, order Gigartinales, class 
Rhodophyceae, phylum Rhodophyta) was collected at depths of 2-3 m from Yanuca in 
the Fiji Islands (18° 23’ 57” S, 177° 57’ 59” E) in 2008 and at depths from 9-15 m near 
Harold’s Passage, Astrolobe Reef, Kadavu Province, Fiji (18° 46’ 37” S, 178° 27’ 74” E) 
in 2004. Amphiroa crassa (family Corallinaceae, order Corallinales, class 
Florideophyceae, phylum Rhodophyta) was collected at a depth of 20 m from the Coral 
Coast, Fiji (18o 12’ 15” S, 177o 39’ 35” W) in 2004. Samples were frozen at –80° C until 
extraction. Voucher specimens were identified by comparison with previously described 
morphological traits,123 preserved in aqueous formalin, and deposited at the University of 
the South Pacific in Suva, Fiji and at Georgia Institute of Technology as ICBG-2004-23, 
ICBG-2004-43, ICBG-G-0004, ICBG-G-0005, ICBG-G-0021, and ICBG-G-0049 for C. 
serratus and ICBG-2004-103 for A. crassa. 
Chemicals. Solvents used for extractions were reagent grade, and those used for HPLC 
and LC-MS were HPLC or Optima grade (Fisher Scientific). NMR solvents were 
purchased from Cambridge Isotope Laboratories. Commercially available reagents were 
purchased from Sigma-Aldrich (Milwaukee, WI) and used as received. 
Isolation. Frozen C. serratus and A. crassa were each extracted with MeOH and 
MeOH/DCM (1:1, 1:2) and subjected to liquid partitioning between MeOH/H2O (9:1) and 
petroleum ether. The MeOH/H2O ratio of each species’ aqueous fraction was then 
adjusted to 3:2 and partitioned against chloroform. The chloroform-soluble fraction for 
each species was then separated with multiple rounds of reversed-phase C18 HPLC 
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(Alltech Alltima C18, 5 µm, 10 × 250 mm) with a gradient of MeCN (aq) to yield 1-6 from 
C. serratus and 9-10 from A. crassa.  
Hydrolysis of callophycolide A (1). N2-flushed vial was charged with 1 (4.0 mg, 9.4 
µmol, 1.0 eq) in 45 µL Optima-grade MeOH, followed by 5 µL of 10M aqueous NaOH 
(3.0 mg, 75 µmol, 8.0 eq) at 20 ºC. The reaction was allowed to stir at 40 ºC for 18 h. 
After cooling to 22 ºC, 10 µL of 1 M HCl was added. The solution was separated via 
reversed-phase HPLC (Alltech Alltima C18, 250 × 10 mm, 5 µm) without further work-up. 
Hydrolyzed callophycolide A eluted with 86% aqueous MeCN (2.0 mg, 58% yield, based 
on recovered starting material); methylated-hydrolyzed 7 eluted with 92% aqueous 
MeCN (1.3 mg, 38% yield, based on recovered starting material); and 1 was recollected, 
eluting with 98% aqueous MeCN (0.8 mg). 
Preparation of MTPA Derivatives of 16. An N2-flushed vial was charged with 16 (0.6 
mg, 1.3 µmol, 1.0 eq) and dimethylaminopyridine (DMAP, 1.3 mg, 10.4 µmol, 8.0 eq) in 
65 µL anhydrous pyridine and the solution was allowed to stir at 22 ºC for 25 min. R-(−)-
α-methoxy-α-(trifluoromethyl)phenylacetyl chloride (10 µL, 10.4 µmol, 8.0 eq) was then 
added slowly via syringe. The reaction was allowed to stir at 22 ºC for 2 h under N2. The 
solvent was removed under vacuum, and the resultant crude mixture was purified via 
reversed-phase HPLC (Alltech Alltima C18, 250 × 10 mm, 5 µm). The S-MTPA ester 
(16a, 0.60 mg, 52% yield) eluted with 100% ACN. An identical procedure was carried out 
to obtain the R-MTPA ester (16b, 0.58 mg, 51% yield) with S-(+)-α-methoxy-α-
(trifluoromethyl)phenylacetyl chloride. 
Preparation of in situ Mo2-complex formed with 16. Methanolysis product 16 (0.5 mg) 
was dissolved in 1.5 ml DMSO with dimolybdenum tetraacetate so that the molar ratio of 
the Mo2-complex to 16 was 1:1. The solution was prepared 2 h before recording the CD 
spectrum. 
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Computational Method of Mo2-complex formed with 16. Molecular modeling was 
performed on a personal computer using HyperChem for Windows (Student Version 7.5 
from Hypercube, Inc.) using the molecular mechanics MM+ force field method as 
described in Górecki et al.117b 
Oxidation of δ-tocopherylhydroquinone (14). An N2-flushed vial was charged with 14 
(0.35 mg, 0.8 µmol, 1.0 eq) in 0.15 ml MeCN and cooled to 0 ºC over an ice bath. 16 µL 
of a 0.5 M aqueous stock of ceric ammonium nitrate (4.5 mg, 8.3 µmol, 10 eq) was 
added via syringe to the vial and allowed to stir for 60 min at 0 ºC. Saturated NaHCO3 
(aq) was added (0.5 ml) to the reaction and extracted with EtOAc (3 × 0.5 ml). The 
combined organics were washed with brine, dried over MgSO4, and concentrated in 
vacuo. Desired product 15 was purified with reversed-phase HPLC (Zorbax SB-C8, 250 
× 4.6 mm, 5 µm), eluting with 100% MeCN (0.32 mg, 92% yield). 1H and 13C NMR 
spectral data for 15 were identical to previously reported literature values.124 
Analytical and spectroscopic methods. UV spectra were recorded in MeOH with a 
Spectronic 21D spectrophotometer using quartz cuvettes. Optical rotations were 
measured on a Jasco P-1010 spectropolarimeter with a 10 cm (8 ml) cell, with 
compounds dissolved in MeOH. Circular dichroism spectra were acquired on a Jasco J-
810 spectropolarimeter and 1 mm pathlength cells were used. High-resolution mass 
spectra were generated using electrospray ionization with an Applied Biosystems 
QSTAR-XL hybrid Quadrupole-Time-of-Flight tandem mass spectrometer and Analyst 
QS software. LC-MS analyses were conducted using a Waters 2695 HPLC with Waters 
2996 photodiode array UV detection and Micromass ZQ 2000 mass spectrometer with 
electrospray ionization. LC-MS chromatography was achieved with an Alltech Alltima C18 
column (3 µm, 2.1 × 150 mm), using gradient mobile phases of MeCN (aq) with 0.1% 
acetic acid. NMR spectra were recorded on a Bruker DRX-500 instrument, using a 5 mm 
inverse detection probe for 1H, COSY, ROESY, HSQC, and HMBC experiments, and a 5 
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mm broadband probe for 1H, 13C, and DEPT-135, and referenced to residual CHCl3 (7.24 
and 77.0 ppm, for 1H and 13C, respectively).   
Pharmacological assays. All pharmacological assays were performed as previously 
described.18b, 44a Briefly, antimalarial activity was determined with a SYBR Green based 
parasite proliferation assay, adapted from Smilkstein125 and Bennett.126 Plasmodium 
falciparum parasites (3D7 strain MR4/ATCC, Manassas, VA) were cultured in human O+ 
erythrocytes as previously described.127 Compounds were diluted in complete medium 
and 40 µl transferred to 96-well assay plates. To this 80 µl of complete media with 3D7 
infected erythrocytes were dispensed in order to obtain a 2.5% hematocrit and 0.5% 
parasitemia in the assay. Uninfected erythrocytes were dispensed into the background 
wells at the same final hematocrit. Plates were incubated for 72 h in a low oxygen 
environment (96% N2, 3% CO2, 1% O2) in a modular incubation chamber. The plates 
were sealed and placed in a -80 oC freezer overnight then thawed, and 120 µl of lysis 
buffer (20 mM Tris-HCl, pH 7.5, 5mM EDTA, 0.08% Triton X-100, 0.008% saponin with 
0.2  µl/ml Sybr Green I) was dispensed into each well and incubated at 37 oC in the dark 
for 6 h. The plates were read with a Molecular Devices SpectraMAX Gemini EM at ex: 
495 nm, em: 525 nm with 515 nm cut-off. 
 Antibacterial assays were performed using methicillin-resistant Staphylococcus 
aureus (MRSA, ATCC #33591) and vancoymcin-resistant Enterococcus faecium (VREF, 
ATCC #700221) as test pathogens. These bacterial strains were grown overnight at 37 
oC in nutrient broth (BD DifcoTM) and brain heart infusion (BD BactoTM) media, 
respectively. Assay cultures were diluted to an optical density of 0.05, diluted 10-fold, 
and added to 96-well microtiter plates. Treatments and controls were suspended in 
DMSO, added to the top row of assay plates (final concentration 250 µg/ml), and serially 
diluted 1:1 down each column. Vancomycin and chloramphenicol were used as positive 
controls for MRSA and VREF, respectively, and DMSO was used as negative control. All 
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assay plates were sealed with parafilm and incubated overnight at 37 oC. The optical 
density was measured at 600 nm using a microplate reader, and the MIC of each 
compound was calculated using the analysis program SOFTmax PRO.  
  For the antifungal assay, amphotericin B-resistant Candida albicans (ATCC #90873) 
was grown overnight at 37 oC in YPM media (2 g yeast extract, 2 g peptone, 4 g D-
Mannitol, 1 L DI water). A hemocytometer was used to determine cell density, and the 
assay culture was diluted to 1 × 104 cells/ml, before it was added to 96-well microliter 
plates. Treatments and controls were suspended in DMSO, added to the top row of the 
assay plate (final concentration 250 µg/ml), and serially diluted 1:1 down each column. A 
mixed nystatin/amphotericin B solution was used as a positive control, and DMSO was 
used as a negative control. All assay plates were incubated overnight at 37 oC. The 
optical density was then measured at 600 nm using a microplate reader and the optical 
density was measured at 600 nm using a microplate reader, and the MIC of each 
compound was calculated using the analysis program SOFTmax PRO. 
 Natural products were evaluated against a panel of 12 tumor cell lines including 
breast, colon, lung, prostate, and ovarian cancer cells. Specific cell lines were: BT-549, 
DU4475, MDA-MD-468, PC-3, SHP-77, LNCaP-FGC, HCT116, MDA-MB-231, 
A2780/DDP-S, Du145, CCRF-CEM, and A549. In vitro cytotoxicity was tested with the 
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxylmethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium inner salt) MTS dye conversion assay as described previously.128 
 Antitubercular activity was assessed against Mycobacterium tuberculosis strain 
H37Rv (ATCC 27294) using the alamar blue susceptibility test (MABA) as described 
previously.129  Compounds were tested at a maximum concentration of 100 µM. 
Callophycolide A (1):  pale yellow oil (4.0 mg, 0.021% dry mass); [α]24D  +200 (c 0.01 
g/100 ml, MeOH); UV (MeOH) λmax (log ε) 260 (4.06) nm; 1H NMR (CDCl3, 500 MHz) 
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and 13C NMR (CDCl3, 125 MHz) data, Table 3.1; NOE, COSY, and HMBC NMR data, 
see Appendix A; HRESIMS [M + H]+ m/z 427.2825 (calcd for C27H39O4, 427.2842) and 
[M + Na] m/z 449.2623 (calcd for C27H38O4Na, 449.2668). 
Bromophycolide L (2): white amorphous solid (0.3 mg, 0.007% dry mass); [α]24D  +70 
(c 0.033 g/100 ml, MeOH); UV (MeOH) λmax (log ε) 262 (3.72) nm; 1H NMR (CDCl3, 500 
MHz) and 13C NMR (CDCl3, 125 MHz) data, Table 3.1; NOE, COSY, and HMBC NMR 
data, see Appendix A; HRESIMS [M – H]- m/z 501.1677 (calcd for C27H34O4Br, 
501.1640). 
Bromophycolide N (3): white amorphous solid (1.0 mg, 0.023% dry mass); [α]24D  +101 
(c 0.033 g/100 ml, MeOH); UV (MeOH) λmax (log ε) 260 (3.42) nm; 1H NMR (CDCl3, 500 
MHz) and 13C NMR (CDCl3, 125 MHz) data, Table 3.1; NOE, COSY, and HMBC NMR 
data, see Appendix A; HRESIMS [M – H]- m/z 581.0907 (calcd for C27H35O4Br2, 
581.0902). 
Bromophycolide O (4):  white amorphous solid (0.5 mg, 0.012% dry mass); [α]24D  +88 
(c 0.011 g/100 ml, MeOH); UV (MeOH) λmax (log ε) 260 (3.54) nm; 1H NMR (CDCl3, 500 
MHz) and 13C NMR (CDCl3, 125 MHz) data, Table 3.1; NOE, COSY, and HMBC NMR 
data, see Appendix A; HRESIMS [M – H]- m/z 661.0182 (calcd for C27H36O4Br3, 
661.0169). 
Callophycoic acid C (5):  white amorphous solid (2.5 mg, 0.009% dry mass); [α]24D  -49 
(c 0.031 g/100 ml, MeOH); UV (MeOH) λmax (log ε) 258 (4.03) nm; 1H NMR (CDCl3, 500 
MHz) and 13C NMR (CDCl3, 125 MHz) data, Table 3.1; NOE, COSY, and HMBC NMR 
data, see Appendix A; HR ESI-MS [M – H]- m/z 581.0895 (calcd for C27H35O4Br2, 
581.0902). 
Callophycoic acid D (6):  white amorphous solid (1.6 mg, 0.006% dry mass); [α]24D 
 +85 (c 0.018 g/100 ml, MeOH); UV (MeOH) λmax (log ε) 258 (3.81) nm; 1H NMR (CDCl3, 
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500 MHz) and 13C NMR (CDCl3, 125 MHz) data, Table 3.1; NOE, COSY, and 
HMBC NMR data, see Appendix A; HR ESI-MS [M – H]- m/z 581.0889 (calcd for 
C27H35O4Br2, 581.0902). 
β-Tocopherylhydroquinone (13): colorless oil (1.2 mg, 0.003% dry mass); [α]24D  +2.2 
(c 0.06 g/100 ml, MeOH); UV (MeOH) λmax (log ε) 255 (3.93) nm; 1H NMR (CDCl3, 500 
MHz) and 13C NMR (CDCl3, 125 MHz) data, Table 3.1; COSY and HMBC NMR data, 
see Appendix A; HRESIMS [M−H−H2O]- m/z 415.3553 (calcd for C28H47O2, 415.3576). 
δ-Tocopherylhydroquinone (14): brown oil (2.8 mg, 0.006% dry mass); [α]24D  +1.3 (c 
0.14 g/100 ml, MeOH); UV (MeOH) λmax (log ε) 255 (3.56) nm; 1H NMR (CDCl3, 500 
MHz) and 13C NMR (CDCl3, 125 MHz) data, Table 3.1; COSY, and HMBC NMR data, 
see Appendix A; HRESIMS [M−H−H2O]- m/z 401.3414 (calcd for C27H45O2, 401.3419); 
[2M−H−2H2O]- m/z 803.6876 (calcd for C54H91O4, 803.6917). 
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CHAPTER 4 
BROMOPHYCOLIDE A TARGETS HEME CRYSTALLIZATION IN THE HUMAN 
MALARIA PARASITE PLASMODIUM FALCIPARUM 
 
 Plasmodium falciparum, the most deadly human malaria parasite, poses a major 
threat to human health worldwide with over 500 million clinical cases and 1-2 million 
deaths annually.16 Natural products and their synthetic derivatives have provided the 
greatest number of successful antimalarial treatments to date, representing 
approximately 65% of current drugs.11 Quinine, discovered from cinchona tree bark, has 
been used to treat malaria since the 17th century and was the primary antimalarial drug 
until it was replaced by chloroquine, a synthetic derivative, in the 1940s.130 Chloroquine 
became the mainstay antimalarial agent until resistant strains began to appear over a 
decade after its introduction. Artemisinin, isolated from the plant Artemisia annua used in 
traditional Chinese medicine, ushered in a new wave of antimalarials and became the 
most potent and rapid-acting drug available.131 Several artemisinin synthetic derivatives 
have since been developed, and artemisinin-based combination therapies are currently 
being used throughout the world to treat this parasitic disease. However, artemisinin-
resistant strains have recently been reported,132 and new antiparasitic drugs are urgently 
needed.  
 Therapeutic development is complex due to the intricate host-guest interactions 
during the plasmodial life cycle. During its maturation, the malaria parasite is transferred 
to human hosts via mosquitoes, and after a transitory stage in the liver, the parasite 
resides in the hosts’ red blood cells. While residing in red blood cells, the parasite 
catabolizes hemoglobin within its food vacuole for its nutritional benefit. This hemoglobin 
catabolism can be lethal as it releases free heme molecules which are toxic to the 
parasite.133 However, the parasite overcomes heme toxicity through the crystallization of 
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free heme into non–toxic hemozoin, a non–enzymatic process which is crucial to 
parasite survival and thus an excellent antimalarial drug target.134 Chloroquine has been 
shown to inhibit heme crystallization,135 and structurally related antimalarial drugs such 
as quinine, amodiaquine and mefloquine have also been proposed to disrupt hemozoin 
formation. Resistance to chloroquine has been shown to occur through multiple 
mutations in a P. falciparum transmembrane protein that, when mutated, pumps 
chloroquine out of the food vacuole, significantly reducing the concentration of the 
drug.136 The primary mechanism of action (MOA) for artemisinin remains in debate, 
although several hypotheses have been reported, including alkylation of heme by 
carbon-centered free radicals,137 interference with proteins such as the 
sarcoplasmic/endoplasmic calcium ATPase (SERCA),138 as well as damaging of normal 
mitochondrial functions.139    
 The identification of molecular targets for bioactive natural products is essential 
for understanding their MOAs, developing new drug leads, and anticipating evolution of 
resistance. We previously discovered a unique group of brominated macrocyclic 
meroditerpenes from the Fijian red macroalga Callophycus serratus44a, b and showed that 
this class of natural products is cytotoxic to P. falciparum.18b, 44c The most abundant 
natural product of this class with sub–micromolar inhibition of P. falciparum proliferation, 
bromophycolide A (1), induces a strong arrest of the parasite erythrocytic cycle,140 and 
was therefore used to develop a fluorescent probe for both molecular imaging and 




Figure 4.1. Bromophycolides A (1), C (2), D (3), E (4), M (5), and debromophycolide A 
(6) isolated from Callophycus serratus18b, 44a, b and semi-synthetic derivatives of 
bromophycolide A (7-13).  
 
 In order to maintain antimalarial activity while not compromising the integrity of 
potential receptor binding, attempts initially focused on connecting a linker through the 
tertiary alcohol at C11 since changes at this position resulted in only minor differences in 
activity, based on structure–activity relationship (SAR) trends gleaned from the known C. 
serratus natural products (see Figures 4.1 and 4.2). Unfortunately, all synthetic efforts 
failed at this position, likely due to both poor reactivity of tertiary alcohols and steric 




































1 R1=H, R2=Br, R3=H




7 R1=Ac, R2=Br, R3=H
8 R1=Me, R2=Br, R3=H





























position in 1 is the phenolic hydroxyl at C18. Because the C18 phenol was conserved in 
all C. serratus metabolites and thus SAR data was lacking, we acetylated the phenol in 1 
to test for changes in activity. Fortuitously, the acetylated derivative 7 resulted in an 
increase in activity (IC50 value of 241 nM, Table 4.1). Therefore, two fluorescent 
immunoaffinity fluorescent (IAF) tags23 with varying chain lengths were each 
synthetically appended to 1 through an acetyl linkage (Scheme 4.1). The IC50 value of 
probe 15 was 271 nM, similar to that of 7. Furthermore, both tag 14a and 14b were 
inactive against P. falciparum, exhibiting IC50 values >100 µM, suggesting that the 
activity observed in probe 15 was a result of the natural product. 
 
 
Figure 4.2. Structure-activity relationship summary of C. serratus natural products and 
bromophycolide A (1) semi-synthetic derivatives. Greater potency is indicated by “>”, 

























Scheme 4.1. Probes 15 and 17 were prepared by coupling acids 14 and 16, 
respectively, with bromophycolide A (1). EDC = N’-(3-dimethylaminopropyl)-N-
ethylcarbodiimide; DMAP = 4-dimethylaminopyridine; EtNiPr2 = N,N-
diisopropylethylamine; DMF = dimethylformamide.  
  
 With active probes in hand, we turned to confocal microscopy to study the 
intracellular distribution of probe 15 in P. falciparum–infected erythrocytes. Fluorescence 
was observed as small pockets in close proximity to the food vacuole (Figure 4.3), which 
was distinguished by the presence of hemozoin (dark crystals, Hz). No fluorescence was 
observed when P. falciparum–infected erythrocytes were incubated with either 14a or 
14b, providing further evidence that 15 provided an effective mimic of the natural product 
(Figure 4.3). In order to determine its specific intracellular target, the histological 
localization of probe 15 was compared with that of fluorescent organelle and lipid probes 
by co–incubation and imaging using multichannel fluorescence confocal microscopy. 



























































repeatedly showed co–localization of the two stains, suggesting that 15 was associating 
with intracellular neutral lipids (Figure 4.4). Pisciotta et al. established that heme 
crystallization occurs inside neutral lipid nanospheres, which encompass hemozoin in P. 
falciparum food vacuoles.141 Therefore, molecular imaging studies with 15 and infected 
erythrocytes suggested that heme crystallization was a putative target of 1. 
 
 
Figure 4.3. Intracellular localization images of probe 15 and controls in mixed-stage P. 
falciparum–infected erythrocytes. Confocal microscopy images of live parasites 
incubated with either 2 µM of bromophycolide A probe 15, control tag 14a, or 14b in 
complete medium. Hemozoin (Hz) crystals were identified in the transmitted light image 
by dark crystals. Probe 15 localized around Hz, as seen in the fluorescent image. No 
fluorescence was observed when P. falciparum–infected erythrocytes were incubated 
with either 14a or 14b. Scale bar denotes 10 µm. 
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Figure 4.4. Confocal images of fixed parasites incubated with 2 µM probe 15 (green), 30 
nM Nile Red (red), and 70 nM DAPI (blue). Co–localization of 15 and Nile Red (neutral 
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lipids) is indicated by the yellow merged image. Interesting, while probe 15 emission 
spectra showed a maximum at 450±10 nm (blue channel) in both complete medium and 
methanol, 15 fluoresced in the green channel (FITC) after parasite fixation with 
paraformaldehyde. The latter effect could result from solvatochromic effects while 
localized within the lipid environment. Bars denote 5 µm. 
  
 To further explore possible heme–bromophycolide interactions, the absorbance 
spectra of ferriprotoporphyrin IX (Fe(III)PPIX), commercially available heme, was 
recorded in 20 mM Hepes, pH 7.4 containing 40% DMSO, conditions that were 
previously demonstrated to evaluate monomeric Fe(III)PPIX.142 Fe(III)PPIX gives 
characteristic absorption spectra with an intense Soret band at 402 nm and addition of 1 
resulted in up to a 35% decrease in absorption at 402 nm, suggesting 1 forms a 
saturable complex with Fe(III)PPIX (Figure 4.5a). Absorption spectra with Fe(III)PPIX 
and 1 were collected over an 8 h period incubating at 37 ºC, and absorption at 402 nm 
continually decreased throughout the first 6 h and then reached a plateau (Figure 4.5b), 
implying that 1 is potentially a slower acting drug when compared to artemisinin.143 
Because heme crystallization is non-enzymatic, parasite-free colorimetric high-
throughput screens for heme crystallization inhibitors have been developed144 and 
refined.145 Both 1 and 7 were tested for heme crystallization inhibition with the potent 
antimalarial drug amodiaquine acting as a positive control. Natural product 1 inhibited 
heme crystallization with an IC50 value of 2.5 molar equivalents of drug to heme, and 7 
was slightly more effective than 1, with an IC50 of 2.0 molar equivalents, consistent with 
growth inhibition assays (Table 4.2); IC50 values for amodiaquine were consistent with 
previously reported values.144 Collectively, these data provided compelling evidence of 




Figure 4.5. Spectroscopic changes observed when Fe(III)PPIX (hemin) is incubated with 
various concentrations of bromophycolide A (1). (a) Changes in the Soret band (402 nm) 
of hemin. The absorbance (Abs) at 402 nm decreases as concentration of 1 increases. 
Molar equivalent (mol eq) ratios are shown as natural product (1) to hemin. Spectra have 
been corrected for dilution by subtracting a reference cell at each concentration of 1. (b) 
Incubation of hemin in the presence of 1 results in a continual decrease in absorbance at 
402 nm over the course of several hours at 37 ºC, equilibrating around 6 h (n = 3); ▼ = 
1:1 mol eq 1: hemin; ■ = 2.5:1 mol eq 1: hemin; ● = 10:1 mol eq 1: hemin. Error bars 
indicate standard deviation. Conditions: 37 ºC (dark), 40% DMSO, 20 mM HEPES 
buffer, pH 7.4. 
  
 With a MOA established for 1, potential protein targets were also explored. 
Taking advantage of the dual utility of probes 15 and 17, P. falciparum lysates were 
screened for bromophycolide–binding protein targets. A selective monoclonal antibody 
(mAb) against the fluorescent tag146 was available for co-immunoprecipitation (co-IP) 
with P. falciparum lysates and both probes 15 and 17. Repeated IP experiments failed to 
result in isolation of any bromophycolide–binding proteins (see Appendix B). This anti–
IAF–mAb affinity method has been successful with IP of protein targets in multiple 
systems in our labs, from cancerous cells24, 146 to micro-invertebrates.27 While a negative 
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IP experiment cannot prove the lack of a protein target, the lack of an isolated binding 
protein supports the observation that an MOA of 1 involves heme crystallization 
inhibition.    
 To date, we have isolated 33 unique C. serratus metabolites and IC50 values 
ranged from 0.3 to >100 µM, providing a small library to analyze SAR trends 
(representative natural products 1–6, Figure 4.1).18, 44 Several semi–synthetic derivatives 
of 1 were also prepared (7–13) to further enhance SAR studies and to provide insights 
for potential future designs of bromophycolide–inspired synthetic compounds. When 
examining the natural product SAR trends, the most striking observation related to the 
diterpene head. While replacing the bromine at C15 with an isoprene functionality 
caused little change in antimalarial activity, substitution of a hydroxyl group at C15 
exhibited dramatic loss of activity (Table 4.1), suggesting that a hydrogen bond donating 
group is poorly suited in this position (Figure 4.2). 
 
Table 4.1.  Antimalarial activities of bromophycolides A (1), C (2), D (3), E (4), M (5), 
debromophycolide A (6), semi-synthetic derivatives of bromophycolide A (7-13), and 
probe 15.   


















 Moving to functional groups in the aliphatic macrocycle, synthetic modifications at 
C10 and C11 also did not significantly affect activity, and replacing the bromine at C10 
with chlorine resulted in a slight decrease in activity, although it should be noted that the 
configuration at C10 was inverted (4 vs. 10). Regioisomerization of the double bond in 
the cyclohexene ring in both natural products and synthetic derivatives also 
demonstrated only minor alterations in activity (Figure 4.2). Interestingly, elimination of 
all bromines from 1 only moderately decreased the IC50 value from 0.65 to 3.5 µM (1 vs. 
12) whereas the natural product 6 was completely inactive. The final portion of 1 to 
investigate was the p–hydroxybenzoate group. As previously discussed, acylation of the 
phenol in 1 to 7 resulted in a slight increase in activity. Surprisingly, methylation of the 
phenol in 1 to 8 led to a 30–fold decrease in activity. Collectively, these data suggest 
that positions C15 and C18 have the most striking effects on antimalarial activity. 
 The discovery and development of heme crystallization inhibitors remains an 
excellent malaria drug target because heme crystallization is a physicochemical process 
and thus less likely to provide the means for evolution of resistance.147 Drug resistance 
most commonly involves mutations in a drug’s target protein or proteins which regulate 
efflux in order to remove the drug ,148 as the latter was shown for chloroquine resistance. 
Furthermore, both 1 and 7 effectively inhibited chloroquine-resistant parasites (Dd2) with 
IC50 values of 497 and 304 nM, respectively (Table 4.2), while exhibiting between 50- 
and 300-fold differences in activity between P. falciparum parasites and human Vero 
cells (Table 4.3).  
 Potential interactions of drug 1 with heme include π−π complexation, hydrophobic 
interactions between heme and 1, and hydroxyl group coordination to the iron center.142 
The increased potency of 1 (C18-OH) and 7 (C18-OAc) over 8 (C18-OMe) potentially 
suggests coordination of C18-OH with the iron center in heme, although π−π 
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complexation and hydrophobic interactions between heme and bromophycolides are 
also possible. The increased potency of 7 relative to 1 can be attributed to a higher 
affinity of an acetyl functionality for iron over a free hydroxyl group, while also explaining 
the significant decrease in activity when the phenolic hydroxyl was methylated as in 8. 
Alternatively, Fe–OH coordination of bromophycolides with heme may require that the 
C18–OAc derivative 7 undergoes deacylation by esterases, making 7 a prodrug of the 
hydrophobic natural product 1. This, however, is not supported by the cellular studies 
with probe 15 as shown in Figure 4.3 and 4.4.  
 
Table 4.2. Efficacies of bromophycolide A (1), 18-OAc-bromophycolide A (7) and 
amodiaquine (AMQ) against three Plasmodium falciparum strains, in inhibition of heme 








IC50 for heme 
crystallization 
(equivalents)c  
1  658 497 565 2.5 ± 0.13 
7  241 304 431 2.0 ± 0.15 
AMQ  7.8d 14d 8.5d 1.2 ± 0.19 
  a3D7 and HB3 = chloroquine-sensitive parasites 
  bDd2 = chloroquine-resistant parasite 
  cIC50 values in Ncokazi & Egan144 were reported as molar equivalents of drug to heme 
  dFrom Hawley et al.149 
 
 
Table 4.3. Cytotoxicity of 1 and 7 against healthy human cells. 
cmpd 
Cytotoxicity (IC50 µM) 
 Vero J774 HepG2 
1  34.6 19.0 21.3 




 The molecular structures of the bromophycolides are notably different from 
quinine, chloroquine, and other known heme crystallization inhibitors, thus suggesting a 
new class of compounds that target heme crystallization. Moreover, red algae may 
represent an excellent source for the discovery of new antimalarials, as a recent study 
revealed a common evolutionary lineage for red algae and the malaria parasite.150 Thus, 
red algae may produce secondary metabolites more likely to inhibit malaria parasite 
proliferation than many other organisms. As historically evident, natural products 
continue to provide a rich resource for the discovery of unique antimalarial drugs.   
 
Experimental Section 
General methods. Commercially available reagents were purchased from Sigma-
Aldrich (Milwaukee, WI) or VWR Scientific (Brisbane, CA), and used as received. All 
reactions were performed under a nitrogen atmosphere unless otherwise noted. 
Reactions were monitored using thin-layer chromatography (TLC) using Silica Gel 60 
F254 plates from EMD Chemicals (San Diego, CA), and visualized with a UV lamp at 
254 nm. Solvents used for HPLC and LC-MS were HPLC or Optima grade (Fisher 
Scientific). NMR solvents were purchased from Cambridge Isotope Laboratories. 2,5-
Dimethylfuran was used as an internal standard for quantitation by 1H NMR 
spectroscopy.151  
Structural analyses. NMR spectra were recorded on a Bruker DRX-500 instrument in 
CDCl3 using a 5 mm inverse detection probe for 1H, COSY, HSQC, and HMBC 
experiments, and a 5 mm broadband probe for 1H and 13C experiments, and referenced 
to residual CHCl3 (7.24 and 77.0 ppm, for 1H and 13C, respectively). 13C NMR spectra 
were not collected for compounds < 1.0 mg due to inadequate sensitivity. In these 
cases, structures were determined by analysis of 1H NMR and high-resolution mass 
spectra and comparison to the 33 previously identified natural products for which 
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extensive 1- and 2D NMR spectral data were available, since synthetic modifications 
occurred at positions throughout the macrocycle for which well-resolved 1H NMR 
chemical signals were apparent. High-resolution mass spectra were generated using 
electrospray ionization with an Applied Biosystems QSTAR-XL hybrid Quadrupole-Time-
of-Flight tandem mass spectrometer and Analyst QS software in the mass spectral 
facilities at Georgia Institute of Technology. LC-MS analyses were conducted using a 
Waters 2695 HPLC with Waters 2996 photodiode array UV detection and Micromass ZQ 
2000 mass spectrometer with electrospray ionization. LC-MS chromatography was 
achieved with an Alltech Alltima C18 (3 µm, 2.1 × 150 mm) column, using gradient mobile 
phases of aqueous acetonitrile with 0.1% acetic acid.   
18-O-acetyl-bromophycolide A (7). Acetic anhydride (10 µl, 108 µmol) was added 
dropwise to a solution of bromophycolide A (1) (1.0 mg, 1.5 µmol) in anhydrous pyridine 
(50 µl) and allowed to stir at rt for 4 h. The reaction was concentrated in vacuo and the 
product was purified by reversed-phase HPLC using a gradient of aqueous MeCN 
(Alltech Alltima C18, 10 × 250 mm, 5 µm) to yield 7 as a colorless oil (0.8 mg, 75%). 1H 
NMR (CDCl3, 500 MHz) δ: 8.08 (s, 1H); 7.93 (d, 1H, J = 10 Hz); 7.16 (d, 1H, J = 10 Hz); 
4.67 (dd, 1H, J = 5, 15 Hz); 4.46 (t, 1H, J = 7.5 Hz); 3.48 (dd, 1H, J = 5, 15 Hz); 3.41 (d, 
1H, J = 20 Hz); 3.17 (d, 1H, J = 20 Hz); 2.25-2.29 (m, 2H); 2.22 (s, 3H); 1.85-2.18 (m, 
7H); 1.81 (s, 3H); 1.8 (s, 3H); 1.68-1.78 (m, 3H); 1.38 (s, 3H); 1.29 (s, 3H); 1.26 (s, 3H); 
1.08 (m, 1H). HRESIMS: [M + H]+ m/z 705.0467 (calcd for C29H40Br3O5, 705.0425); [M + 
Na] m/z 727.0170 (calcd for C29H39Br3O5Na, 727.0245). 
18-methoxy-bromophycolide A (8). A solution of 1 (3.0 mg, 4.5 µmol) in THF (50 µl) 
was added dropwise to a suspension of sodium hydride (60% dispersion in mineral oil 
pre-washed with Et2O, 0.54 mg, 14 µmol) in THF (150 µl) at 0 ºC. The mixture was 
stirred for 30 min at the same temperature. Methyl iodide (27 µl of a 0.5 M solution in 
THF) was added dropwise to the solution at 0 ºC and the resulting mixture was stirred for 
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7 h at rt. Saturated NH4Cl (aq) was added to the solution at 0 ºC, followed by extraction 
with EtOAc (3 × 300 µl). The combined organic layers were washed with brine, dried 
over MgSO4, and evaporated in vacuo. Purification of the product by reversed-phase 
HPLC using a gradient of aqueous MeOH (Zorbax C18, 9.4 × 250 mm, 5 µm) yielded 8 
as a colorless oil (2.5 mg, 81%). 1H NMR (CDCl3, 500 MHz) δ: 7.95 (s, 1H); 7.92 (d, 1H, 
J = 10 Hz); 6.89 (d, 1H, J = 10 Hz); 4.65 (dd, 1H, J = 5, 10  Hz); 4.48 (dd, 1H, J = 5, 12 
Hz); 3.93 (s, 3H); 3.44 (m, 1H); 3.42 (d, 1H, J = 18 Hz); 3.21 (d, 1H, J = 18 Hz); 2.22-
2.33 (m, 3H); 1.84-2.17 (m, 7H); 1.82 (s, 3H); 1.81 (s, 3H); 1.68-1.80 (m, 3H); 1.38 (s, 
3H); 1.30 (s, 3H); 1.27 (s, 3H); 1.07 (m, 1H). 13C NMR (CDCl3, 125 MHz) δ: 165.9, 
161.4, 133.1, 130.6, 130.4, 130.0, 127.5, 121.0, 109.7, 80.4, 73.9, 72.4, 67.3, 61.1, 55.6, 
43.5, 37.6, 34.3, 33.7, 33.6, 31.6, 31.0, 30.5, 29.5, 28.6, 28.3, 26.1, 21.0. HRESIMS: [M 
+ H]+ m/z 677.0404 (calcd for C28H40Br3O4, 677.0477). 
11, 18-dimethoxy-bromophycolide A (9). A solution of 8 (2.0 mg, 3.0 µmol) in THF (25 
µl) was added dropwise to a suspension of sodium hydroxide (60% dispersion in mineral 
oil pre-washed with Et2O, 0.48 mg, 12 µmol) in THF (50 µl) at 0 ºC. The mixture was 
stirred for 30 min and allowed to reach rt. Methyl iodide (25 µl of a 0.5 M solution in THF) 
was added dropwise to the solution at rt and the resulting mixture was stirred overnight. 
Saturated NH4Cl (aq) was added to the solution, followed by extraction with EtOAc (3 × 
200 µl). The combined organic layers were washed with brine, dried over MgSO4, and 
evaporated in vacuo. Purification of the product by reversed-phase HPLC using a 
gradient of aqueous MeOH (Zorbax C18, 9.4 × 250 mm, 5 µm) yielded 9 as a colorless oil 
(1.0 mg, 49%). 1H NMR (CDCl3, 500 MHz) δ: 7.94 (d, 1H, J = 10 Hz); 7.88 (s, 1H); 6.89 
(d, 1H, J = 10 Hz); 4.96 (dd, 1H, J = 7, 12  Hz); 4.50 (m, 1H); 3.93 (s, 3H); 3.62 (s, 3H); 
3.53 (d, 1H, J = 18 Hz); 3.34 (d, 1H, J = 18 Hz); 3.07 (dd, 1H, J = 5, 10 Hz); 2.47-2.55 
(m, 1H); 2.29 (m, 2H); 2.12-2.19 (m, 1H); 1.83-1.94 (m, 5H); 1.74 (s, 3H); 1.72 (s, 3H); 
1.51 (s, 3H); 1.32-1.42 (m, 3H); 1.16 (s, 3H); 0.89 (s, 3H). 13C NMR (CDCl3, 125 MHz) δ: 
 78
166.3, 161.6, 133.3, 131.8, 131.0, 130.1, 128.1, 120.6, 109.5, 78.6, 68.7, 65.2, 63.8, 
59.9, 55.5, 43.1, 39.9, 31.8, 30.9, 30.4, 29.3, 29.0, 28.1, 24.6, 24.5, 23.9, 20.7, 19.5, 
19.4. HRESIMS: [M + H]+ m/z 691.0584 (calcd for C29H42Br3O4, 691.0633). 
10-(S)-Cl-bromophycolide E (10). Lithium chloride (8 µl, 8.2 µmol, of a 1M solution in 
warmed DMF) was added dropwise to a solution of bromophycolide E (4) (1.6 mg, 2.7 
µmol) in DMF (100 µl) at rt. The reaction was allowed to stir at 70 ºC for 6 h. The 
reaction was allowed to cool and deionized H2O was added (0.5 ml) to the solution, 
followed by extraction with EtOAc (3 × 0.5 ml). The combined organic layers were 
washed with brine, dried over MgSO4, and evaporated in vacuo and the product was 
purified by reversed-phase HPLC using a gradient of aqueous MeOH (Zorbax C18, 9.4 × 
250 mm, 5 µm) to yield 10 as a white powder (0.13 mg, 8.8%). 1H NMR (CDCl3, 500 
MHz) δ: 7.83 (s, 1H); 7.68 (d, 1H, J = 10 Hz); 6.74 (d, 1H, J = 10 Hz); 5.38 (s, 1H); 5.26 
(br s –OH); 5.14 (m, 1H); 4.95 (s, 1H); 4.92 (s, 1H); 4.85 (s, 1H); 4.34 (dd, 1H, J = 5, 12 
Hz); 4.03 (d, 1H, J = 12 Hz); 3.12 (dd, 1H, J = 15, 20 Hz); 2.57 (d, 1H, J = 20 Hz); 2.47 
(m, 1H); 2.29-2.38 (m, 3H); 1.99-2.10 (m, 5H); 1.91 (m, 2H); 1.79 (s, 3H); 1.66-1.75 (m, 
3H); 1.37 (s, 3H); 0.96 (s, 3H). HRESIMS [M – H]- m/z 537.1283 (calcd for C27H35BrClO4, 
537.1407). 
∆9,10- ∆21,22-Bromophycolide A (11). Lithium chloride (3.8 mg, 90 µmol) was added to a 
solution of 1 (10 mg, 15 µmol) in DMF (1 ml) at rt. The reaction was allowed to stir at 70 
ºC for 6 h. The reaction was allowed to cool and deionized H2O was added (5 ml) to the 
solution, followed by extraction with EtOAc (3 × 5 ml). The combined organic layers were 
washed with brine, dried over MgSO4, and evaporated in vacuo and the product was 
purified by reversed-phase HPLC using a gradient of aqueous MeOH (Zorbax C18, 9.4 × 
250 mm, 5 µm) to yield 11 as a white powder (0.1 mg, 1.3%). 1H NMR (CDCl3, 500 MHz) 
δ: 8.37 (s, 1H); 7.68 (d, 1H, J = 10 Hz); 6.74 (d, 1H, J = 10 Hz); 5.42 (m, 1H); 5.41 (m, 
1H); 5.11 (br s, –OH); 4.63 (m, 2H); 3.81 (dd, 1H, J = 8, 17 Hz); 3.65 (d, 1H, J = 20 Hz); 
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3.21 (d, 1H, J = 20 Hz); 2.51 (m, 2H); 1.92-2.10 (m, 5H); 1.74-1.82 (m, 1H); 1.45 (s, 3H); 
1.39 (s, 3H); 1.37 (s, 3H); 1.32 (s, 3H); 1.28 (s, 3H); 1.20 (m, 1H). HRESIMS [M – H]- 
m/z 501.1442 (calcd for C27H34BrO4, 501.1640). 
∆9,10- ∆21,22-Bromophycolide M (12). Lithium chloride (3.8 mg, 90 µmol) was added to a 
solution of 1 (10 mg, 15 µmol) in DMF (1 ml) at rt. The reaction was allowed to stir at 70 
ºC for 6 h. The reaction was allowed to cool and deionized H2O (5 ml) was added to the 
solution, followed by extraction with EtOAc (3 × 5 ml). The combined organic layers were 
washed with brine, dried over MgSO4, and evaporated in vacuo and the product was 
purified by reversed-phase HPLC using a gradient of aqueous MeOH (Zorbax C18, 9.4 × 
250 mm, 5 µm) to yield 12 as a white power (0.15 mg, 2.4%). 1H NMR (CDCl3, 500 MHz) 
δ:7.94 (s, 1H); 7.75 (d, 1H, J = 10 Hz); 6.75 (d, 1H, J = 10 Hz); 5.70 (br d, 1H, J = 10 
Hz); 5.33 (br d, 1H, J = 12 Hz); 5.14 (br s,–OH); 5.10 (br d, 1H, J = 10 Hz); 5.00 (s, 1H); 
4.89 (s, 1H); 4.61 (m, 1H); 3.62 (d, 1H, J = 18 Hz); 3.20 (d, 1H, J = 18 Hz); 2.64-2.78 (m, 
2H); 2.59 (m, 1H); 1.78 (s, 3H); 1.63-1.72 (m, 4H); 1.54 (s, 3H); 1.45 (s, 3H); 1.30-1.37 
(m, 2H); 1.24 (m, 1H); 1.13 (s, 3H). HRESIMS: [M – H]- m/z 421.2430 (calcd for 
C27H33O4, 421.2378). 
10-(S)-Cl-∆21,22-bromophycolide M (13). Lithium chloride (3.8 mg, 90 µmol) was added 
to a solution of 1 (10 mg, 15 µmol) in DMF (1 ml) at rt. The reaction was allowed to stir at 
70 ºC for 6 h. The reaction was allowed to cool and deionized H2O was added (5 ml) to 
the solution, followed by extraction with EtOAc (3 × 5 ml). The combined organic layers 
were washed with brine, dried over MgSO4, and evaporated in vacuo and the product 
was purified by reversed-phase HPLC using a gradient of aqueous MeOH (Zorbax C18, 
9.4 × 250 mm, 5 µm) to yield 13 as a white powder (2.0 mg, 29%). 1H NMR (CDCl3, 500 
MHz) δ: 8.01 (s, 1H); 7.79 (d, 1H, J = 8 Hz); 6.79 (d, 1H, J = 8 Hz); 5.77 (m, 1H); 5.46 (d 
1H, J = 10 Hz); 5.39 (br s, –OH); 5.30 (m, 1H); 5.00 (s, 1H); 4.88 (s, 1H); 3.85 (d, 1H, J = 
10 Hz); 3.49 (d, 1H, J = 17 Hz); 3.35 (d, 1H, J = 17 Hz); 2.75 (d, 1H, J = 22 Hz); 2.64 (d, 
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1H, J = 22 Hz); 1.90-2.02 (m, 3H); 1.77 (s, 3H); 1.63-1.75 (m, 5H); 1.51 (s, 3H); 1.23 (s, 
3H); 1.16 (s, 3H); 0.85 (m, 1H). 13C NMR (CDCl3, 125 MHz) δ: 165.5, 157.5, 143.1, 
135.3, 131.9, 130.8, 129.8, 129.3, 125.4, 122.6, 122.4, 115.0, 111.1, 76.2, 74.6, 72.2, 
40.7, 37.4, 33.7, 31.9, 30.2, 28.7, 28.3, 27.6, 26.6, 20.5, 18.9. HRESIMS [M – H]- m/z 
457.1126 (calcd for C27H34ClO4, 457.2145). 
Bromophycolide A ‘short-linker’ probe (15). N’-(3-dimethylaminopropyl)-N-
ethylcarbodiimide (EDC) (11 µl, 60 µmol) was added to a solution of 2,5-dioxopyrrolidin-
1-yl 2-(2-(7-(dimethylamino)-2-oxo-2H-chromen-4-yl)acetamido)acetate (14) (9.1 mg, 30 
µmol), 4-dimethylaminopyridine (DMAP) (6 µl, 6 µmol, of a 1M solution in DMF), and 1 (5 
mg, 7.5 µmol) in 3:2 DMF/CH2Cl2 (0.3 ml), followed by slow addition of N,N-
diisopropylethylamine (EtNiPr2, 20 µl). The reaction was allowed to stir at rt for 24 h and 
then was quenched with saturated NaHCO3 solution (0.5 ml). The solution was extracted 
with EtOAc (3 × 0.75 ml). The combined organic layers were washed with brine, dried 
over MgSO4, and evaporated in vacuo and the product was purified by reversed-phase 
HPLC using a gradient of aqueous MeCN and 0.2% TFA (Alltech Alltima C18, 10 × 250 
mm, 5 µm) to yield 15 (1.6 mg, 22%). 1H and 13C NMR data table provided in Appendix 
A. HRESIMS: [M + H]+ m/z 949.1286 (calcd for C42H52Br3N2O8, 949.1274). 
IAF tag 16. A three-step process was used to prepare tag 16. HATU (570 mg, 1.5 mmol) 
was added to a solution of 7-dimethylamino-4-coumarin acetic acid (247.2 mg, 1 mmol) 
and EtNiPr2 (0.42 ml, 3 mmol) in anhydrous DMF (3 mL). After 1 h at rt, N-Boc-1,4-
diaminobutane (225.3 mg, 1.2 mmol) in anhydrous DMF (1 ml) was added and the 
mixture was stirred for 4 h at rt. The contents were dried via rotary evaporation. The 
crude product was suspended in DCM (10 ml) and applied to a Dry Column Vacuum 
Chromatography (DCVC) column containing 80 g of Silica Gel (15–40 µm Silica Gel 60 
from EM Sciences) and eluted with 5% MeOH in EtOAc. Drying via rotary evaporation 
provided the Boc-protected amide (395.2 mg) along with approximately 10% of 7-
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dimethylamino-4-methylcoumarin (a product of the decarboxylation of 7-dimethylamino-
4-coumarin acetic acid). This mixture was then dissolved in dry CH2Cl2 (10 ml) using 
ultrasonification and treated with TFA (2 ml) at rt. TLC analysis showed clean removal of 
the Boc protecting group within 4 h. The resulting mixture was dried by the flow of Argon 
and the residue was rotary evaporated twice from EtOAc (20 ml) and toluene (10 ml) 
and then dissolved in anhydrous DMF (5 ml) containing EtNiPr2 (0.84 mL, 6 mmol). Solid 
succinic anhydride (250.1 mg, 2.5 mmol) was added and the mixture was stirred at rt. 
After 12 h, the mixture was dried via rotary evaporation and 16 was obtained by silica 
flash chromatography using a gradient consisting of 2:1 hexanes:EtOAc, 1:1 
hexanes:EtOAc, EtOAc, 1:10 MeOH:EtOAc and 1:5 MeOH:EtOAc. Tag 16 (317.1 mg, 
76%) was obtained as a light yellow powder after evaporation of selected fractions. 1H 
NMR (DMSO-d6, 400 MHz) δ: 12.05 (br s, –OH); 8.18 (t, –NH, J = 5.3); 7.81 (t, –NH, J = 
5.5); 7.52 (d, 1H, J  = 9.0); 6.72 (dd, 1H, J  = 2.3, 9.0); 6.54 (d, 1H, J  = 2.3); 5.98 (s, 
1H); 3.57 (s, 2H); 3.05 (m, 4H); 3.00 (s, 6H); 2.40 (t, 2H, J  = 7.1); 2.27 (t, 2H, J  = 7.0); 
1.37 (m, 4H). 13C NMR (DMSO-d6, 100 MHz) δ: 173.9, 170.7, 167.6, 160.7, 155.4, 
152.8, 151.4, 126.0, 109.4, 109.0, 108.2, 97.5, 38.5, 38.2, 30.0, 29.2, 26.6, 26.4. ESIMS 
[M + H – H2O]+ m/z 400.43; [M + H]+ m/z 418.43; [M + Na] m/z 440.41; [M – H]- m/z 
416.50. 
Bromophycolide A ‘long-linker’ probe (17). EDC (15 µl, 81 µmol) was added to a 
solution of 4-(4-(2-(7-(dimethylamino)-2-oxo-2H-chromen-4-yl)acetamido)butylamino)-4-
oxobutanoic acid (16) (11 mg, 27 µmol), DMAP (10 µl, 10 µmol, of a 1M solution in 
DMF), and 1 (4.5 mg, 6.8 µmol) in 3:2 DMF/CH2Cl2 (0.3 ml), followed by slow addition of 
EtNiPr2 (20 µl). The reaction was allowed to stir at rt for 24 h and then was quenched 
with saturated NaHCO3 solution (0.5 ml). The solution was extracted with EtOAc (3 × 
0.75 ml). The combined organic layers were washed with brine, dried over MgSO4, and 
evaporated in vacuo and the product was purified by reversed-phase HPLC using a 
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gradient of aqueous MeCN and 0.2% TFA (Alltech Alltima C18, 10 × 250 mm, 5 µm) to 
yield 17 (2.1 mg, 29%). 1H and 13C NMR data table provided in Appendix A. HRESIMS: 
[M + H]+ m/z 1062.2021 (calcd for C48H63Br3N3O9, 1062.2114). 
Parasite culture. 3D7, HB3 and Dd2 P. falciparum malaria parasites (MRA-102, 155, 
156, MR4, ATCC® Manassas, Virginia) were cultured in human type O+ erythrocytes in 
complete medium (RPMI 1640, 0.043 mg/ml gentamicin (Gibco), 0.014 mg/ml 
Hypoxanthine (Acros), 38.5 mM HEPES (Sigma), 0.18% sodium bicarbonate (Gibco), 
0.20% glucose (MP Biomedical), 2.57 mM NaOH (Sigma), 0.21% albumax (Gibco), and 
4.3% human serum as previously described.127 Cultures were maintained in 25 cm2 cell 
culture treated flasks (Corning) at a volume of 10 ml and were gassed for 30 s with an 
environment of 3% CO2, 1% O2, and 96% N2, then incubated at 37 °C. Synchronization 
of culture was achieved through sorbitol lysis of mature stage using 5% sorbitol (Fisher) 
and fine tuned by another lysis 8 h later. 
Growth inhibition assay with Plasmodium falciparum. Antimalarial activity was 
determined with a SYBR Green based parasite proliferation assay, adapted from 
Smilkstein125 and Bennett.126 P. falciparum parasites were cultured in human O+ 
erythrocytes as described in the previous section. Compounds were diluted in complete 
medium and 40 µl transferred to 96-well assay plates. To this, 80 µl of complete media 
with malaria infected erythrocytes were dispensed in each well, with final assay 
percentages at 2.5% hematocrit and 0.5% parasitemia. Uninfected erythrocytes were 
added to the background wells at the same final hematocrit percentage. Plates were 
incubated for 72 h in a low oxygen environment (96% N2, 3% CO2, 1% O2) in a modular 
incubation chamber. The plates were sealed and placed in a -80 oC freezer overnight 
then thawed, and 120 µl of lysis buffer (20 mM Tris-HCl, pH 7.5, 5 mM EDTA, 0.08% 
Triton X-100, 0.008% saponin with 0.2  µl/ml Sybr Green I (Invitrogen)) was dispensed 
into each well and incubated at 37 oC in the dark for 6 h. Fluorescence of each well was 
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read with a Molecular Devices SpectraMAX Gemini EM at excitation: 495 nm, emission: 
525 nm with 515 nm cut-off.  
Fluorescence microscopy 
Live cell confocal imaging. Samples were prepared in optical bottom 96-well assay 
plates (Costar #3614, Corning, NY). Parasite cultures were diluted to 0.025% hematocrit 
and 6% parasitemia in complete medium and 240 µl was added to each well. Probe 15 
was incubated with samples for 1 h at 37°C, in the dark at a final concentration of 2 µM. 
The BD Pathway HT (BD Biosciences Bioimaging, Rockville, MD) incubation chamber 
was set at 37 °C and 5% CO2.  
Confocal microscopy with fixed cells. Mixed-stage or synchronized P. falciparum 
cultures at 6-8% parasitemia were incubated with 2 µM probe 15 or control probes 14a 
or 14b for 1 h at 37 ºC. The following conditions were used for the sub-cellular labeling 
of parasites: 50 nM Lysosensor Green 189 for 1 min; 70 nM DAPI for 10 min; 1 µM 
ERTracker Green for 30 min, 500 nM MitoTracker Red 580 for 1 h, 500 nM BODIPY 
505/515 for 30 min or 30 nM Nile Red for 10 min. All stains were diluted fresh into 
complete medium and incubated at 37ºC. Following incubation, infected red blood cells 
were washed in complete medium and 7 µl of the resulting thick pellet was added onto a 
glass slide and allowed to dry in the dark. After drying, samples were fixed using 4% 
paraformaldehyde for 20 minutes at room temperature before mounting. Images were 
obtained using a Leica TCS SP2 confocal microscope (Leica Microsystems Inc., 
Bannockburn, IL). 
Heme-1 UV-VIS spectroscopic analyses 
Spectroscopic analyses were performed similar to those reported in Egan & Ncokazi.152 
A stock solution of porcine hemin (Sigma) was made (0.0012 M) using molecular grade 
DMSO and stored in the dark. Working Fe(III)PPIX solutions (2.0 × 10-6 M) were 
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prepared fresh by mixing 16 µl of stock hemin solution with 4 ml DMSO and 1 ml of 
Hepes buffer (0.2 M, pH 7.4) and making the final volume up to 10 ml with Optima grade 
H2O. These working solutions were adjusted to pH 7.4. Next, 150 µl of working solution 
(40% DMSO, 20 mM HEPES buffer, pH 7.4) was added to each well in a Corning 
Costar® black, clear bottom 96-well assay plate (Promega). Blank wells contained either 
40% DMSO, 20 mM HEPES buffer, pH 7.4 without hemin or 40% DMSO, 20 mM 
HEPES buffer, pH 7.4 with bromophycolide A (1) and no hemin. Bromophycolide A (1) 
was added to wells containing hemin in 3 µl DMSO at various concentrations, ranging 
from 0.5-20 molar equivalents (mol eq) of 1 to 1 mol eq of hemin. UV-VIS spectroscopic 
analyses were performed with a BioTek Synergy 4 multi-mode microplate reader at 37 
ºC in the dark. Absorbance spectra were collected from 350-700 nm with 1 nm steps at 
time = 15 min, 1 h, 2 h, 4 h, 6 h, and 8 h, with 3 replicates for each heme:drug (1) 
concentration. Spectra were corrected for dilution by subtracting a reference cell at each 
concentration of 1.  
Heme crystallization inhibition assay 
Heme crystallization inhibition assays were performed as previously described.144-145 
Briefly, 30 µl of a 0.3 mM solution of hemin in 0.1 M NaOH was added to rows B-H in a 
round-bottom 96-well microtiter plate, and 50 µl of the 0.3 mM hemin solution was added 
to row A. Amodiaquine and DMSO were used as positive and negative controls, 
respectively. Controls, 1, or 7 were added to wells in row A in 10 µl DMSO (starting 
concentration of either 6, 5, or 4 mol eq relative to hemin) and serial diluted by half down 
each column, discarding 30 µl from the final row. Next, 10 µl of a 9.8 M sodium acetate 
solution (pH 4.8) was added to each well, and the plate was incubated for 2 h at 60 ºC. 
After cooling for 15 min, 75 µl of a 14% (v/v) pyridine solution in 20 mM Hepes (pH 7.5) 
was added to each well and the plate was centrifuged at 2000 rpm for 1 min. Next, 50 µl 
of each supernatant was transferred into a flat-bottom 96-well plate and the absorbance 
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was measured at 405 nm using a microplate reader. The IC50 of each compound was 
calculated using the dose concentration at 50% inhibition on a sigmoidal dose response 
curve generated using GraphPad Prism version 4.00 for Windows. 
Immunoprecipitation with P. falciparum cell lysates 
A 0.15% saponin solution was used to lyse erythrocytes and isolate parasites, and 
samples were washed twice with PBS. Parasite pellet was incubated on ice for 5 
minutes in cytoplasmic lysis buffer (20 mM HEPES pH 7.9, 10 mM KCl, 1 mM EDTA, 1 
mM EGTA, 1 mM DTT, 0.5 mM PMSF, 0.65% Igepal, 1x Roche cocktail inhibitor tablet). 
Samples were centrifuged at 1500 g for 10 min at 4 ºC, supernatant was collected, and 
the resulting pellet was re-suspended with nucleus lysis buffer (20 mM HEPES pH7.9, 
0.1 M NaCl, 0.1 mM EDTA, 0.1 mM EGTA, 1.5 mM MgCl2, 1 mM DTT, 25% glycerol, 1 
mM PMSF, 1x Roche cocktail inhibitor tablet) and incubated for 20 min at 4 ºC. After 
centrifugation at 6000 g for 10 min at 4 ºC, the supernatant was collected and combined 
with cytoplasmic proteins. The remaining pellet was sonicated in cytoplasmic lysis buffer, 
centrifuged, and then all supernatants were combined. The total protein concentration 
was determined to be 5 mg/ml total protein by Bradford analysis. Probe 15 or 17 (2 µM 
or 20 µM) was added to lysates for 1 or 4 h and incubated at 4 ºC with constant rotation. 
Next, 50 µl of Affigel 10 resin containing 3.5 mg/ml of the XRI-TF35 mAb was added to 
the probe/lysate mixture for an additional 2 h or 14 h with agitation at 4 ºC. As negative 
controls, tag 14a (2 µM), 14b (2 µM), or 0.7% DMSO was added to lysates. Samples 
were then washed with wash buffer (0.5% Tritonx-100, 25 mM Tris-HCl pH 7.5, 150 mM 
NaCl, 2 mM EDTA, 2 mM PMSF, 1x Roche cocktail inhibitor tablet) three times. Proteins 
were either eluted from the resin by incubation with 35 µl of 1 mg/ml of 14a in RIPA 
buffer for 1 h at rt, or laemmli buffer was added directly to samples and boiled for 5 min 
at 100 ºC to elute proteins. Proteins were resolved by 16% SDS-PAGE and detected 
with Coomassie stain or Silver stain. All SDS-PAGE images of varying 
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ANTIBACTERIAL NEURYMENOLIDES FROM THE FIJIAN RED ALGA 
NEURYMENIA FRAXINIFOLIA 
 
 α-Pyrone-containing natural products have been found in bacteria, fungi, plants, 
and animals, and exhibit a wide range of biological activities, such as antimicrobial, 
antineoplastic, and anti-HIV effects.153 Despite the abundance of α-pyrone analogs in 
nature, only one species, the red alga Phacelocarpus labillardieri, has previously been 
reported to produce macrocyclic α-pyrones.154 Herein we report the discovery of two 
novel macrocyclic α-pyrones, neurymenolides A (1) and B (2), the first report of natural 
products from the red alga Neurymenia fraxinifolia (Figure 5.1). 
 Extracts of N. fraxinifolia collected from Taveuni, Fiji were first separated by 
reversed-phase column chromatography guided by growth-inhibitory effects against 
methicillin-resistant Staphylococcus aureus (MRSA). Following reversed-phase, normal-








Figure 5.1. Novel natural products from N. fraxinifolia, neurymenolides A and B (1 and 
































 Neurymenolide A (1) displayed an [M+H]+ m/z of 369.2428 by HRESIMS, 
suggesting a molecular formula of C24H33O3. Analysis of 1H, 13C, DEPT NMR, and IR 
spectra indicated six carbon-carbon double bonds, one carbonyl, and based upon the 
index of hydrogen deficiency, two rings (Table 5.1). Three quaternary carbons displayed 
13C NMR chemical shifts at 164.7-165.1 ppm, supporting the presence of one ester 
group (IR 1680 cm-1) and two aromatic carbinol carbons, accounting for all three oxygen 
atoms. These data and UV spectrophotometric properties of 1 (λmax = 295 nm) were 
consistent with the literature on hydroxyl-substituted α-pyrones.154b, 155 HMBC 
correlations from the aromatic hydroxyl proton (δ 6.48) to C-3 (δ 164.7) and C-4 
(δ 101.4), as well as correlations from H-4 (δ 5.81) to C-2 (δ 103.9), C-6 (δ 33.5), and C-
1 (δ 165.1) and/or C-5 (δ 165.1), confirmed the hydroxy-substituted α-pyrone ring (Figure 
5.2; Appendix A). Additional 2D NMR spectral data led to the identification of a 
macrocyclic ring connected via the pyrone system by C-5–C-6 and C-2–C-17 bonds, 
with H-17 (δ 4.55) coupled to C-2 and H-6 coupled to C-5 in the HMBC spectrum (Figure 
5.2). Double bonds within the macrocycle were assigned at ∆12,13 (δ 131.0, 126.6) and 
∆15,16 (δ 135.2, 127.0) based upon COSY correlations between olefinic protons and 
adjacent methylenes (Figure 5.2). Finally, the unsaturated 7-carbon aliphatic chain at C-













Table 5.1.  13C and 1H NMR spectral data for 1 and 2 (500 MHz; in CDCl3). 
 
1 2 
δ 13C δ 1H  
(JH,H) 
δ 13C δ 1H  
(JH,H) 
1 165.1 - 165.0 - 
2 103.9 - 103.8 - 
3 164.7 - 164.3 - 
4 101.4 5.81 s 101.2 5.77 s 
5 165.1 - 165.0 - 
6 33.5 2.30 ddd (14, 
11, 3.3), 2.61 
ddd (14, 10, 
3.1) 
33.3 2.26 ddd (15, 11, 
3.2), 2.63 ddd (15, 
11 3.4) 
7 25.6 1.57 m, 1.86 m 24.6 1.49 m, 1.82 m 
8 26.9 1.24 m, 1.34 m 25.2 1.15 m, 1.22 m 
9 27.7 1.18 m, 1.35 m 27.1 1.08 m, 1.25 m 
10 27.1 1.07 m, 1.15 m 29.7 1.24 m, 1.30 m 
11 26.6 1.76 m, 1.83 m 28.7 1.18 m, 1.23 m 
12 131.0 5.23 m 26.7 1.20 m, 1.27 m 
13 126.6 5.21 m 27.6 1.88 m, 2.01 m 
14 27.0 2.52 br d (17), 
2.85 m 
131.3 5.34 m 
15 135.2 5.65 m 126.4 5.32 m 
16 127.0 5.64 m 26.8 2.63 m, 2.94 m 
17 36.5 4.55 br s 134.9 5.60 m 
18 129.4 5.61 m 127.0 5.67 m 
19 129.9 5.61 m 36.2 4.61 br s 
20 30.0 2.77 m 129.9 5.62 m 
21 125.9 5.30 dt (11, 7.2) 130.4 5.62 m 
22 132.9 5.42 dt (11, 7.2) 35.3 2.71 m 
23 20.5 2.00 p (15, 7.4) 126.8 5.33 m 
24 14.2 0.93 t (7.4) 133.5 5.43 m 
25 - - 25.5 1.99 m 
26 - - 13.8 0.94 t (7.5) 
OH - 6.48 br s - 6.40 br s 
br=broad; s=singlet; d=doublet; dd=doublet of doublets; t=triplet; m=multiplet 
 
 Due to substantial chemical shift overlap in the olefinic region of the 1H NMR 
spectrum of 1, E/Z stereochemistry could not be assigned using J couplings. Instead, 
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ROESY NMR spectral data for well resolved allylic protons were used (Figure 5.2). 
NOEs were observed between H-11b (δ 1.83) and both H-14s (δ 2.52, 2.85), suggesting 
a Z configuration at ∆12,13. Similarly, correlations between both H-14s and H-17 implied a 
Z configuration at ∆15,16. No NOEs were observed between H-17 and H2-20 (δ 2.77), 
suggesting an E configuration at ∆18,19. Finally, NOEs between H2-20 and H2-23 (δ 2.00) 
were evident, supporting a Z configuration at ∆21,22. We were unable to assign the 







Figure 5.2. Key COSY (bold) and HMBC (red single-headed arrow) correlations 
established the macrocyclic α-pyrone system of neurymenolide A (1). NOE correlations 
(blue double-headed arrows) established the configurations of the double bonds in 1. 
 
 High-resolution mass spectral data indicated that neurymenolide B (2) possessed 
two additional methylene units relative to 1, displaying an [M+H]+ m/z 397.2765, 
consistent with a molecular formula of C26H37O3. Comparison of 1H and 13C NMR 
spectral data of 2 with that of 1 suggested that the α-pyrone and linear aliphatic systems 
were identical. The two extra methylenes were assigned in the macrocyclic ring, based 
on a combination of COSY and HMBC correlations (Appendix A). Equivalent NOEs were 
observed for 1 and 2, suggesting that the E/Z stereochemistry is identical for both 













 HPLC purification of 1 using several different stationary phases consistently 
resulted in two peaks, each of which split again into the same two peaks when re-
analyzed using the same HPLC column. NMR spectral and optical rotation data were 
identical for material collected from each of these peaks, which led to the hypothesis that 
1 consists of quickly interchanging rotational isomers (atropisomers). Synthetic reports of 
related compounds suggest planar chirality due to the restricted rotation about the α-
pyrone ring.156 Because 1 contains a stereogenic carbon (C-17), these two atropisomers 
would be expected to behave as diastereomers. To further explore this hypothesis, 1 
was acetylated to yield 3-O-acetylneurymenolide A, separated by HPLC, and then 
analyzed by 1H NMR spectroscopy. The added bulk of the acyl group slowed the rotation 
about the α-pyrone enough to yield two distinguishable sets of 1H chemical shifts and 
two HPLC peaks that equilibrated over the course of several hours, rather than the 
minute time-scale conversion observed for atropisomers of 1. Rotational isomerization 
was not observed with 2, which is reasonable given the larger macrocyclic ring size of 2 
relative to 1. 
 The two unique macrolides described in this study each represent new carbon 
skeletons and only the second example of macrocyclic α-pyrones occurring in nature. 
Macrocyclic pyrones isolated from Phacelocarpus labillardieri (e.g., 3; Figure 5.1) are 
connected through an ether bond at C-3, unlike the neurymenolides. However, all of 
these macrocyclic pyrones would be expected to share a common biogenesis. Given the 
similar chemistry of N. fraxinifolia and P. labillardieri, it is interesting to note that the two 
red algal species are only distantly related, sharing the class Florideophyceae. This is 
the first report of chemistry from the red alga N. fraxinifolia, although its family, 
Rhodomelaceae, is well studied.29  
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 The biosynthesis of the neurymenolides is expected to occur by successive 
condensations of malonyl-CoA, beginning at the aliphatic chain terminus and ending at 
the α-pyrone carbonyl. These natural products may be formed by a mixed 
polyketide/fatty acid biosynthetic pathway,35 with previous such examples reported 
involving both prokaryotes and eukaryotes.157 One could envision the neurymenolides 
arising from diketide extention of eicosapentaenoic acid or docosahexaenoic acid, with 
macrocyclization promoted by an enolate attack with loss of water (Scheme 5.1); 
however, it is unclear whether the macrocyclization or the α-pyrone formation occurs 
first. The E configuration at ∆18,19 could potentially occur through a free radical process 
common to eicosanoids.35  
 
 
Scheme 5.1. Proposed biosynthesis of neurymenolide A (1) from a putative polyketide-
extended eicosapentaenoic acid-derived precursor.  
  
 Neurymenolide A (1) exhibited moderately potent activity against methicillin-
resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus 
faecium (VREF) (IC50 of 2.1 µM and 4.5 µM, respectively, Table 5.2). Moderate in vitro 
cytotoxicity against DU4475 breast tumor cells was also observed for 1 (IC50 of 3.9 µM), 





















ranging from 5.4 to 28 µM, Table 5.3).  Neurymenolide B (2) was slightly less active 
against MRSA and considerably less active in all other pharmacological assays (Table 
5.2 and 5.3), suggesting that the size or conformational restriction of the macrocyclic ring 
is important for biological activity. 3-O-acetylneurymenolide A (mixed atropisomers) was 
also less active against MRSA (IC50 of 11 µM), signifying the importance of the aromatic 
hydroxyl group for antibacterial activity.  
 
Table 5.2. Antibacterial activities of 1-2. 
 antibacterial IC50 (µM) 
cmpd MRSA VREF M. tuberculosis 
1 2.1 4.5 >100 
2 7.8 31 >100 
 
 
Table 5.3. Additional pharmacological activities of 1-2. 
  anticancer IC50 (µM)  




1  8.8 3.9 68 >680 
2  39 19 >100 >680 
  a Mean of 12 cell lines; b breast tumor cell line 
  
 The current study describes structurally novel macrocyclic α-pyrones, 
establishing the first report of chemistry from the red alga Neurymenia fraxinifolia. 
Determining 1 to be present as interchanging atropisomers presented an exciting 
chemical challenge, and the putative polyketide/fatty acid biogenesis of the 
neurymenolides represents another example of the diversity of the acetogenic pathway. 
Neurymenolide A (1) shows promise as a novel template for the design and 




Biological material. Neurymenia fraxinifolia (family Rhodomelaceae, order Ceramiales, 
class Florideophyceae, phylum Rhodophyta) was collected at depths of 20-25 m from 
Taveuni, Fiji, offshore from Waitabu Marine Protected Area near Lavena Village (16o 48’ 
97” S, 179o 50’ 84” W) in July 2006. N. fraxinifolia was stored at -60 oC until extraction 15 
months later. One sample was placed directly in methanol and stored until further 
analysis. One voucher specimen (G-0086) was deposited at the University of the South 
Pacific, Fiji, and the second was stored at Georgia Institute of Technology. 
Chemicals. Solvents used for extractions were reagent grade, and those used for HPLC 
and LC-MS were HPLC or Optima grade (Fisher Scientific). NMR solvents were 
purchased from Cambridge Isotope Laboratories. Commercially available reagents were 
purchased from Sigma-Aldrich (Milwaukee, WI) and used as received. 
Isolation. N. fraxinifolia was exhaustively extracted with methanol and 
methanol/dichloromethane (1:1, 1:2). The extracts were combined, filtered, and reduced 
in vacuo. The crude extract was separated with HP20ss resin into four fractions, eluting 
with (1) 1:1 methanol: water, (2) 4:1 methanol: water, (3) 100% methanol, and (4) 100% 
acetone. The antibacterial HP20ss fractions 3 and 4 were separated by C18 reversed-
phase HPLC (Alltech Alltima C18, 5 µm, 10 × 250 mm) using a gradient of methanol and 
water, followed by normal phase silica gel HPLC (Agilent Zorbax RX-SIL, 5 µm, 9.4 × 
250 mm) with 85:15 hexanes: ethyl acetate to yield neurymenolides A and B (1-2). 
Because 1 appeared to isomerize on normal phase silica gel, separation by chiral HPLC 
(Astec Chirobiotic T, 5 µm, 4.6 × 250 mm) was attempted with 78:12 hexanes: ethyl 
acetate; again, 1 eluted as two peaks. When the material from each peak was reinjected 
onto the chiral column, the same two peaks consistently reappeared. The two HPLC 
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peaks from 1 were stored separately under N2 at -80 oC, along with 2, until 
characterization and pharmacological testing was conducted.  
Acetylation of neurymenolide A (1). To a solution of 1 (10 mg, 0.027 mmol) in pyridine 
(0.5 ml) was added acetic anhydride (20 µl, 0.21 mmol) under a nitrogen atmosphere. 
The reaction was stirred at room temperature for 12 h and then diluted with cold water 
(10 ml) and extracted with ethyl acetate (10 ml). The organic layer was dried over 
MgSO4 and evaporated. The residue was separated via reversed-phase HPLC (Alltech 
Alltima C18, 5 µm, 10 × 250 mm), eluting with 100% acetonitrile, yielding 9.8 mg (88% 
yield) of 3-O-acetylneurymenolide A, acetylated atropisomers of 1. The two atropisomers 
were present in a 3:2 ratio, based on HPLC-UV peak integration and 1H NMR spectral 
integration. Only 1H chemical shifts differing from that of 1 (Table 5.1) are listed. 1H-NMR 
(CDCl3, 500 MHz) for major atropisomer δ: 5.98 (H-4, s); 4.49 (H-17, br s); 2.80 (H-14b, 
m); 2.72 (H2-20, m); 2.43 (H-14a, br d, J = 17); 2.21 (H3-26, s) ppm. 13C-NMR (CDCl3, 
250 MHz) for major atropisomer δ: 166.6; 164.2; 163.7; 158.5; 132.5; 130.2; 130.0; 
129.8; 129.4; 129.3; 127.2; 126.3; 117.3; 103.7; 37.1; 33.7; 30.0; 27.2; 27.1; 26.9; 26.4; 
26.2; 25.5; 21.2; 20.5; 14.2 ppm. 1H-NMR (CDCl3, 500 MHz) for minor atropisomer δ: 6.0 
(H-4, s); 4.14 (H-17, m); 2.80 (H-14b, m); 2.72 (H2-20, m); 2.43 (H-14a, br d, J = 17); 
2.34 (H3-26, s) ppm. 13C-NMR (CDCl3, 250 MHz) for minor atropisomer δ: 167.1; 165.0; 
162.1; 157.2; 132.6; 130.1; 129.8; 129.7; 129.4; 129.4; 127.5; 126.3; 116.9; 102.5; 37.5; 
33.8; 30.0; 27.6; 27.4; 27.1; 26.9; 25.8; 25.5; 20.9; 20.5; 14.2 ppm. ESI-MS for both 
atropisomers [M + H]+ m/z 411.3, 100%, [M + H – COCH3]+ m/z 369.3, 15%. 
Analytical and spectroscopic methods. UV spectra were recorded in MeOH with a 
Spectronic 21D spectrophotometer using quartz cuvettes. Optical rotations were 
measured on a Jasco P-1010 spectropolarimeter with a 10 cm (8 ml) cell, with 
compounds dissolved in MeOH. Circular dichroism spectra were acquired on a Jasco J-
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810 spectropolarimeter and 1 mm pathlength cells were used. High-resolution mass 
spectra were generated using electrospray ionization with an Applied Biosystems 
QSTAR-XL hybrid Quadrupole-Time-of-Flight tandem mass spectrometer and Analyst 
QS software. LC-MS analyses were conducted using a Waters 2695 HPLC with Waters 
2996 photodiode array UV detection and Micromass ZQ 2000 mass spectrometer with 
electrospray ionization. LC-MS chromatography was achieved with an Alltech Alltima C18 
column (3 µm, 2.1 × 150 mm), using gradient mobile phases of MeCN (aq) with 0.1% 
acetic acid. NMR spectra were recorded on a Bruker DRX-500 instrument, using a 5 mm 
inverse detection probe for 1H, COSY, ROESY, HSQC, and HMBC experiments, and a 5 
mm broadband probe for 1H, 13C, and DEPT-135, and referenced to residual CHCl3 (7.24 
and 77.0 ppm, for 1H and 13C, respectively).   
Pharmacological assays. All pharmacological assays were performed as outlined in 
the Experimental Section of Chapter 3.  
Neurymenolide A (1): colorless oil (2.9 mg, 0.098% plant dry mass); [α]24D  -150 (c 0.02 
g/100 ml, MeOH); UV (ACN) λmax 295 nm (log ε = 3.39); IR (NaCl) νmax 3350 (br), 3010, 
2860, 2660, 1680, 1570, 1440, 1280, 1160, 970 cm-1; 1H and 13C NMR (CDCl3, 500 
MHz) data see Table 1; COSY, HMBC,  and NOE data, see Appendix A; HR ESI-MS [M 
+ H]+ m/z 369.2428 (calcd for C24H33O3, 369.2429).   
Neurymenolide B (2): colorless oil (1.0 mg, 0.013% plant dry mass); [α]24D  -240 (c 0.02 
g/100 ml, MeOH); UV (ACN) λmax 295 nm (log ε = 3.41); 1H and 13C NMR (CDCl3, 500 
MHz) data see Table 1; COSY, HMBC,  and NOE data, see Appendix A; HR ESI-MS [M 
+ H]+ m/z 397.2756 (calcd for C26H37O3, 397.2743). 
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CHAPTER 6 




 Sex steroids and their receptors have been well studied in vertebrate animals, 
but much less is known about the mechanisms by which they regulate physiology and 
behavior in invertebrates.158 Recent gene sequencing, bioinformatics, and protein 
synthesis approaches suggested that modern nuclear steroid receptors evolved from an 
ancient receptor which arose 0.6 to 1.2 billion years ago, before a common bilateral 
ancestor diverged into the deuterostomes and protostomes.159 This ancient receptor is 
postulated to have been activated by estrogen, the terminal product in steroid 
biosynthesis, with intermediates progesterone and testosterone acquiring uses as 
hormones later in evolutionary history.160 The discovery of estrogen receptor homologs 
in mollusks161 and annelids162 indicated that Lophotrochozoan lineages have not lost this 
type of hormone chemoreception, despite the use of non-androgen steroid hormones in 
Ecdyzoans (e.g., ecdysteroids in insects; dafachronic acids in C. elegans). Recently an 
estrogen-like receptor was identified in C.elegans,163 supporting the hypothesis that 
steroid receptors are ancient and widespread. In addition, progesterone activates non-
nuclear, membrane-associated receptors in vertebrates and invertebrates with impacts 
on behavior and reproduction.164 However, substantial gaps still remain in the 
phylogenetic distribution of sex steroid receptors in many invertebrates and their 
functions in sexual differentiation, development, reproduction, and behavior are unclear. 
 The invertebrate monogonont rotifer Brachionus manjavacas belongs to the 
Lophotrochozoa, one of the three major animal clades whose origin pre-dates the 
Cambrian period 543 million years ago.165 An essential attribute of monogonont rotifers 
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is their ability to reproduce both asexually and sexually. Although this flexible 
reproductive strategy is central to their evolutionary success, little is known about how 
reproduction is regulated in rotifers or the molecules involved in reproductive signaling in 
most non-arthropod invertebrates.166 
 The switch from asexual to sexual reproduction in B. manjavacas is triggered in a 
quorum sensing process by a secreted pheromone called the mixis-inducing protein.167 
N-terminal sequencing of 17 amino acids from the mixis-inducing protein established 
that this fragment was identical to a putative steroidogenesis-inducing protein reported 
from humans.168 This observation led to the hypothesis that steroid hormones may be 
involved in regulating sexual reproduction in B. manjavacas. We were also encouraged 
by the fact that the sex steroid receptor family is ancient, arising early in metazoan 
evolution.159 Genome-mining of a rotifer cDNA library led to the identification of a 799 
nucleotide sequence (GenBank accession FJ829246) with 60-80% homology to multiple 
membrane-associated progesterone receptors, including that of the sea urchin 
Strongylocentrotus purpuratus and several Drosophila species. The presence of a 
progesterone receptor in B. manjavacas led us to explore its role in endocrine signaling 













Figure 6.1. Progesterone (1), and a panel of probes including the IAF-labeled 
progesterone probe 2, an IAF-labeled control steroid probe 3, and a reactive steroid 
probe 4. 
 
 We designed and synthesized a molecular probe suitable for both histological 
analyses in live rotifers and subsequent protein isolation studies by immunoaffinity 
methods. By installing a 7-dimethylamino-4-coumarin tag,23 also called an 
immunoaffinity fluorescent (IAF) tag,146 onto progesterone (1), the resulting probe (2, 
Figure 6.1) could be used for both receptor imaging and in vitro isolation of a 
progesterone-binding receptor in B. manjavacas because of the availability of a selective 
monoclonal antibody (mAb) against the IAF tag. Incubation of live and dead rotifers with 
2 consistently resulted in its localization in reproductive organs, including the ovaries, 
vitellarium (yolk gland), oviduct, and egg in females, and the seminal vesicle, 
rudimentary gut, and sperm duct in males (Figure 6.2a). Eggs attached to females 









































Using the natural auto-fluorescence of the algal food Tetraselmis suecica (excitation at 
488 nm) to compare with localization of 2 (excitation at 375 nm), we confirmed that 2 
was not localizing in the digestive system as a result of ingestion (Figure 6.2b). 
Furthermore, male rotifers do not feed and lack stomachs, providing evidence that the 
staining of male reproductive organs is due to the membrane permeability of 2 rather 
than digestive absorption. 
 
 
Scheme 6.1. Synthesis of steroid probes. (a) Synthesis of IAF labeled progesterone 
probe 2. Reagents and conditions: a) N-boc-1,4,-butyldiamine, HATU, DMF, 89%; b) 
TFA, CH2Cl2, rt; c) 7-dimethylamino-4-coumarinacetic acid, EtNiPr2, HATU, DMF, 67% 
over two steps. (b) Synthesis of IAF labeled control probe 3. Reagents and conditions: a) 
N-boc-1,4-butanediamine, Et3N, HATU, DMF, 80%; b) TFA, CH2Cl2, rt; c) 7-
dimethylamino-4-coumarinacetic acid, Et3N, HATU, DMF, 52% over two steps. (c) 
















































































 The specificity of the rotifer progesterone receptor for progestin-like molecules 
was investigated. An IAF-labeled control steroid probe (3, Figure 1) was synthesized in a 
similar method as 2 (Scheme 6.1a), but using cholic acid as a starting material (Scheme 
6.1b). Imaging experiments with live rotifers resulted in a lack of localization of 3 or a dye 
control in the reproductive organs of either B. manjavacas females or males (Figure 
6.2a). These results suggest that the rotifer progesterone receptor exhibits strong 




Figure 6.2. Imaging studies with the rotifer Brachionus manjavacas. (a) Confocal 
fluorescence microscopic images depicting rotifers treated with 2 or 3. (b) Two-color 
confocal images showing a female rotifer fed Tetraselmis suecica then treated with 2; T. 
suecica autofluoresces in the red channel, and 2 fluoresces in the blue channel. Scale 
bars denote 100 µm. Blue and red fluorescence were collected with excitation at 375±10 
nm and emission at 458±10 nm and excitation at 488±10 nm and emission at 518±10 
nm, respectively. Organelles are noted by: vit = vitellarium (yolk gland); o = ovaries; ov = 
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oviduct; e = egg; sv = seminal vesicle; rg = rudimentary gut; st = stomach, and sd = 
sperm duct. 
 
 These observations led us to screen for the presence of steroid hormones in 
rotifers. B. manjavacas biomass was extracted and lipophilic (i.e., steroid-containing) 
fractions were subjected to normal-phase high performance liquid chromatography 
(HPLC). Three sterols were isolated in sufficient quantities for characterization, identified 
as campesterol (5) at 18 mg/g dry biomass, campesta-5,7-dien-3-β-ol (6) at 12 mg/g, 
and 5-α-campest-7-en-3-β-ol (7) at 4.1 mg/g (Figure 6.3). Campesterol (5) is a known 
plant sterol found in the green alga T. suecica, the food of B. manjavacas;169 thus, it was 
concluded that sterols 5-7 were of dietary origin. When rotifer extracts were screened 
using a progesterone enzyme immunoassay (EIA), we found that 1 was present at a 
concentration of 3.1 ng/g dry biomass. To further support these data, we analyzed 
partially purified rotifer extracts using LC-tandem mass spectrometry (LC-MS/MS) in 
multiple reaction monitoring mode and unequivocally showed that 1 was present at a 
concentration of 4.4 ng/g dry rotifer biomass, comparable to the progesterone EIA result. 
 
 
Figure 6.3. Steroids isolated from Brachionus manjavacas including campesterol (24R-
ergost-5-en-3β-ol, 5), campesta-5,7-dien-3-β-ol (6), and 5-α-campest-7-en-3-β-ol (7). 






structures. Campesterol was purchased as a 65:35 mixture of crystalline 24R-ergost-5-
en-3β-ol and 24S-ergost-5-en-3β-ol, distinguishable via 13C NMR spectroscopy. Carbon-
13 NMR spectral data was acquired for both the authentic standard and the isolated 
rotifer steroid. 13C NMR spectral data for the isolated rotifer steroid 5 were identical to 
24R-ergost-5-en-3β-ol 13C NMR chemical shifts, consistent with the hypothesis that 5-7 
were of dietary (algal) origin. Sterol 6 was identified by comparing spectrometric data to 
reported literature values. 
 
 We then applied an immunoprecipitation (IP) technique146 to screen for 
progesterone-binding proteins in crude lysates of B. manjavacas. Lysates were 
incubated with 2 and immunoprecipitated with an Affigel-Hz resin containing a mouse 
mAb engineered with affinity against the IAF tag. Two bands at approximately 70 and 82 
kDa were observed by SDS-PAGE over several repeated experiments (L2 and L3, 
Figure 6.4a). These bands were confirmed to arise from selective binding to 2 since the 




Figure 6.4. Immunoprecipitation (IP) of a rotifer progesterone receptor (PR). (a) SDS-
PAGE analysis depicting the IP of B. manjavacas lysate (L1) in the presence of 2 (L2-
L3). IP of lysates treated with 1 showed a reduction in the isolated proteins (L4). (b) 
Reactive probe 4 was designed to form a covalent adduct with a PR by formation of an 
amide with the side chain amine of a lysine residue. The resulting covalent adducts can 
be selectively identified using an anti-progesterone mAb (anti-P) and can be validated 
using an anti-progesterone receptor mAb (anti-PR). (c) Demonstration of 4 using 
mammalian MCF-7 cell lysates. Western blot analyses depicting the presence of a 100 
kDa protein in MCF-7 cell lysates incubated with 4. Comparable bands corresponding to 
the MCF-7 PR were identified after incubation with an anti-P mAb in L5 or an established 
anti-PR mAb in L6. (d) Western blot analysis of B. manjavacas lysate treated with 4 
showed a single major band at 82 kDa after treatment with 4 (L8-L9). This band could be 
ablated by the co-treatment with 1 (L7). Loading control was conducted with actin (A). 
 
 Tryptic-digest LC-MS/MS analyses were conducted on crude IP mixtures 
incubated with 2 and compared to crude lysates obtained without 2. Over three 
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repetitions, we identified two key tryptic fragments with m/z of 1239.57 and 1589.74 
appearing only in IP lysates treated with 2. Subsequent in-gel digestion gave 
comparable fragments m/z of 1239.12 and 1589.48 from the band at 82 kDa (PR, Figure 
6.4a). Analyses of the digested peptides indicated that these masses arose from the 
respective peptides EWEMQFLEK and DFYGPGGPYSVFAGR, as predicted by the 
nucleotide sequence of FJ829246, and were up to 92% identical to peptide sequences 
observed in related progesterone receptors. These data provided strong evidence for the 
presence of a progesterone receptor within B. manjavacas. 
 To further support this conclusion, we designed and synthesized a probe 
containing a reactive 7-aza-benzotriazole ester (4, Figure 6.1 and Scheme 6.1c), with 
the goal of covalently labeling the active site of a progesterone receptor through 
formation of an amide bond by displacement of the 7-aza-benzotriazole ester in 4 via 
nucleophilic side-chain residues proximal to the steroidal binding pocket of the receptor. 
This approach was validated by Western blot analysis of a human cell lysate (MCF-7), 
which delivered a band at 100 kDa when treated with 4 and developed with an anti-
progesterone mAb (anti-P mAb).  A comparable band corresponding to the MCF-7 
progesterone receptor was identified after staining with an established anti-progesterone 
receptor mAb (L5 and L6, Figure 6.4c), thereby confirming the assignment. Reactive 
probe 4 was presented to protein lysates prepared from whole B. manjavacas, which 
were then immunoprecipitated using the anti-P mAb to isolate proteins that bound to or 
were modified by 4 (Figure 6.4d). Over multiple repetitions, Western blot analyses 
identified a band at 82 kDa (L8 and L9, Figure 6.4d) corresponding to the rotifer 
progesterone receptor, which could be blocked by pre-treating the lysates with 1 (L7, 
Figure 6.4d). 
 The function of the rotifer progesterone receptor was explored using RNA 
interference (RNAi) by transfection of female rotifers with dsRNA representing a 507 bp 
 107
fragment of the progesterone receptor gene (FJ829246). Quantitative real-time PCR 
demonstrated a 62% decrease (n = 12) in expression of this gene relative to phosphate 
buffered saline (PBS)-control treated animals. Using confocal fluorescence microscopy 
we observed an 85% reduction in binding of 2 (n = 6, two sample, one-tailed paired t-
test, P = <0.0001, Figure 6.5a) when compared to rotifers treated with dsRNA from the 
rotifer elongation factor gene (control). The decrease in binding of 2, and therefore 
progesterone, in RNAi experiments confirms that the rotifer gene FJ829246 functions as 
a progesterone receptor. 
Figure 6.5. RNAi experiments with female rotifers transfected with dsRNA from the 
rotifer progesterone receptor gene (treatment), dsRNA from the rotifer enlongation factor 
gene (control for a), or with PBS (control for b). (a) Relative fluorescence intensity of 
female rotifers incubated with 2 (n = 6, two sample, one-tailed paired t-Test, P < 0.0001; 
error bars denote standard error). (b) Percent sexual females in first generation rotifer 
daughters, F1, and second generation rotifer daughters, F2 (n = 4, two sample, one-
tailed paired t-Test, P = 0.045 for F1; n = 4, two sample, one-tailed paired t-Test, P = 
0.434 for F2; error bars denote standard error). 
 
 RNAi experiments were also used to gain mechanistic insights of the rotifer 
progesterone receptor and effects on rotifer reproduction. Females transfected with the 
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dsRNA progesterone receptor gene fragment or with PBS buffer were incubated for 72 
hours, followed by counting of sexual and asexual females. Rotifers exposed to the 
dsRNA rotifer progesterone receptor gene fragment experienced a 64% decrease in 
induction of sexuality in first generation daughters (F1) when compared to controls (n = 
4, two sample, one-tailed paired t-test, P = 0.045), but no significant effect on induction 
of sexuality was observed in second generation females (F2) after an additional 96 hour 
incubation (n = 4, two sample, one-tailed paired t-test, P = 0.434, Figure 6.5b). Mating 
behavior of males towards sexual females was also explored by counting the number of 
males circling females, and no significant difference was observed between RNAi 
treatments and controls (36% circling for RNAi treatments, 39% circling for buffer-only 
controls; n = 3, two sample, one-tailed paired t-test, P = 0.374). Almost twice as many 
asexual maternal females failed to produce clonal daughters when transfected with the 
dsRNA rotifer progesterone receptor gene fragment compared to controls (n = 9, two 
sample, one-tailed t-test, P = 0.022). 
Discussion 
 These studies identify a rotifer progesterone receptor and provide evidence that 
supports progesterone chemoreception as a key regulatory step involved in rotifer 
reproduction. Using a dual fluorescent and affinity probe (2), we demonstrated 
localization of a progesterone-specific chemoreceptor to sex organs within female and 
male rotifers, while also establishing ligand-selective binding using a control steroid 
probe (Figure 6.2). These data are consistent with specific recognition of 3-keto steroids 
by their receptor, as illustrated by progesterone binding interactions to the human 
progesterone receptor.170  Because of the structural similarity of progesterone (1) and 
testosterone, 2 may have been expected to detect testosterone receptors in our imaging 
experiments. However, testosterone receptors were not detected in the transcriptomes 
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of either female or male B. manjavacas, although these transcriptomes are not yet fully 
sequenced. 
 Two complementary methods, progesterone EIA and LC-MS/MS, established the 
presence of 1 in rotifer tissues at 3-4 ng/g dry biomass, consistent with its role as a 
natural ligand for the progesterone receptor. Progesterone (1) is present in mammals at 
very low levels, generally <2 ng/ml in human blood with the exception of pregnant 
females,171 comparable to the low concentration of progesterone observed in rotifers. 
Although we conclude that rotifers use progesterone, the involvement of additional very 
closely related invertebrate steroids, such as 6β-hydroxyprogesterone found in 
hemolymph of the crayfish Astacus leptodactylus,172 cannot be ruled out. 
 In vitro target elucidation studies with fluorescent probe 2 and reactive probe 4 
suggested the presence of an 82 kDa rotifer progesterone receptor through the use of 
two affinity methods173 and were supported by the peptides EWEMQFLEK and 
DFYGPGGPYSVFAGR found via MS/MS analyses (Figure 6.4 and Appendix B). While 
the 82 kDa band is consistent with the size of many membrane progesterone receptors 
belonging to the progestin and adiponectin receptor family (PAQR),174 it did not match 
the predicted ~20 kDa size of our rotifer nucleotide sequence (FJ829246). The rotifer 
progesterone receptor gene is most closely related to progesterone receptor membrane 
components (PGRMC); previously identified PGRMCs range in size from 18-22 kDa but 
form complexes with larger proteins such as cytochrome b5, thus resulting in complexes 
of much higher molecular weights.175 The observed 82 kDa band may represent a 
protein complex containing the rotifer PGRMC or a larger rotifer membrane 
progesterone receptor related to the PAQR family. Complete identification of the gene 
sequences for additional steroid receptors in B. manjavacas will be available upon the 
full sequencing of its genome. 
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 RNAi knockdown of the gene FJ829246 further confirmed the identification of the 
rotifer progesterone receptor, with a 62% decrease in gene expression measured by 
qPCR and an 85% decrease in progesterone binding to the receptor in intact rotifers 
(Figure 6.5a), establishing the function of our gene. The 64% decrease in induction of 
sexuality for daughters of female rotifers exposed to RNAi (Figure 6.5b), while other 
biological functions such as mating behavior were unaffected, indicated that the 
progesterone signaling is necessary for hormonal regulation in these animals. 
Furthermore, RNAi treated maternal females showed a doubling of the rate of 
reproductive failure among asexual females. Together, these data suggest that the 
rotifer progesterone receptor plays a central role in rotifer sexual reproduction, including 
the transition from asexual to sexual reproduction. These findings build on the growing 
evidence of evolutionary conservation of progesterone receptor function and mechanism 
over a wide span of eukaryotes.176 
 Collectively, our data demonstrate that progesterone (1), a well-studied hormone 
with known importance in mammalian reproduction, plays a central role in reproduction 
of the ancestral microinvertebrate B. manjavacas (Rotifera), and thus progesterone and 
its receptor exhibits a conservation of function over a broad expanse of animal 
phylogeny. This study provides further evidence to support the ancient origin of steroid 
hormonal regulation and suggests that endocrine regulation of mammalian reproduction 
may be derived from primitive regulatory pathways. 
 
Experimental Section 
General methods. Commercially available reagents were purchased from Sigma-
Aldrich (Milwaukee, WI), AK Scientific (Mountain View, CA), or VWR Scientific 
(Brisbane, CA), and used as received unless otherwise noted. All reactions were 
performed under a nitrogen atmosphere unless otherwise noted. Reactions were 
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monitored using thin-layer chromatography (TLC) using Silica Gel 60 F254 plates from 
EMD Chemicals (San Diego, CA), and visualized with a UV lamp at 254 nm or by 
staining with Hannesian’s stain (90 ml Water, 2.5 g of (NH4)6Mo7O24•4H2O, 1 g of 
Ce(NH4) 4(SO4) 4•2H2O, 10 ml of conc. H2SO4). Additional experimental details are 
provided in Appendix B. 
Compound purification and analyses. Flash chromatography was performed using 
Geduran Silica gel 40–63 µm particle size from EMD Chemicals (San Diego, CA). HPLC 
was performed using an Alltima C18 column (10 × 250 mm, 5 µm) from Alltech 
Associates (Deerfield, Il) with a linear gradient of acetonitrile and water for IAF-labeled 
control steroid probe synthesis. NMR spectra were recorded at 500 MHz and 125 MHz 
for 1H and 13C NMR, respectively, and referenced to residual CHCl3 (7.24 and 77.0 ppm, 
for 1H and 13C, respectively). High-resolution mass spectra (HRMS) were obtained from 
the mass spectral facilities at Georgia Institute of Technology or the University of 
California, San Diego. 
Rotifer strains. We used Brachionus manjavacas177 as test animals, a species originally 
collected from the Azov Sea,178 and formerly known as B. plicatilis Russian.168 This 
species has been cultured continuously in the lab since 1983, with periodic collection 
and storage of resting eggs. 
Rotifer culturing. Rotifers were obtained by hatching resting eggs in 15 ppt artificial 
seawater (ASW) made from Instant Ocean sea salts at 25°C under constant fluorescent 
illumination of 2000 lux. Rotifers were fed the green alga Tetraselmis suecica cultured in 
f/2 medium179 at 25°C and ASW in 5 L bags under constant fluorescent illumination. 
Flask cultures were inoculated by transferring about 100 females into a dense T. suecica 
culture of 250 ml and gently aerating at 25°C. Males were obtained from the five-day old 
cultures in log phase growth. 
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Confocal fluorescence microscopy. B. manjavacas ovigerous females and males 
were transferred to 24-well plates in 1 ml 15 ppt ASW with or without T. suecica, and 1 
µg of 2 or 3 was added to each well in DMSO (0.5 mg/ml solution). The rotifers were 
allowed to incubate with 2 or 3 at 25°C in the dark for 30 min. The rotifers were 
anesthetized with 0.5 ml seltzer water and then fixed with 50 µl 10% formalin. The 
rotifers were imaged immediately using a Zeiss LSM/NLO 510 confocal/multi-photon 
microscope at Georgia Institute of Technology, with magnifications of 10× (females) or 
20× (males) with excitiation at 375±10 nm and emission at 458±10 nm and excitiation at 
488±10 nm and emission at 518±10 nm for DAPI and FITC, respectively. 
Isolation of dietary steroids from B. manjavacas extracts. B. manjavacas bodies 
were exhaustively extracted with MeOH and MeOH/DCM mixtures (1:1 and 1:2). The 
combined extracts were filtered, reduced in vacuo, and partitioned between MeOH/H2O 
(9:1) and petroleum ether. The aqueous fraction was adjusted to MeOH/H2O (3:2) and 
then partitioned against CHCl3. The petroleum ether fraction was separated by normal-
phase HPLC (Agilent Zorbax RX-SIL, 9.4 × 250 mm, 5 µm) using a linear gradient of 
hexanes/ethyl acetate to yield campesterol (5), campesta-5,7-dien-3-β-ol (6), and 5-α-
campest-7-en-3-β-ol (7). Crude fractions used in the progesterone EIA were generated 
by saponification of the petroleum ether fraction using 0.3M KOH in 90% aqueous 
MeOH. After heating for 2 h at 90 oC, steroids were extracted using hexanes, combined, 
and concentrated in vacuo, and used without further purification. 
LC-MS/MS rotifer steroid analysis. LC-tandem mass spectrometry analyses were 
carried out using normal-phase HPLC fractions generated from the petroleum ether 
fraction. A Shimadzu LC-10 AD VP binary pump system coupled to a Perkin Elmer 
Series 200 autoinjector was interfaced to a 4000 quadrupole linear-ion trap operating in 
multiple reaction monitoring (MRM) mode. An Ascentis C18 column (1.0 × 150 mm, 3 µm) 
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was held at 30 ºC. The effulent was directed to the ion source needle held at 5500V and 
a heated desolvation gas of 200 ºC. Two MRM channels were optimized with regard to 
declustering potential (DP), collision energy (CE), and collision exit potential (CXP). 
They were as follows:  m/z 315.3 / 109.0, DP - 80, CE – 38V, CXP – 8V and m/z 315.3 / 
97.1, DP – 80V, CE – 35V, CXP – 6V. Serial dilutions of known concentrations of 
progesterone were used to generate a calibration curve for determination of 
concentration of progesterone in the extracted sample. 
Progesterone enzyme immunoassay (EIA). The progesterone EIA kit (Cat. No. 900-
011) was purchased from Assay Designs (Ann Arbor, MI). The assay was run according 
to the provided protocol. Both fractions generated from saponification of the petroleum 
ether fraction (i.e. steroid-containing fraction and saponified fatty acid fraction) were 
tested in the assay, along with controls. A progesterone standard curve was generated 
as outlined in the protocol. The steroid-containing fraction (4.8 mg, 0.06% crude extract) 
was taken up in 400 ml of the provided assay buffer, and the fraction was serially diluted 
by half twice, to provide a total of 3 samples, each sample assayed in duplicate. The 
fatty acid-containing fraction (29 mg, 1.5% crude extract) was also treated in a similar 
manner, to provide a total of 3 samples, with each tested in duplicate. Progesterone was 
present only in the treatment wells containing the steroid-containing fraction. 
B. manjavacas lysate. Adult rotifer biomass (1 g wet weight) was placed in modified 
RIPA buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.4, 1% Triton X-100, 1 mM EDTA, 1 
mM PMSF, 5 µg/ml aprotinin, 1 µg/ml pepstatin-A, 2 µg/ml lLeupeptin, 1 mM Na3VO4, 1 
mM NaF). The cells were ruptured by sonication for 5 min at 4 °C and centrifuged for 5 
min at 13,000 RPM at 4 °C. The soluble fraction was spin dialysed 3 volumes of RIPA 
buffer on an Ultracel YM-3 3 kDa filter and concentrated to 1.3 mg/ml by Bradford 
analysis. 
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Immunoprecipitation studies with probe 2. Samples of the resulting lysate (200 µl) 
were treated with 10 µl of a 0.1 mg/ml DMSO stock of probe 2. The sample was 
incubated with rotary shaking for 4 h at 4 °C. The sample was then immunoprecipitated 
by the addition of Affigel 10 resin containing 3.5 mg/ml of the XRI-TF35 mAb (40 µl). The 
resulting mixture was agitated for 12 h at 4 °C with the resin. The resin was then washed 
with ice cold PBS (3 x 2 ml). The bound protein was eluted from the resin incubating with 
35 µl of 1 mg/ml of dimethylamino-4-coumarin acetic acid in RIPA buffer for 1 h at rt. 
SDS-PAGE analysis was run on a 4-12% gradient gel (Novex) with MOPS running buffer 
and silver stained (Invitrogen). Samples of the identified bands were excised and 
submitted to Nano-LC/MS/MS analysis conducted by contract services from the Center 
for Functional Genomics (CFG) at the University of Albany, State University of New York 
or the University of California, San Diego. 
Western blotting studies using probe 4. An aliquot of rotifer lysate (400 µl) was 
treated with 20 µl of a 1 mg/ml stock of 4 in DMSO for 4 h at 4 °C. The sample was then 
immunoprecipitated by the addition of 15 µl of a ~0.01 mg/ml stock of a mouse anti-
progesterone IgG mAb (Ann Arbor, MI) containing 1 mg/ml of bovine serum albumin 
(BSA) for 2 h at 4 °C. This was then followed by addition of 50 µl of protein A fast flow 
resin from GE Healthcare (Piscataway, NJ). The resulting mixture was agitated for 12 h 
at 4 °C with the resin. The resin was then washed with ice cold PBS (2 x 1 ml). The 
bound protein was boiled in SDS-PAGE gel loading buffer S3401-1VL (Sigma-Aldrich). 
SDS-PAGE gel analysis was conducted on a Novex X-cell station using NuPage 4-12% 
Bis-Tris gels and MOPS SDS running buffer. Western blotting was conducted by transfer 
to Hybond-P PVDF membrane by GE Healthcare (Piscataway, NJ) followed by blocking 
for 2 h with a solution of 0.1% Tween-20 with 5% w/v nonfat dry milk 20 in tris-buffered 
saline (TBS, pH 7.6), staining with the primary antibody, a mouse anti-progesterone IgG 
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mAb from Assay Designs (Ann Arbor, MI), in 0.1% Tween-20 with 5% BSA in TBS, 
mouse anti-progesterone mAb and a Goat anti-mouse IgG HRP mAb conjugate from 
Promega (Madison, WI) in 0.1% Tween-20 with 5% BSA in TBS. The primary and 
secondary antibodies were applied at 1:100 and 1:2,000 dilution, respectively, from their 
manufactures preparation. The total protein content in each gel was determined by 
staining with ponceau S from Promega (Madison, WI). 
RNAi knockdown methods. B. manjavacas resting eggs were decapsulated in order to 
render them more permeable to dsRNA.180 Resting eggs were then hatched in 15 ppt 
ASW with transfection solution for the progesterone receptor treatment or elongation 
factor 1α control (for binding assay), and the hatchlings were isolated fresh 15 ppt ASW 
and exposed to freshly prepared transfection solution overnight. The transfection 
solution consisted of 2 µl Fugene HD lipofection transfection reagent (Roche 
Diagnostics), 43 µl sterile PBS, plus 5 µl sterile water containing 10–20 ng progesterone 
receptor or elongation factor dsRNA. dsRNA derived from B. manjavacas progesterone 
receptor and elongation factor gene was synthesized in vitro.181  Intensity of 
fluorescence in confocal microscopy images was quantified using ImageJ and a two 
sample, one-tailed paired t-Test (n = 8) was calculated. 
Gene expression analysis. After 24h exposure of rotifer hatchlings to transfection 
solution, individual rotifers were preserved in RNAlater (Qiagen) for up to 5 days at -80 
°C prior to RNA extraction. RNA extractions were performed immediately prior to qPCR. 
Total RNA was isolated from individual rotifers using RNeasy Micro Kit (Qiagen) with the 
modification that rotifer cells were disrupted by vortexing with glass beads (425-600 µm). 
A 1:9 dilution of rotifer RNA was used as template for triplicate one-step reverse 
transcription and qPCR reactions using EXPRESS One-Step SYBR GreenER Kit 
(Invitrogen). qPCR primers for the target progesterone receptor gene (qPR1for 5’-
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CGGTCCGTATTCCGTATTTG-3’, qPR1rev 5’-TTCGGCTGACTCTTCTTCGT-3’) were 
designed from B. manjavacas progesterone receptor membrane component 1-like 
protein nucleotide sequence (FJ829246). qPCR primers for the actin reference 
housekeeping gene (actinQBfor 5’-GCATCCACGAGACCACCTAT-3’, actinQBrev 5’-
TAGGATCGAACCACCAATCC-3’) were designed from B. plicatilis actin mRNA 
nucleotide sequence (GenBank accession AB111352). Amplification and detection of 
progesterone receptor and actin genes were conducted using a Mastercycler Realplex 2 
(Eppendorf). Expression levels of progesterone receptor were normalized to actin levels 
and relative expression of progesterone receptor gene in progesterone receptor-
transfected rotifers to PBS control rotifers was determined using the ∆∆CT method.182 
Mixis and mating bioassays. Mixis168 and mating181 bioassays were performed as 
previously described. RNAi knockdown for treatments and controls for each bioassay 





  Natural products represent a valuable resource for biomedical research and drug 
discovery, necessitating continued activity in this vital area. Rare and understudied 
macroalgal species are excellent sources of novel and exciting secondary metabolites, 
including compounds of mixed biogenesis, such as the bromophycolides. As evident 
from the study of Callophycus serratus and Neurymenia fraxinifolia, tropical macroalgae 
represent a treasure trove of unique bioactive natural products, and these natural 
products (i.e., bromophycolides and neurymenolides) have pharmaceutical potential 
against relevant human diseases including drug-resistant malarial strains and bacterial 
infections.  
  Following elucidation of bromophycolide A’s antimalarial mechanism of action as 
a heme crystallization inhibitor, new bromophycolide-inspired compounds can now be 
pursued through chemical synthesis and optimized for interaction with heme with the aid 
of molecular modeling. Heme represents an excellent drug target because heme 
crystallization is a physicochemical process rather than an enzymatic one that allows for 
facile evolution of resistance by the parasite. These studies identified a new class of 
natural products that target heme detoxification, suggesting an avenue to circumvent 
drug resistance. Not only is bromophycolide A potent against drug-sensitive Plasmodium 
falciparum, the natural product is even more effective against chloroquine-resistant P. 
falciparum.   
  Despite its exciting mechanism of action and promising potency, bromophycolide 
A is unlikely to become a commercial drug for a number of reasons. First, 
bromophycolide A is impractical and environmentally unsustainable to procure through 
large-scale collections and extraction of the macroalga Callophycus serratus. While the 
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structural complexity of bromophycolide A – 27 carbons, 5 stereocenters – makes this 
natural product a daunting but exciting challenge for organic synthesis, a short and 
concise total synthesis on a multi-gram scale is needed to make this compound feasible 
for further in vitro and in vivo studies. Furthermore, the antimalarial activity of 
bromophycolide A is ~660 nM, and while inhibition of this magnitude can result in good 
leads, more potent activity is often necessary for the continued development of new 
drugs. For instance, current antimalarial drugs inhibit parasite growth in the low 
nanomolar range (i.e., artemisinin IC50 value against the malaria parasite is 7 nM). 
Resistance of human cells and tissues is also important when developing new drug 
leads, such that the drug should be selective for the disease-causing organisms and not 
toxic to the human host. Bromophycolide A exhibited a 50-fold difference in activity 
between P. falciparum parasites and human Vero cells, whereas a 200-fold or greater 
difference in activity is ideal for potential drug candidates. Lastly, bioavailability of a drug 
candidate is crucial for advancing a drug lead into a new drug. The physical properties of 
bromophycolide A, such as its strong hydrophobicity and low solubility in aqueous 
environments, make this natural product less than ideal from a pharmacokinetics 
perspective. Therefore, synthesizing optimized derivatives inspired by bromophycolide A 
with increased potency, selectivity, and bioavailability is the next logical step to further 
progress this class of molecules as antimalarial drugs. For example, as demonstrated 
with callophycolide A (Chapter 3), bromines are not essential for antimalarial activity. 
Thus, a compound without bromines (lower molecular weight) and additional polar 
groups such as amines or amides (to slightly increase compound polarity) could 
represent a reasonable starting point for further development of bromophycolide-inspired 
derivatives.      
  Drug resistance is also of immense concern with antibacterial infections. The 
neurymenolides represent structurally unique, but relatively simple compounds with 
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promising antibacterial activity. These compounds inhibited both Gram-positive and 
Gram-negative bacteria, and thus could be utilized as broad spectrum antibiotics. 
Through collaboration with researchers at Rutgers University, initial studies suggested 
that neurymenolide A inhibits bacterial RNA polymerase (Professors Richard Ebright and 
Eddy Arnold, unpublished), an essential enzyme in both Gram-positive and Gram-
negative bacteria. Furthermore, while bacteria RNA polymerase subunit sequences are 
highly conserved, eukaryotic RNA polymerase subunit sequences are not, making this 
enzyme an excellent target for bacterial inhibition while also permitting therapeutic 
selectivity. Future research further exploring this potential mechanism of action, coupled 
with synthesis of neurymenolide-inspired analogs could result in the development of a 
new scaffold for antibiotic drug discovery. For example, reports of syntheses of 
structurally related compounds are available in the literature and thus a similar carbon 
skeleton to that of neurymenolide A can be synthesized from inexpensive starting 
materials in only 3-5 steps, depending on the desired size of the macrocylic ring. Thus, 
several synthetic avenues exist to elaborate or simplify the core structure of the 
neurymenolides. The synthetic derivatives could then be assessed by collaborators at 
Rutgers University for their ability to effectively inhibit RNA polymerase. Overall, this 
project is worthwhile to pursue since a potential mechanism of action has been 
proposed, synthetic derivatives can be easily prepared, and an efficient synthetic plan 
could allow for variation of functional groups to explore structure-activity relationships for 
the therapeutic target.   
  As previously discussed, natural products are not only essential in drug 
discovery, but are also essential as molecular probes in the understanding of 
biochemical processes. Unlike almost all other animals currently in existence, the 
ancient marine micro-invertebrate Brachionus manjavacas benefits from both asexual 
and sexual reproduction, a strategy central to their evolutionary success. By exploring 
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chemical signaling in B. manjavacas using a fluorescent probe synthesized from 
progesterone, we were able to gain insights into their reproductive signaling. This work 
suggested that the well-studied mammalian hormone progesterone plays an essential 
role in B. manjavacas reproduction and that endocrine regulation of mammalian 
reproduction may be derived from primitive regulatory pathways.  
  Collectively, the continued study of marine natural products will enrich the drug 
discovery library, provide exciting challenges for organic synthesis, and can be used to 




NMR SPECTRAL DATA 
 
1 and 2D NMR Spectral Data for Chapter 3 
 
 
Figure A.1. Natural products isolated from Fijian red macroalgae; callophycolide A (1) 
from Callophycus serratus; β-tocopherylhydroquinone (13) and δ-
tocopherylhydroquinone (14) from Amphiroa crassa. 
 
Table A.1. 13C and 1H NMR spectroscopic data for 1 and 13-14 (500 MHz; in CDCl3). 
 
 
1 13 14 
δ C δ H (J in Hz) δ C δ H (J in Hz) δ C δ H (J in Hz)
1 169.2 - 146.0 - 146.1 - 
2 122.4 - 124.1 - 127.4 - 
3 131.1 7.85 s 115.3 6.46 s 115.6 6.45 d (2.8)
4 127.7 - 145.6 - 147.6 - 
5 26.0 3.17 dd (17, 
7.0), 3.49 dd 
(17, 8.5) 
119.1 - 112.5 6.37 d (2.8)
6 122.7 5.45 dd (7.6, 120.3 - 121.5 - 












































Table A.1 continued 
8 39.3 2.17 m, 2.27 
m 
31.4 1.75 dt (13, 
7.0), 1.78 
dt (13, 6.5) 
31.3 1.72 dt (14, 
6.8), 1.76 
dt (14, 6.7) 
9 23.8 2.15 m, 2.23 
m 
74.5 - 75.6 - 
10 123.5 5.19 m 39.7 1.52 m 39.9 1.52 m 
11 135.2 - 21.0 1.35 m, 
1.41 m 
21.0 1.35 m, 1.41 
m 
12 35.8 1.87 dd (12.3, 
9.4), 2.11 m 
37.4 1.24 m 37.4 1.24 m 
13 29.2 1.61 m, 2.03 
m 
32.8 1.36 m 32.8 1.36 m 
14 82.1 4.75 d (11) 37.4 1.04 m 37.4 1.04 m 
15 74.8 - 24.4 1.19 m 24.4 1.19 m 
16 40.0 1.48 m, 1.52 
m 
37.4 1.24 m 37.4 1.24 m 
17 21.9 2.14 m 32.8 1.36 m 32.8 1.36 m 
18 124.3 5.10 t (6.9) 37.4 1.04 m 37.4 1.04 m 
19 131.8 - 24.8 1.28 m 24.8 1.28 m 
20 25.7 1.66 s 39.4 1.13 m 39.4 1.13 m 
21 129.6 7.73 d (8.3) 28.0 1.50 m 28.0 1.50 m 
22 114.8 6.78 d (8.3) 22.7 0.86 d (6.7) 22.7 0.86 d (6.7)
23 158.0 - 23.8 1.20 s 24.1 1.22 s 
24 14.5 1.60 s 19.6 0.85 d (6.4) 19.6 0.85 d (6.4)
25 15.7 1.59 s 19.6 0.85 d (6.4) 19.6 0.85 d (6.4)
26 22.0 1.16 s 22.7 0.86 d (6.7) 22.7 0.86 d (6.7)
27 17.7 1.60 s 15.8 2.08 s 16.1 2.10 s 
28 NA NA 10.9 2.06 s NA NA 
OH - 5.83 br s - - - - 
br=broad; s=singlet; d=doublet; dd=doublet of doublets; t=triplet; m=multiplet 
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8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 ppm 
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EXPNO                 4
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AQ            0.2048500 sec
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Figure A.15. Natural products isolated from the Fijian red macroalga Callophycus 
serratus; bromophycolides L (2), N (3), and O (4). 
 
Table A.2. 13C and 1H NMR spectroscopic data for 2-4 (500 MHz; in CDCl3). 
 
 
2 3 4 
δ 13C δ 1H (JH,H) δ 13C δ1H (JH,H) δ 13C δ 1H (JH,H) 
1 165.9 - 164.7 - 165.5 - 
2 122.9 - 123.0 - 123.0 - 
3 132.3 7.67 d (1.9) 131.4 7.82 s 129.5 7.89 s 
4 124.6 - 129.5 - 128.4 - 
5 29.7 3.22 d (15), 3.46 d (15) 27.3 
2.60 d (15), 
2.83 dd (15, 
9.0) 
25.8 2.82 m, 2.98 d (13) 
6 132.6 - 47.8 2.67 m 43.7 2.84 m 
7 49.0 3.41 m 41.3 - 40.9 - 
8 27.1 1.53 m, 1.97 m 37.2 
1.58 m, 
2.18 m 36.6 
1.23 m, 
2.08 m 
9 30.7 2.44 m, 2.50 
m 
26.0 2.20 m, 
2.39 m 
28.5 1.98 m, 
2.00 m 
10 67.8 3.97 dd (11, 
3) 
66.4 4.20 d (11) 70.0 3.79 d (11) 











































Table A.2 continued 
12 31.6 1.67 m, 1.74 m 32.2 
1.86 m 
2.02 m 
33.8 1.53 m, 1.98 m 
13 25.8 1.73 m, 1.86 m 27.0 
1.70 m 
2.05 m 
26.4 2.13 m, 2.47 m 
14 74.9 5.52 brs 76.0 5.23 brs 79.2 5.00 dd (9.4, 3.4) 
15 140.7 - 140.9 - 66.5 - 
16 129.2 7.73 dd (8.4, 1.9) 129.3 7.75 d (7.9) 129.3 7.74 d (8.3) 
17 115.6 6.78 d (8.3) 115.9 6.76 d (8.3) 115.7 6.81 d (8.3) 
18 158.0 - 156.6 - 156.5 - 
19 136.8 - 137.2 - 135.8 - 
20 37.8 2.30 m, 2.42 m 120.3 5.19 m 119.4 5.33 br s 
21 122.5 4.81 t (6.5) 34.4 2.53 m 2.59 m 34.0 2.65 m 
22 138.8 - 59.8 4.28 dd (11, 5.3) 60.2 
4.24 dd 
(6.8, 6.2) 
23 14.0 1.89 s 20.9 1.50 s 22.0 1.65 s 
24 18.2 1.38 s 17.1 1.06 s 18.8 0.89 s 
25 27.5 1.30 s 28.0 1.40 s 29.3 1.32 s 
26 111.5 4.98 s, 5.07 s 111.0 4.84 s 4.95 
s 
30.2 1.81 s 
27 19.5 1.79 s 19.7 1.79 s 31.5 1.83 s 
OH - 5.31 s - 5.33   brs - 5.21 brs 


























































































Figure A.20. 1H NMR spectrum of bromophycolide N (3) (500 MHz; CDCl3) 
 
 




























































































































































































Figure A.28. Natural products isolated from the Fijian red macroalga Callophycus 
serratus; callophycolic acid C-D (5-6). 
 
Table A.3. 13C and 1H NMR spectroscopic data for 5-6 (500 MHz; (CD3)2CO) 
 
5 6 
δ 13C δ 1H (JH,H) δ 13C δ 1H (JH,H) 
1 167.2 - 167.1 - 
2 124.2 - 127.4 - 
3 135.6 7.91br s 133.0 8.08br s 





30.5 3.20m, 3.28dd (13.3, 4.3) 
6 42.8 2.98m 44.1 2.64dd (10.1, 3.7) 





41.8 1.76m, 1.96m 
9 20.8 1.41m, 1.46m 20.5 1.43m, 1.74m 
10 57.6 1.29dd (3.9, 3.9) 58.0 1.35m 

































Table A.3 continued 
12 44.4 1.60m, 1.69m 44.5 1.70m, 1.84m 
13 32.7 2.00dd (12.9, 3.3), 2.08m 33.5 2.13m 
14 68.9 4.10dd (12.2, 4.4) 68.9 
4.15dd (11.0, 
5.4) 
15 41.6 - 41.9 - 
16 30.8 1.16s 30.8 1.19s 
17 129.9 7.73d (8.4) 130.0 7.83d (8.0) 
18 119.5 6.84d (8.4) 120.2 7.00d (8.1) 
19 163.2 - 164.2 - 
20 74.6 4.44d (13.5), 4.97d (13.5) 140.9 6.61br s 
21 138.9 - 122.6 - 
22 123.6 5.63br s 33.2 2.08m 
23 36.1 2.66m, 2.77m 35.2 2.07m, 2.18m 
24 60.6 4.68dd (10.9, 6.0) 63.9 
4.61dd (11.5, 
4.0) 
25 16.1 0.91s 17.9 0.92s 
26 23.1 0.99s 23.5 1.32s 
27 17.7 0.87s 18.0 0.98s 
br=broad; s=singlet; d=doublet; dd=doublet of doublets; t=triplet; m=multiplet 
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Table A.4. 1H-1H COSY correlations for 5-6. For diastereotopic protons with dissimilar 
chemical shifts, the proton whose chemical shift is listed first in Table A.3 is termed “a” 




COSY correlations observed between 
protons listed on far left and those below: 
5 6 
3 17 17 
5a 5b, 6 5b, 6 
5b 5a, 6 5a, 6 
6 5a, 5b, 22 5a, 5b 
7a NA NA 
7b NA NA 
8a 8b, 9a, 9b 8b, 9a, 9b 
8b 8a, 9a, 9b 8a, 9a, 9b 
9a 8a, 8b, 9b, 10 8a, 8b, 9b, 10 
9b 8a, 8b, 9a, 10 8a, 8b, 9a, 10 
10a 9a, 9b 9a, 9b 
10b NA NA 
11a NA NA 
11b NA NA 
12a 12b, 13a, 13b 12b, 13 
12b 12a, 13a, 13b 12a, 13 
13a 12a, 12b, 13b, 14 12a, 12b, 14 
13b 12a, 12b, 13a, 14 NA 
14a 13a, 13b 13 
14b NA NA 
15a NA NA 
15b NA NA 
16 - - 
17 3, 18 3, 18 
18 17 17 
20a 20b - 
20b 20a NA 
21a NA NA 
21b NA NA 
22a 6, 23a, 23b 23a, 23b 
22b NA - 
23a 22, 23b, 24 22, 23b, 24 
23b 22, 23a, 24 22, 23a, 24 
24 23a, 23b 23a, 23b 
25 - - 
26a - - 
26b NA NA 
27 - - 
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Table A.5. HMBC correlations for 5-6. For diastereotopic protons with dissimilar 
chemical shifts, the proton whose chemical shift is listed first in Tables A.3 is termed “a” 




HMBC correlations observed between protons listed on 
far left and carbons at positions listed below: 
5 6 
3 1, 5, 17, 19 1, 5, 17, 19 
5a 3, 4, 6, 19, 21 3, 4, 6, 19, 21 
5b 4, 6, 21 3, 4, 6, 19, 21 
6 4, 5, 7, 21 5, 7 
7a NA NA 
7b NA NA 
8a 7, 9, 24 7, 9, 10 
8b 7, 24 9, 10, 24 
9a 8, 10, 11 8, 10 
9b 8, 10, 11 8 
10a 9, 11, 15, 16 9, 11, 15, 26 
10b NA NA 
11a NA NA 
11b NA NA 
12a 11, 13, 26 11 
12b 11, 13, 26 10 
13a 14 11, 12 
13b 14 NA 
14a 13, 16, 27 16, 27 
14b NA NA 
15a NA NA 
15b NA NA 
16 10, 14, 15, 27 10, 14, 15, 27 
17 1, 3, 19 3, 19 
18 2, 4, 19 2, 4, 19 
20a 6, 19, 21, 22 6, 19, 21, 22 
20b 19, 21, 22 NA 
21a NA NA 
21b NA NA 
22a - 6, 20, 21, 23 
22b NA NA 
23a 7, 21, 22, 24 7, 21, 22, 24 
23b 7, 21, 22, 24 21 
24 7, 23, 25 23 
25 6, 7, 8, 24 6, 7, 8, 24 
26a 10, 11, 12 10, 11, 12 
26b NA NA 




Table A.6. Observed NOEs from ROESY NMR experiments 5-6. For diastereotopic 
protons with dissimilar chemical shifts, the proton whose chemical shift is listed first in 
Table A.3 is termed “a” and the other is “b”.  Only NOEs important to determinations of 
stereochemistry are listed. 
1H at position #: 
NOE observed between protons listed on far left 
and protons at positions listed below: 
5 6 
5a 25 25 
5b 25 25 
6 9b, 24 9b, 24 
7a   
7b   
8a 10, 16, 25 10, 16, 25 
8b 10, 25 10, 25 
9a 16, 24, 27 16, 24, 27 
9b 6, 26 6, 26 
10 8a, 8b, 12a, 14, 16 8a, 8b, 12a, 14, 16 
12a 10, 14 10, 14 
12b 26 26 
14a 10, 12a, 16 10, 12a, 16 
14b   
16 8a, 9a, 10, 14 8a, 9a, 10, 14 
18   
20a 22 22 
20b   
22a 20 20 
22b   
23   
24 6, 9a 6, 9a 
25 5a, 5b, 8a, 8b, 12b 5a, 5b, 8a, 8b 
26 9b, 12b, 27 9b, 12b, 27 























NMR Spectral Data for Chapter 4 
 
Figure A.31. Fluorescent IAF-labeled bromophycolide A probes. 
 
Table A.7. NMR Spectral Data for Probes 15 and 17 (500 MHz, CDCl3)a 
position 
15 17 
δC δH mult. (J, Hz) δC δH mult. (J, Hz) 
1 165.0 - 164.9 - 
2 127.1 - 127.0 - 
3 131.0 8.08 s 131.0 8.06 s 
4 131.8 - 131.9 - 
5 29.1 3.16 d (18), 3.37 d (18) 29.1 3.20 m, 3.41 d (18)
6 129.4 - 129.4 - 
7 43.4 - 43.4 - 
8 37.4 1.25 m, 1.88 m 37.4 1.26 m, 1.86 m 
9 28.7 1.73 m, 2.02 m 28.7 1.73 m, 2.02 m 
10 73.1 3.47 m 73.3 3.47 m 
11 72.2 - 72.2 - 
12 34.2 1.05 m, 1.73 m 34.3 1.05 m, 1.71 m 
13 28.3 2.05 m, 2.12 m 28.3 2.05 m, 2.12 m 
14 80.9 4.66 d (10.9) 80.9 4.66 d (9.3) 
15 67.0 - 66.9 - 
16 129.2 7.92 dd (1.5,8.3) 129.2 7.91 d (8.3) 
17 122.4 7.14 d (8.3) 122.4 7.16 d (8.3) 
18 152.3 - 152.8 - 
19 134.0 - 134.0 - 
20 33.2 2.01 m, 2.27 m 33.3 2.01 m, 2.27 m 
21 30.5 2.26 m 30.5 2.26 m 
22 60.6 4.45 dd (5.7, 8.2)  60.6 4.46 m 
23 21.0 1.35 s 21.0 1.35 s 
24 26.1 1.24 s 26.1 1.27 s 






































































Table A.7 continued  
 
26 30.9 1.81 s 30.9 1.81 s 
27 31.7 1.80 s 31.7 1.80 s 
1’ 166.5 - 170.6 - 
2’ 41.8 4.32 dd (5.8, 7.8) 30.2 2.62 m 
3’ 169.4 - 29.5 2.98 m 
3’-NH - 6.32 t (5.5) NA NA 
4’ 39.9 3.76 s 171.0 - 
4’-NH NA NA - 6.01 t (5.9) 
5’ 149.2 - 39.0 3.21 m 
6’ 110.3 6.13 s 26.3 1.45 m 
7’ 162.4 - 26.3 1.45 m 
8’ 156.0 - 39.0 3.21 m 
9’ 98.1 6.51 d (2.4) 168.5 - 
9’-NH NA NA - 6.15 t (5.6) 
10’ 154.3 - 40.5 3.60 s 
11’ 109.6 6.62 dd (2.4, 9.0) 149.2 - 
12’ 125.5 7.46 d (9.0) 110.3 6.03 s 
13’ 108.2 - 162.4 - 
14’ 40.0 3.04 s 156.0 - 
15’ 40.0 3.04 s 98.1 6.48 d (2.3) 
16’ NA NA 154.3 - 
17’ NA NA 109.3 6.61 dd (2.3, 8.9) 
18’ NA NA 125.5 7.45 d (8.9) 
19’ NA NA 108.2 - 
20’ NA NA 40.0 3.03 s 
21’ NA NA 40.0 3.03 s 
 















































Figure A.34. Natural products isolated from the Fijian red macroalga Neurymenia 
fraxinifolia; neurymenolides A-B (1-2). 
 
Table A.8. 1H-1H COSY correlations for 1-2. For diastereotopic protons with dissimilar 
chemical shifts, the proton whose chemical shift is listed first in Table 5.1 is termed “a” 




COSY correlations observed between protons listed 
on far left and those below: 
1 2 
4 - - 
6a 6b, 7a, 7b 6b, 7a, 7b 
6b 6a, 7a, 7b 6a, 7a, 7b 
7a 6a, 6b, 7b, 8a 6a, 6b, 7b, 8a, 8b 
7b 6a, 6b, 7a, 8b 6a, 6b, 7a, 8b 
8a 7a 7a 
8b 7b, 9a 7a, 7b, 9a 
9a 8b, 9b 8b, 9b, 10a, 10b 
9b 9a, 10a, 10b 9a 
10a 9b 9a 
10b 9b, 11a, 11b 9a 
11a 10b - 
11b 10b, 12 - 
12a 11b 13a, 13b 
12b NA 13a, 13b 
13a 14a, 14b 12a, 12b, 13b, 14 
13b NA 12a, 12b, 13a, 14 





















Table A.8 continued 
   
14b 13, 14a, 15 NA 
15 14a, 14b 16a, 16b 
16a 17 15, 16b, 17 
16b NA 15, 16a, 17 
17 16, 18 16a, 16b 
18 17 19 
19 20 18, 20 
20 19, 21 19 
21 20, 22 22 
22 21, 23 21, 23 
23 22, 24 22, 24 
24 23 23, 25 
25 NA 24, 26 
26 NA 25 
 
Table A.9. HMBC correlations for 1-2. For diastereotopic protons with dissimilar 
chemical shifts, the proton whose chemical shift is listed first in Table 1 of the main 
article is termed “a” and the other is “b”. “NA” (not applicable) indicates that no proton 
signal exists for that position. 
1H at 
position #: 
HMBC correlations observed between protons 
listed on far left and those below: 
1 2 
4 2, 5, 6 2, 5, 6 
6a 4, 5, 7 - 
6b 4, 5, 7 5 
7 - - 
8 - - 
9a 8, 10 - 
9b 8, 10 - 
10a 9 9 
10b 9 9 
11a 10 - 
11b - 10 
12a 14 - 
12b NA 13 
13a 14 14 
13b NA 14 
14a - 13 
14b 15 NA 
15 14, 17 16 
16a 17 - 
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Table A.9 continued 
   
16b NA 15 
17 2, 18 - 
18 17, 20 - 
19 17, 20 - 
20 19, 21 19,22 
21 - 19, 22 
22 - 21 
23 22, 24 - 
24 22, 23 - 
25 NA 23, 24, 26 
26 NA 24, 25 
-OH 3, 4 2, 3, 4  
 
 
Table A.10. Observed NOEs from ROESY NMR experiments 1-2. For diastereotopic 
protons with dissimilar chemical shifts, the proton whose chemical shift is listed first in 
Table 5.1 is termed “a” and the other is “b”. Only NOEs important to determinations of 
stereochemistry are listed. 
1H at 
position #: 
NOEs observed between protons listed on far 
left and protons at positions listed below: 
1 2 
4 9a  
9a 4  
11a -  
11b 14a, 14b  
13a  16a 
13b  16b 
14a 11b, 17  
14b 11b, 17  
16a  13a, 19 
16b  13b, 19 
17 14a, 14b  
19  16a, 16b 
20 23  
22  25 
23 20  














































ADDITIONAL EXPERIMENTAL DATA 
 
 
Experimental Data for Chapter 6 
 
Supporting Figures  
 
Figure B.1. Brachionus manjavacas hatchlings incubated with the IAF-labeled 
progesterone probe 2 (right) and a fluorescent control 8 (left) at 10 µg/ml. Uptake of 8 























Figure B.2. MS/MS detection of peptides: (top) daughter ions of m/z 1239.57 
corresponding to EWEMQFLEK and (bottom) daughter ions of m/z 1589.74 
corresponding to DFYGPGGPYSVFAGR. 
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Figure B.3. Blast searches on the respective peptides EWEMQFLEK (P1) and 
DFYGPGGPYSVFAGR (P2). Peptide A1 is found in the progestin membrane receptor 
component 2 from Oncorhynchus mykiss (gb|ABD58973.1|, 88% identities); B1 is found 
in the progesterone receptor membrane component 1 from Strongylocentrotus 
purpuratus (ref|XP_783332.1|, 88% identities); and C1 is found in the progesterone 
receptor membrane component 2 from Danio rerio (gb|AAH53415.1|, 88% identities). 
Peptide A2 is found in the progestin membrane receptor component 1 from Penaeus 
monodon (gb|ACC62174.1|, 92% identities); B2 is found in the steroid binding protein 1 
from Thalassiosira pseudonana (gb|EED96317.1|, 92% identities); and C2 is found in the 




















Figure B.4. ORF within the rotifer progesterone gene (GenBank accession FJ829246) 
from the Brachionus manjavacas cDNA database. This is the reverse complement of the 
contig sequence. Bold and underlined bases indicate primer sequences; yellow indicates 
area amplified for the dsRNA used in RNAi knockdown experiments. 
 
Supporting Western Blot Methods 
Western blotting studies using reactive probe 4 
The method was first tested by screening for PR expression in a MCF-7 cell lysates. 
Whole MCF-7 cell lysate was prepared by homogenization in modified RIPA buffer (150 
mM NaCl, 50 mM Tris-HCl, pH 7.4, 1% Triton X-100, 1 mM EDTA, 1 mM PMSF, 5 µg/ml 
aprotinin, 1 µg/ml pepstatin-A, 2 µg/ml lLeupeptin, 1 mM Na3VO4, 1 mM NaF). The 
debris was removed by centrifugation and the protein concentration was concentrated to 
1 mg/mL using a 3 kDa cutoff filter. An aliquot of this lysate (500 µL) was treated with 20 
µL of a 1 mg/mL stock of 4 in DMSO at 4 °C. A 50 µL sample was taken at 4 h and 
boiled for 5 min in SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% SDS, 
0.01% bromophenol blue containing 5% -mercaptoethanol). SDS-PAGE gel analysis 
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was conducted on a Novex X-cell station using NuPage 4-12% Bis-Tris gels and MOPS 
SDS running buffer. Western blotting was conducted by transfer to Hybond-P PVDF 
membrane by GE Healthcare (Piscataway, NJ) followed by blocking for 2 h with a 
solution of 0.1% Tween-20 with 5% w/v nonfat dry milk 20 in tris-buffered saline (TBS, 
pH 7.6). One lane was stained with a mouse anti-progesterone receptor 00005241-M01 
Anti-PGR (1-110) mAb (anti-PR) from Abnova (Ann Arbor, MI), in 0.1% Tween-20 with 
5% BSA in TBS, and a Goat anti-mouse IgG HRP mAb conjugate from Promega 
(Madison, WI) in 0.1% Tween-20 with 5% BSA in TBS. A second lane was stained a 
mouse anti-progesterone IgG mAb (anti-P) from Assay Designs (Tapei City, Taiwan), in 
0.1% Tween-20 with 5% BSA in TBS, and a Goat anti-mouse IgG HRP mAb conjugate 
from Promega (Madison, WI) in 0.1% Tween-20 with 5% BSA in TBS. For both 
experiments, the primary and secondary antibodies were applied at 1:100 and 1:2,000 
dilution, respectively, from their manufactures preparation. The total protein content in 
each gel was determined by staining with ponceau S from Promega (Madison, WI).  
 
Synthetic Procedures and Compound Characterization 
tert-butyl-4-((8S,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-
2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta-[α]phenanthrene-17-
carboxamido)butylcarbamate (10). HATU (157 mg, 0.41 mmol) was added to a mixture 
of 3-keto-4-etiocholenic acid 9 (65 mg, 0.021 mmol), N-boc-1,4-butyldiamine (53.5 mg, 
0.28 mmol), and EtNiPr2 (108 µL, 0.62 mmol) in anhydrous DMF (5 mL). The reaction 
was allowed to stir for 12 h at rt and then dried under vacuum. Any remaining HATU was 
precipitated with CH2Cl2 and removed via filtration. Compound 10 (94 mg) was obtained 
as a colorless oil, 89% yield. 1H NMR (CDCl3, 500 MHz) δ: 7.98 (bs, 1H); 6.99 (bs, 1H); 
6.51 (s, 1H); 3.63 (m, 1H); 3.35 (m 3H); 2.90 (s, 6H); 2.66-2.41 (m, 2H); 2.36-2.22 (m, 
1H); 2.27-2.16 (m, 3H); 2.11-2.01 (m, 2H); 2.00-1.88 (m, 1H); 1.87-1.73 (m, 1H); 1.67-
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1.42 (m, 6H); 1.41-1.25 (m, 5H); 1.23 (s, 3H); 1.19-1.05 (m, 3H); 1.02 (s, 3H); 0.94-0.58 
(m, 4H); 0.39 (s, 3H). 13C NMR (CDCl3, 100 MHz) δ: 197.5; 171.7; 170.3; 155.9; 123.5; 
77.5; 56.4; 55.6; 54.1; 43.6; 39.9; 38.6; 38.5; 38.2; 37.9; 35.8; 35.6; 33.7; 32.5; 32.1; 
27.9; 27.5; 27.2; 24.4; 23.5; 20.8; 16.8; 13.0. HR-ESI-MS (m/z): Calcd for C31H51N2O4 [M 




hydro-1H-cyclopenta-[ α]phenanthren-17-yl)pentanamide (2). Intermediate 10 (54 mg, 
0.10 mmol) was dissolved in CH2Cl2 (1 mL). Trifluoroacetic acid (0.020 mL, 0.285 mmol) 
was added dropwise and the reaction was allowed to stir at room temperature for 1 h. 
The reaction was then diluted with CH2Cl2 (10 mL) and washed with 0.001 N NaOH (1 
mL) and water. The organic layer was concentrated in vacuo, and crude amine was 
used without further purification. HATU (80 mg, 0.20 mmol) was added to a solution of 
the crude amine, 7-dimethylamino-4-coumarinacetic acid (31 mg, 0.13 mmol), and 
EtNiPr2 (55 µL, 0.31 mmol) in anhydrous DMF (1.5 mL). The reaction was allowed to stir 
for 16 h and then dried. Remaining HATU was precipitated with MeOH and removed via 
filtration. The crude product was subjected to flash chromatography (2:1 hexanes/EtOAc 
to 1:5 MeOH/EtOAc) with 2, eluting with 1:10 MeOH/EtOAc, collected as a yellow wax 
(45 mg, 67% yield). 1H NMR (acetone-d6, 500 MHz) δ: 9.44 (s, 2H); 8.99 (d, 1H, J = 
11.3Hz) ;8.94 (bm, 1H); 8.00 (bm, 1H); 7.91 (dd, 1H, J = 3.2, 11.2 Hz); 7.72 (d, 1H, J = 
3.2 Hz); 7.01 (s, 1H); 6.50 (s, 1H); 4.35 (m, 2H); 4.21 (dt, 1H, J = 8.0, 8.0, 16.1 Hz); 4.06 
(s, 2H); 3.70 (m, 2H); 3.59 (m, 1H); 3.51 (m, 2H); 3.39 (m, 1H); 3.34 (s, 2H); 2.90 (s, 
6H); 2.61-2.42 (m, 3H); 2.33 (ddd, 1H, J = 3.0, 5.0, 18.1 Hz); 2.26-2.17 (m, 2H); 2.09-
1.97 (m, 1H); 1.95-1.78 (m, 3H); 1.62-1.42 (m, 4H); 1.41-1.22 (m, 2H); 1.28 (s, 3H); 1.27 
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(s, 3H); 1.24 (d, 3H, J = 9.1 Hz); 1.17-1.04 (m, 4H); 1.01 (s, 3H); 0.90-0.63 (m, 4H); 0.35 




butylcarbamate (11). HATU (175 mg, 0.46 mmol) was added to a solution of cholic acid 
(100 mg, 0.24 mmol), N-boc-1,4-butanediamine (95 mL, 0.49 mmol), and Et3N (0.15 mL, 
1.1 mmol) in anhydrous DMF (1.5 mL). The reaction was allowed to stir for 16 h, then 
diluted with deionized H2O (20 mL) and extracted with EtOAc (20 mL). The organics 
were washed three times with deionized H2O (15 mL), dried over MgSO4, and 
concentrated in vacuo. Any remaining HATU was precipitated with CH2Cl2 and removed 
via filtration. Compound 11 (114 mg) was obtained as a clear oil, 80% yield. 1H NMR 
(CDCl3, 500 MHz) δ: 6.58 (br s, 1H); 4.92 (br s, 1H); 3.90 (s, 1H); 3.78 (s, 1H); 3.41 (s, 
9H); 3.17 (br d, 2H, J = 5.4 Hz); 3.06 (br d, 2H, J = 4.6 Hz); 2.27 (br s, 2H); 2.15 (t, 2H, J 
= 13.2 Hz); 1.14 (m, 1H); 1.88-1.75 (m, 2H); 1.70 (t, 3H, J = 13.7 Hz); 1.65-1.49 (m, 2H); 
1.47 (br s, 6H); 1.38 (s, 12H); 1.2 (m, 1H); 1.02 (m, 1H); 0.94 (d, 3H, J = 5.5 Hz); 0.83 (s, 
3H); 0.62 (s, 3H). 13C NMR (CDCl3, 125 MHz) δ: 174.5; 156.3; 79.1; 73.1; 71.8; 68.4; 
50.4; 46.3; 41.5; 41.3; 40.1; 39.5; 39.3; 39.0; 35.3; 35.2; 34.7; 34.6; 32.9; 31.7; 30.2; 
28.3 (3C); 28.0; 27.5; 27.4; 26.6; 26.2; 23.2; 22.3; 17.4; 12.4. HR-ESI-MS (m/z): Calcd 




hexadecahydro-1H-cyclopenta-[ α]-phenanthren-17-yl)pentanamide (3). Intermediate 11 
(55 mg, 0.095 mmol) was dissolved in CH2Cl2 (1 mL). Trifluoroacetic acid (0.020 mL, 
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0.285 mmol) was added dropwise and the reaction was allowed to stir at room 
temperature for 1 h. The reaction was then diluted with CH2Cl2 (10 mL) and washed with 
deionized H2O (10 mL). The organic layer was concentrated in vacuo, and crude amine 
was used without further purification. HATU (63 mg, 0.167 mmol) was added to a 
solution of the crude amine, 7-dimethylamino-4-coumarinacetic acid (21 mg, 0.084 
mmol), and Et3N (0.035 mL, 0.25 mmol) in anhydrous DMF (1.5 mL). The reaction was 
allowed to stir for 16 h, then diluted with deionized H2O (25 mL) and extracted with 
EtOAc (25 mL). The organics were washed 3× with deionized H2O (20 mL), dried over 
MgSO4, and concentrated in vacuo. Remaining HATU was precipitated with MeOH and 
removed via filtration. The organics were subjected to reversed-phase HPLC, and 2, 
eluting with 58% aqueous acetonitrile, was collected as a yellow powder (35 mg, 52% 
yield). 1H NMR (CDCl3, 500 MHz) d: 7.49 (d, 1H, J = 9.0 Hz); 7.00 (t, 1H, J = 5.2 Hz); 
6.57 (dd, 1H, J = 9.0, 2.4 Hz); 6.45 (t, 1H, J = 5.2 Hz); 6.39 (d, 1H, J = 2.4 Hz); 6.05 (s, 
1H); 3.92 (br m, 1H); 3.8 (br s, 1H); 3.61 (s, 2H); 3.46 (d, 1H, J = 5.5 Hz); 3.40 (br m, 
1H); 3.25-3.10 (m, 4H); 3.00 (s, 6H); 2.65 (s, 1H); 2.18 (t, 2H, J = 11.7 Hz); 2.10-1.95 (m, 
4H); 1.79 (m, 2H); 1.82-1.53 (m, 8H); 1.48 (br m, 9H); 1.36 (m, 2H); 1.21 (m, 1H); 1.07 
(m, 1H); 0.96 (d, 3H, J = 5.8 Hz); 0.85 (s, 3H); 0.63 (s, 3H). 13C NMR (CDCl3, 125 MHz) 
d: 174.5; 168.5; 162.3; 155.9; 153.0; 150.7; 125.9; 109.9; 109.2; 108.6; 98.0; 73.0; 71.9; 
68.4; 46.4; 46.2; 41.8; 41.5; 40.3; 40.1 (3C); 39.7; 39.6; 39.5; 38.9; 35.3; 34.7 (2C); 32.7; 
31.7; 30.5; 28.2; 27.6; 27.0; 26.4; 26.3; 23.2; 22.5; 17.5; 12.5. HR-ESI-MS (m/z): Calcd 







dimethylhexadecahydro-1H-cyclopenta-[a]phenanthren-17-yl)pentanamide (4). HATU 
(157 mg, 0.41 mmol) was added to a mixture of 3-keto-4-etiocholenic acid 9 (65 mg, 
0.021 mmol), and EtNiPr2 (108 µL, 0.62 mmol) in anhydrous DMF (5 mL). The reaction 
was allowed to stir for 12 h at rt and then dried under vacuum. Compound 4 (84 mg) was 
obtained as a clear wax, 94% yield after flash chromatography (2:1 hexanes/EtOAc to 
1:10 MeOH/EtOAc). 1H-NMR (CDCl3, 500 MHz) δ: 8.70 (d, 1H, J = 4.5 Hz); 8.40 (d, 1H J 
= 8.4 Hz); 7.48 (dd, 1H, J = 4.5, 8.4 Hz); 5.73 (s, 1H); 4.09 (dd, 1J, J = 7.1, 7.1 Hz); 2.89 
(t, 1H, J = 9.3 Hz); 2.49-2.16 (m, 6H); 2.14-2.03 (m, 2H); 1.95-1.77 (m, 5H); 1.76-1.37 
(m, 2H); 1.35-1.22 (m, 1H); 1.21 (s, 3H); 1.18-1.00 (m, 2H); 1.00 (s, 3H). 13C-NMR 
(CDCl3, 125 MHz) δ: 199.7; 170.8; 170.2; 151.8; 140.8; 135.2; 129.7; 124.3; 121; 60.6; 
55.8; 53.8; 52.9; 45.6; 38.8; 38; 36.1; 36; 34.2; 32.9; 32.1; 24.8; 24.2; 21.3; 17.6; 14.4; 






1. Newman, D. J.; Cragg, G. M.; Snader, K. M., The influence of natural products 
upon drug discovery. Nat. Prod. Rep. 2000, 17 (3), 215-234. 
2. Konig, H. G. G. M., Terpenoids from marine organisms: unique structures and 
their pharmacological potential. Phytochem. Rev. 2006, 5, 115-141. 
3. McClintock, J. B.; Baker, B. J., Marine Chemical Ecology. CRC Press: New York, 
2001. 
4. Coseri, S., Natural Products and their Analogues as Efficient Anticancer Drugs. 
Mini-Rev. Med. Chem. 2009, 9 (5), 560-571. 
5. (a) Haefner, B., Drugs from the deep: marine natural products as drug 
candidates. Drug Discov. Today 2003, 8 (12), 536-544; (b) van Kesteren, C.; de Vooght, 
M. M. M.; Lopez-Lazaro, L.; Mathot, R. A. A.; Schellens, J. H. M.; Jimeno, J. M.; Beijnen, 
J. H., Yondelis (R) (trabectedin, ET-743): the development of an anticancer agent of 
marine origin. Anti-Cancer Drugs 2003, 14 (7), 487-502; (c) Jimeno, J.; Lopez-Martin, J. 
A.; Ruiz-Casado, A.; Izquierdo, M. A.; Scheuer, P. J.; Rinehart, K., Progress in the 
clinical development of new marine-derived anticancer compounds. Anti-Cancer Drugs 
2004, 15 (4), 321-329. 
6. Newman, D. J.; Cragg, G. M., Marine natural products and related compounds in 
clinical and advanced preclinical trials. J. Nat. Prod. 2004, 67 (8), 1216-1238. 
7. (a) Pettit, G. R.; Kamano, Y.; Herald, C. L.; Tuinman, A. A.; Boettner, F. E.; Kizu, 
H.; Schmidt, J. M.; Baczynskyj, L.; Tomer, K. B.; Bontems, R. J., The isolation and 
structure of a remarkable marine animal antineoplastic constituent: dolastatin 10. J. Am. 
Chem. Soc. 1987, 109 (22), 6883-6885; (b) Bai, R.; Petit, G. R.; Hamel, E., Dolastatin 
10, a powerful cytostatic peptide derived from a marine animal: Inhibition of tubulin 
 170
polymerization mediated through the vinca alkaloid binding domain. Biochem. 
Pharmacol. 1990, 39 (12), 1941-1949. 
8. (a) Gunasekera, S. P.; Gunasekera, M.; Longley, R. E.; Schulte, G. K., 
Discodermolide: a new bioactive polyhydroxylated lactone from the marine sponge 
Discodermia dissoluta. J. Org. Chem. 1990, 55 (16), 4912-4915; (b) terHaar, E.; 
Kowalski, R. J.; Hamel, E.; Lin, C. M.; Longley, R. E.; Gunasekera, S. P.; Rosenkranz, 
H. S.; Day, B. W., Discodermolide, a cytotoxic marine agent that stabilizes microtubules 
more potently than taxol. Biochemistry 1996, 35 (1), 243-250. 
9. (a) Hamann, M. T.; Scheuer, P. J., Kahalalide F: a bioactive depsipeptide from 
the sacoglossan mollusk Elysia rufescens and the green alga Bryopsis sp. J. Am. Chem. 
Soc. 1993, 115 (13), 5825-5826; (b) GarciaRocha, M.; Bonay, P.; Avila, J., The 
antitumoral compound Kahalalide F acts on cell lysosomes. Cancer Lett. 1996, 99 (1), 
43-50. 
10. Pettit, G. R.; Herald, C. L.; Doubek, D. L.; Herald, D. L.; Arnold, E.; Clardy, J., 
Isolation and structure of bryostatin 1. J. Am. Chem. Soc. 1982, 104 (24), 6846-6848. 
11. Newman, D. J.; Cragg, G. M., Natural products as sources of new drugs over the 
last 25 years. J. Nat. Prod. 2007, 70 (3), 461-477. 
12. Fischbach, M. A.; Walsh, C. T., Antibiotics for emerging pathogens. Science 
2009, 325, 1089-1093. 
13. Rahman, H.; Austin, B.; Mitchell, W. J.; Morris, P. C.; Jamieson, D. J.; Adams, D. 
R.; Spragg, A. M.; Schweizer, M., Novel Anti-Infective Compounds from Marine Bacteria. 
Marine Drugs 2010, 8 (3), 498-518. 
14. (a) Lane, A. L.; Kubanek, J., Secondary metabolite defenses against pathogens 
and biofoulers. In Algal Chemical Ecology, Amsler, C. D., Ed. Springer-Verlag Berlin 
Heidelberg: 2008; pp 229-243; (b) Stout, E. P.; Hasemeyer, A. P.; Lane, A. L.; 
Davenport, T. M.; Engel, S.; Hay, M. E.; Fairchild, C. R.; Prudhomme, J.; Le Roch, K.; 
 171
Aalbersberg, W.; Kubanek, J., Antibacterial Neurymenolides from the Fijian Red Alga 
Neurymenia fraxinifolia. Org. Lett. 2009, 11 (1), 225-228. 
15. Yousaf, M.; Hammond, N. L.; Peng, J. N.; Wahyuono, S.; McIntosh, K. A.; 
Charman, W. N.; Mayer, A. M. S.; Hamann, M. T., New manzamine alkaloids from an 
indo-pacific sponge. Pharmacokinetics, oral availability, and the significant activity of 
several manzamines against HIV-I, AIDS opportunistic infections, and inflammatory 
diseases. J. Med. Chem. 2004, 47 (14), 3512-3517. 
16. Snow, R. W.; Guerra, C. A.; Noor, A. M.; Myint, H. Y.; Hay, S. I., The global 
distribution of clinical episodes of Plasmodium falciparum malaria. Nature 2005, 434 
(7030), 214-217. 
17. Kaur, K.; Jain, M.; Kaur, T.; Jain, R., Antimalarials from nature. Bioorg. Med. 
Chem. 2009, 17 (9), 3229-3256. 
18. (a) Lane, A. L.; Stout, E. P.; Hay, M. E.; Prusak, A. C.; Hardcastle, K.; Fairchild, 
C. R.; Franzblau, S. G.; Le Roch, K.; Prudhomme, J.; Aalbersberg, W.; Kubanek, J., 
Callophycoic acids and callophycols from the Fijian red alga Callophycus serratus. J. 
Org. Chem. 2007, 72 (19), 7343-7351; (b) Lane, A. L.; Stout, E. P.; Lin, A. S.; 
Prudhomme, J.; Le Roch, K.; Fairchild, C. R.; Franzblau, S. G.; Hay, M. E.; Aalbersberg, 
W.; Kubanek, J., Antimalarial Bromophycolides J-Q from the Fijian Red Alga 
Callophycus serratus. J. Org. Chem. 2009, 74 (7), 2736-2742; (c) Stout, E. P.; 
Prudhomme, J.; Le Roch, K.; Fairchild, C. R.; Franzblau, S. G.; Aalbersberg, W.; Hay, 
M. E.; Kubanek, J., Unusual Antimalarial Meroditerpenes from Tropical Red Macroalgae. 
Bioorg. Med. Chem. Lett. 2010. 
19. (a) Hamel, E., Antimitotic natural products and their interactions with tubulin. 
Med. Res. Rev. 1996, 16 (2), 207-231; (b) Kingston, D. G. I., Tubulin-Interactive Natural 
Products as Anticancer Agents. J. Nat. Prod. 2009, 72 (3), 507-515. 
 172
20. Parsons, A. B.; Lopez, A.; Givoni, I. E.; Williams, D. E.; Gray, C. A.; Porter, J.; 
Chua, G.; Sopko, R.; Brost, R. L.; Ho, C. H.; Wang, J. Y.; Ketela, T.; Brenner, C.; Brill, J. 
A.; Fernandez, G. E.; Lorenz, T. C.; Payne, G. S.; Ishihara, S.; Ohya, Y.; Andrews, B.; 
Hughes, T. R.; Frey, B. J.; Graham, T. R.; Andersen, R. J.; Boone, C., Exploring the 
mode-of-action of bioactive compounds by chemical-genetic profiling in yeast. Cell 2006, 
126 (3), 611-625. 
21. Bottcher, T.; Pitscheider, M.; Sieber, S. A., Natural Products and Their Biological 
Targets: Proteomic and Metabolomic Labeling Strategies. Angewandte Chemie-
International Edition 2010, 49 (15), 2680-2698. 
22. Carlson, E. E., Natural Products as Chemical Probes. ACS Chem. Biol. 2010, 5 
(7), 639-653. 
23. Alexander, M. D.; Burkart, M. D.; Leonard, M. S.; Portonovo, P.; Liang, B.; Ding, 
X. B.; Joullie, M. M.; Gulledge, B. M.; Aggen, J. B.; Chamberlin, A. R.; Sandler, J.; 
Fenical, W.; Cui, J.; Gharpure, S. J.; Polosukhin, A.; Zhang, H. R.; Evans, P. A.; 
Richardson, A. D.; Harper, M. K.; Ireland, C. M.; Vong, B. G.; Brady, T. P.; Theodorakis, 
E. A.; La Clair, J. J., A central strategy for converting natural products into fluorescent 
probes. ChemBioChem 2006, 7 (3), 409-416. 
24. Hughes, C. C.; Yang, Y. L.; Liu, W. T.; Dorrestein, P. C.; La Clair, J. J.; Fenical, 
W., Marinopyrrole A Target Elucidation by Acyl Dye Transfer. J. Am. Chem. Soc. 2009, 
131 (34), 12094-12096. 
25. Taunton, J.; Collins, J. L.; Schreiber, S. L., Synthesis of natural and modified 
trapoxins, useful reagents for exploring histone deacetylase function. J. Am. Chem. Soc. 
1996, 118 (43), 10412-10422. 
26. Taunton, J.; Hassig, C. A.; Schreiber, S. L., A mammalian histone deacetylase 
related to the yeast transcriptional regulator Rpd3p. Science 1996, 272 (5260), 408-411. 
 173
27. Stout, E. P.; La Clair, J. J.; Snell, T. W.; Shearer, T. L.; Kubanek, J., 
Conservation of progesterone hormone function in invertebrate reproduction. Proc. Natl. 
Acad. Sci. U. S. A. 2010, 107 (26), 11859-11864. 
28. Kobayashi, J.; Ishibashi, M., Marine Natural Products and Marine Chemical 
Ecology. In Comprehensive Natural Products Chemistry, 1st ed.; Barton, D.; Nakanishi, 
K.; Meth-Cohn, O.; Mori, K., Eds. Elsevier: Amsterdam, 1999; Vol. 8, pp 415-637. 
29. Blunt, J. W.; Copp, B. R.; Munro, M. H. G.; Northcote, P. T.; Prinsep, M. R., 
Marine natural products. Nat. Prod. Rep. 2010, 27 (2), 165-237. 
30. Mayer, A. M. S.; Gustafson, K. R., Marine pharmacology in 2005-2006: 
Antitumour and cytotoxic compounds. Eur. J. Cancer 2008, 44 (16), 2357-2387. 
31. Bourguet-Kondracki, M.; Kornprobst, J. M., Marine pharmacology: Potentialities 
in the treatment of infectious diseases, osteoporosis and Alzheimer's disease. In Marine 
Biotechnology II, 2005; Vol. 97, pp 105-131. 
32. Bhadury, P.; Wright, P. C., Exploitation of marine algae: biogenic compounds for 
potential antifouling applications. Planta 2004, 219 (4), 561-578. 
33. Torssell, K. B. G., Natural Product Chemistry: A Mechanistic, Biosynthetic, and 
Ecological Approach. 2nd ed.; Swedish Pharmaceutical Society: Stockholm, 1997. 
34. (a) Hay, M. E.; Fenical, W., Marine plant-herbivore interactions - the ecology of 
chemical defense. Annu. Rev. Ecol. Syst. 1988, 19, 111-145; (b) Paul, V. J., Ecological 
Roles of Marine Natural Products. Comstock Publishing Associates: Ithaca, NY, 1992. 
35. Dewick, P. M., Medicinal Natural Products: A Biosynthetic Approach. 2nd ed.; 
John Wiley & Sons, Ltd.: West Sussex, England, 2001. 
36. Chinou, I., Labdanes of natural origin-biological activities (1981-2004). Curr. 
Med. Chem. 2005, 12 (11), 1295-1317. 
37. Iliopoulou, D.; Mihopoulos, N.; Roussis, V.; Vagias, C., New brominated labdane 
diterpenes from the red alga Laurencia obtusa. J. Nat. Prod. 2003, 66 (9), 1225-1228. 
 174
38. Briand, A.; Kornprobst, J. M.; AlEasa, H. S.; Rizk, A. F. M.; Toupet, L., (-)-
paniculatol, a new ent-labdane bromoditerpene from Laurencia paniculata. Tetrahedron 
Lett. 1997, 38 (19), 3399-3400. 
39. Suzuki, M.; Nakano, S.; Takahashi, Y.; Abe, T.; Masuda, T. A. M.; Takahashi, H.; 
Kobayashi, K., Brominated labdane-type diterpenoids from an Okinawan Laurencia sp. 
J. Nat. Prod. 2002, 65 (6), 801-804. 
40. Estrada, D. M.; Ravelo, J. L.; Ruizperez, C.; Martin, J. D.; Solans, X., 
Dactylomelol, a new class of diterpene from the sea hare Aplysia dactylomela. 
Tetrahedron Lett. 1989, 30 (45), 6219-6220. 
41. Findlay, J. A.; Li, G. Q., Novel terpenoids from the Sea Hare Aplysia punctata. 
Can. J. Chem. 2002, 80 (12), 1697-1707. 
42. Etahiri, S.; Bultel-Ponce, V.; Caux, C.; Guyot, M., New bromoditerpenes from the 
red alga Sphaerococcus coronopifolius. J. Nat. Prod. 2001, 64 (8), 1024-1027. 
43. Fernandez, J. J.; Souto, M. L.; Gil, L. V.; Norte, M., Isolation of naturally 
occurring dactylomelane metabolites as Laurencia constituents. Tetrahedron 2005, 61 
(37), 8910-8915. 
44. (a) Kubanek, J.; Prusak, A. C.; Snell, T. W.; Giese, R. A.; Hardcastle, K. I.; 
Fairchild, C. R.; Aalbersberg, W.; Raventos-Suarez, C.; Hay, M. E., Antineoplastic 
diterpene-benzoate macrolides from the Fijian red alga Callophycus serratus. Org. Lett. 
2005, 7 (23), 5261-5264; (b) Kubanek, J.; Prusak, A. C.; Snell, T. W.; Giese, R. A.; 
Fairchild, C. R.; Aalbersberg, W.; Hay, M. E., Bromophycolides C-I from the Fijian red 
alga Callophycus serratus. J. Nat. Prod. 2006, 69 (5), 731-735; (c) Lin, A. S.; Stout, E. 
P.; Prudhomme, J.; Le Roch, K.; Fairchild, C. R.; Franzblau, S. G.; Aalbersberg, W.; 
Hay, M. E.; Kubanek, J., Bioactive Bromophycolides R-U from the Fijian Red Alga 
Callophycus serratus. J. Nat. Prod. 2010, 73 (2), 275-278. 
 175
45. Lane, A. L.; Nyadong, L.; Galhena, A. S.; Shearer, T. L.; Stout, E. P.; Parry, R. 
M.; Kwasnik, M.; Wang, M. D.; Hay, M. E.; Fernandez, F. M.; Kubanek, J., Desorption 
electrospray ionization mass spectrometry reveals surface-mediated antifungal chemical 
defense of a tropical seaweed. Proc. Natl. Acad. Sci. U. S. A. 2009, 106 (18), 7314-
7319. 
46. Navarro, G.; Fernandez, J. J.; Norte, M., Novel meroditerpenes from the brown 
alga Cystoseira sp. J. Nat. Prod. 2004, 67 (3), 495-499. 
47. Hay, M. E., Marine chemical ecology: What's known and what's next? J. Exp. 
Mar. Biol. Ecol. 1996, 200 (1-2), 103-134. 
48. (a) Lubchenco, J.; Gaines, S. D., A unified approach to marine plant-herbivore 
interactions .1. populations and communities. Annu. Rev. Ecol. Syst. 1981, 12, 405-437; 
(b) Duffy, J. E.; Hay, M. E., Seaweed adaptations to herbivory - chemical, structural, and 
morphological defenses are often adjusted to spatial or temporal patterns of attack. 
Bioscience 1990, 40 (5), 368-375. 
49. Bolser, R. C.; Hay, M. E., Are tropical plants better defended? Palatability and 
defenses of temperate vs tropical seaweeds. Ecology 1996, 77 (8), 2269-2286. 
50. (a) Littler, M. M.; Littler, D. S.; Taylor, P. R., Animal plant defense associations - 
effects on the distribution and abundance of tropical reef macrophytes. J. Exp. Mar. Biol. 
Ecol. 1987, 105 (2-3), 107-121; (b) Hay, M. E.; Fenical, W.; Gustafson, K., Chemical 
defense against diverse coral-reef herbivores. Ecology 1987, 68 (6), 1581-1591. 
51. Hardt, I. H.; Fenical, W.; Cronin, G.; Hay, M. E., Acutilols, potent herbivore 
feeding deterrents from the tropical brown alga, Dictyota acutiloba. Phytochemistry 
1996, 43 (1), 71-73. 
52. Cronin, G.; Paul, V. J.; Hay, M. E.; Fenical, W., Are tropical herbivores more 
resistant than temperate herbivores to seaweed chemical defenses? Diterpenoid 
 176
metabolites from Dictyota acutiloba as feeding deterrents for tropical versus temperate 
fishes and urchins. J. Chem. Ecol. 1997, 23 (2), 289-302. 
53. Cruz-Rivera, E.; Hay, M. E., Prey nutritional quality interacts with chemical 
defenses to affect consumer feeding and fitness. Ecol. Monogr. 2003, 73 (3), 483-506. 
54. Hillis-Colinvaux, L., Ecology and taxonomy of Halimeda: primary producer of 
coral reefs. Academic Press: London, 1980; Vol. 17. 
55. Paul, V. J.; Fenical, W., Novel bioactive diterpenoid metabolites from tropical 
marine algae of the genus Halimeda (Chlorophyta). Tetrahedron 1984, 40 (16), 3053-
3062. 
56. Paul, V. J.; Vanalstyne, K. L., Chemical defense and chemical variation in some 
tropical pacific species of Halimeda (Halimedaceae, Chlorophyta). Coral Reefs 1988, 6 
(3-4), 263-269. 
57. Paul, V. J.; Vanalstyne, K. L., Activation of chemical defenses in the tropical 
green algae Halimeda spp. J. Exp. Mar. Biol. Ecol. 1992, 160 (2), 191-203. 
58. Cetrulo, G. L.; Hay, M. E., Activated chemical defenses in tropical versus 
temperate seaweeds. Marine Ecology-Progress Series 2000, 207, 243-253. 
59. Jung, V.; Pohnert, G., Rapid wound-activated transformation of the green algal 
defensive metabolite caulerpenyne. Tetrahedron 2001, 57 (33), 7169-7172. 
60. Jonassohn, M.; Davidsson, R.; Kahnberg, P.; Sterner, O., The reactivity of 
drimane unsaturated dialdehydes towards nucleophiles. Tetrahedron 1997, 53 (1), 237-
244. 
61. (a) Jahn, A.; Griebe, T.; Nielsen, P. H., Composition of Pseudomonas putida 
biofilms: Accumulation of protein in the biofilm matrix. Biofouling 1999, 14 (1), 49-57; (b) 
Bhosale, S. H.; Nagle, V. L.; Jagtap, T. G., Antifouling potential of some marine 
organisms from India against species of Bacillus and Pseudomonas. Mar. Biotechnol. 
2002, 4 (2), 111-118. 
 177
62. Konig, G. M.; Wright, A. D., Laurencia rigida: Chemical investigations of its 
antifouling dichloromethane extract. J. Nat. Prod. 1997, 60 (10), 967-970. 
63. de Nys, R.; Leya, T.; Maximillien , R.; Afsar, A.; Nair, P. S. R.; Steinberg, P., The 
need for standardised broad scale bioassay testing: A case study using the red alga 
Laurencia rigida Biofouling 1996, 10 (1-3), 213-224. 
64. Smyrniotopoulos, V.; Abatis, D.; Tziveleka, L. A.; Tsitsimpikou, C.; Roussis, V.; 
Loukis, A.; Vagias, C., Acetylene sesquiterpenoid esters from the green alga Caulerpa 
prolifera. J. Nat. Prod. 2003, 66 (1), 21-24. 
65. Engel, S.; Jensen, P. R.; Fenical, W., Chemical ecology of marine microbial 
defense. J. Chem. Ecol. 2002, 28 (10), 1971-1985. 
66. Puglisi, M. P.; Tan, L. T.; Jensen, P. R.; Fenical, W., Capisterones A and B from 
the tropical green alga Penicillus capitatus: unexpected anti-fungal defenses targeting 
the marine pathogen Lindra thallasiae. Tetrahedron 2004, 60 (33), 7035-7039. 
67. Fuller, R. W.; Cardellina, J. H.; Kato, Y.; Brinen, L. S.; Clardy, J.; Snader, K. M.; 
Boyd, M. R., A pentahalogenated monoterpene from the red alga Portieria hornemannii 
produces a novel cytotoxicity profile against a diverse panel of human tumor-cell lines. J. 
Med. Chem. 1992, 35 (16), 3007-3011. 
68. (a) Schlama, T.; Baati, R.; Gouverneur, V.; Valleix, A.; Falck, J. R.; Mioskowski, 
C., Total synthesis of (+/-)-halomon by a Johnson-Claisen rearrangement. Angewandte 
Chemie-International Edition 1998, 37 (15), 2085-2087; (b) Sotokawa, T.; Noda, T.; Pi, 
S.; Hirama, M., A three-step synthesis of halomon. Angewandte Chemie-International 
Edition 2000, 39 (19), 3430-+. 
69. Jha, R. K.; Zi-rong, X., Biomedical compounds from marine organisms. Marine 
Drugs 2004, 2, 123-146. 
 178
70. Blunt, J. W.; Hartshorn, M. P.; McLennan, T. J.; Munro, M. H. G.; Robinson, W. 
T.; Yorke, S. C., Thyrsiferol: a squalene-derived metabolite of. Tetrahedron Lett. 1978, 
19 (1), 69-72. 
71. Gonzalez, A. G.; Arteaga, J. M.; Fernandez, J. J.; Martin, J. D.; Norte, M.; Ruano, 
J. Z., Terpenoids of the red alga laurencia pinnatifida. Tetrahedron 1984, 40 (14), 2751-
2755. 
72. Suzuki, T.; Suzuki, M.; Furusaki, A.; Matsumoto, T.; Kato, A.; Imanaka, Y.; 
Kurosawa, E., Teurilene and thyrsiferyl 23-acetate, meso and remarkably cytotoxic 
compounds from the marine red alga laurencia obtusa (hudson) lamouroux. Tetrahedron 
Lett. 1985, 26 (10), 1329-1332. 
73. Matsuzawa, S.-i.; Suzuki, T.; Suzuki, M.; Matsuda, A.; Kawamura, T.; Mizuno, Y.; 
Kikuchi, K., Thyrsiferyl 23-acetate is a novel specific inhibitor of protein phosphatase 
PP2A. FEBS Lett. 1994, 356 (2-3), 272-274. 
74. (a) Fernández, J.; Souto, M. L.; Norte, M., Evaluation of the cytotoxic activity of 
polyethers isolated from Laurencia. Bioorg. Med. Chem. 1998, 6 (12), 2237-2243; (b) 
Souto, M. L.; Manríquez, C. P.; Norte, M.; Leira, F.; Fernández, J. J., The inhibitory 
effects of squalene-derived triterpenes on protein phosphatase PP2A. Bioorg. Med. 
Chem. Lett. 2003, 13 (7), 1261-1264. 
75. Albizati, K. F.; Martin, V. A.; Agharahimi, M. R.; Stolze, D. A., Synthesis of Marine 
Natural Products 1: Terpenoids. In Bioorganic Marine Chemistry, Scheuer, P. J., Ed. 
Springer-Verlag: Berlin, 1992; Vol. 5, p 254. 
76. Rodríguez, A. D.; González, E.; Ramírez, C., The structural chemistry, reactivity, 
and total synthesis of dolabellane diterpenes. Tetrahedron 1998, 54 (39), 11683-11729. 
77. Durán, R.; Zubía, E.; Ortega, M. J.; Salvá, J., New diterpenoids from the alga 
Dictyota dichotoma. Tetrahedron 1997, 53 (25), 8675-8688. 
 179
78. Tringali, C.; Piattelli, M.; Nicolosi, G., Structure and conformation of new 
diterpenes based on the dolabellane skeleton from a Dictyota species. Tetrahedron 
1984, 40 (4), 799-803. 
79. Piattelli, M.; Tringali, C.; Neri, P.; Rocco, C., Stereochemistry and Conformation 
of Dolabellane Diterpenes: An Nmr and Molecular Mechanics Study. J. Nat. Prod. 1995, 
58 (5), 697-704. 
80. Suzuki, M.; Takahashi, Y.; Matsuo, Y.; Guiry, M. D.; Masuda, M., Scanlonenyne, 
a novel halogenated C15 acetogenin from the red alga Laurencia obtusa in Irish waters. 
Tetrahedron 1997, 53 (12), 4271-4278. 
81. (a) Suzuki, M.; Sasage, Y.; Ikura, M.; Hikichi, K.; Kurosawa, E., Structure revision 
of okamurallene and structure elucidation of further C15 non-terpenoid bromoallenes 
from Laurencia intricata. Phytochemistry 1989, 28 (8), 2145-2148; (b) Suzuki, M.; 
Kawamoto, T.; Vairappan, C. S.; Ishii, T.; Abe, T.; Masuda, M., Halogenated metabolites 
from Japanese Laurencia spp. Phytochemistry 2005, 66 (23), 2787-2793. 
82. Ji, N.-Y.; Li, X.-M.; Li, K.; Wang, B.-G., Laurendecumallenes A–B and 
Laurendecumenynes A–B, Halogenated Nonterpenoid C15-Acetogenins from the Marine 
Red Alga Laurencia decumbens. J. Nat. Prod. 2007, 70 (9), 1499-1502. 
83. Kubanek, J.; Jensen, P. R.; Keifer, P. A.; Sullards, M. C.; Collins, D. O.; Fenical, 
W., Seaweed resistance to microbial attack: A targeted chemical defense against marine 
fungi. Proc. Natl. Acad. Sci. U. S. A. 2003, 100 (12), 6916-6921. 
84. Carmeli, S.; Moore, R. E.; Patterson, G. M. L., Tolytoxin and New Scytophycins 
from Three Species of Scytonema. J. Nat. Prod. 1990, 53 (6), 1533-1542. 
85. Nagai, H.; Yasumoto, T.; Hokama, Y., Manauealides,1 Some of the Causative 
Agents of a Red Alga Gracilaria coronopifolia Poisoning in Hawaii. J. Nat. Prod. 1997, 60 
(9), 925-928. 
 180
86. Moore, R. E.; Blackman, A. J.; Cheuk, C. E.; Mynderse, J. S.; Matsumoto, G. K.; 
Clardy, J.; Woodard, R. W.; Craig, J. C., Absolute stereochemistries of the aplysiatoxins 
and oscillatoxin A. J. Org. Chem. 1984, 49 (13), 2484-2489. 
87. (a) Kato, Y.; Scheuer, P. J., Aplysiatoxin and debromoaplysiatoxin, constituents 
of the marine mollusk Stylocheilus longicauda. J. Am. Chem. Soc. 1974, 96 (7), 2245-
2246; (b) Mynderse, J. S.; Moore, R. E.; Kashiwagi, M.; Norton, T. R., Anti-leukemia 
activity in Oscillatoriaceae - isolation of debromoaplysiatoxin from Lyngbya. Science 
1977, 196 (4289), 538-540. 
88. McPhail, K. L.; France, D.; Cornell-Kennon, S.; Gerwick, W. H., Peyssonenynes 
A and B, Novel Enediyne Oxylipins with DNA Methyl Transferase Inhibitory Activity from 
the Red Marine Alga Peyssonnelia caulifera. J. Nat. Prod. 2004, 67 (6), 1010-1013. 
89. Paul, V. J.; Fenical, W., Toxic acetylene-containing lipids from the red marine 
alga lamouroux. Tetrahedron Lett. 1980, 21 (35), 3327-3330. 
90. (a) Kazlauskas, R.; Murphy, P. T.; Quinn, R. J.; Wells, R. J., A new class of 
halogenated lactones from the red alga (bonnemaisoniaceae). Tetrahedron Lett. 1977, 
18 (1), 37-40; (b) de Nys, R.; Wright, A. D.; König, G. M.; Sticher, O., New halogenated 
furanones from the marine alga delisea pulchra (cf. fimbriata). Tetrahedron 1993, 49 
(48), 11213-11220. 
91. (a) Maximilien, R.; de Nys, R.; Holmstrom, C.; Gram, L.; Givskov, M.; Crass, K.; 
Kjelleberg, S.; Steinberg, P. D., Chemical mediation of bacterial surface colonisation by 
secondary metabolites from the red alga Delisea pulchra. Aquat. Microb. Ecol. 1998, 15 
(3), 233-246; (b) Steinberg, P. D.; de Nys, R., Chemical mediation of colonization of 
seaweed surfaces. J. Phycol. 2002, 38 (4), 621-629. 
92. Dworjanyn, S. A.; de Nys, R.; Steinberg, P. D., Chemically mediated antifouling 
in the red alga Delisea pulchra. Marine Ecology-Progress Series 2006, 318, 153-163. 
 181
93. Wright, J. T.; de Nys, R.; Poore, A. G. B.; Steinberg, P. D., Chemical defense in a 
marine alga: Heritability and the potential for selection by herbivores. Ecology 2004, 85 
(11), 2946-2959. 
94. Kurata, K.; Taniguchii, K.; Takashima, K.; Hayashi, I.; Suzuki, M., Feeding-
deterrent bromophenols from Odonthalia corymbifera. Phytochemistry 1997, 45 (3), 485-
487. 
95. Xu, N.; Fan, X.; Yan, X.; Li, X.; Niu, R.; Tseng, C. K., Antibacterial bromophenols 
from the marine red alga Rhodomela confervoides. Phytochemistry 2003, 62 (8), 1221-
1224. 
96. Li, K.; Li, X.-M.; Ji, N.-Y.; Wang, B.-G., Bromophenols from the Marine Red Alga 
Polysiphonia urceolata with DPPH Radical Scavenging Activity. J. Nat. Prod. 2007, 71 
(1), 28-30. 
97. Hamann, M. T.; Otto, C. S.; Scheuer, P. J.; Dunbar, D. C., Kahalalides: Bioactive 
peptide from a marine mollusk Elysia rufescens and its algal diet Bryopsis sp. J. Org. 
Chem. 1996, 61 (19), 6594-6600. 
98. Goetz, G.; Yoshida, W. Y.; Scheuer, P. J., The absolute stereochemistry of 
Kahalalide F. Tetrahedron 1999, 55 (25), 7739-7746. 
99. Hill, R. T.; Hamann, M. T.; Enticknap, J.; Rao, K. V. Kahalalide-Producing 
Bacteria and Methods of Identifying Kahalalide-Producing Bacteria and Preparing 
Kahalalides. 2005. 
100. (a) Goetz, G.; Nakao, Y.; Scheuer, P. J., Two Acyclic Kahalalides from the 
Sacoglossan Mollusk Elysia rufescens1. J. Nat. Prod. 1997, 60 (6), 562-567; (b) Kan, Y.; 
Fujita, T.; Sakamoto, B.; Hokama, Y.; Nagai, H., Kahalalide K:  A New Cyclic 
Depsipeptide from the Hawaiian Green Alga Bryopsis Species. J. Nat. Prod. 1999, 62 
(8), 1169-1172; (c) Bonnard, I.; Manzanares, I.; Rinehart, K. L., Stereochemistry of 
Kahalalide F. J. Nat. Prod. 2003, 66 (11), 1466-1470; (d) Horgen, F. D.; delos Santos, D. 
 182
B.; Goetz, G.; Sakamoto, B.; Kan, Y.; Nagai, H.; Scheuer, P. J., A New Depsipeptide 
from the Sacoglossan Mollusk Elysia ornata and the Green Alga Bryopsis Species1. J. 
Nat. Prod. 1999, 63 (1), 152-154; (e) Dmitrenok, A.; Iwashita, T.; Nakajima, T.; 
Sakamoto, B.; Namikoshi, M.; Nagai, H., New cyclic depsipeptides from the green alga 
Bryopsis species; application of a carboxypeptidase hydrolysis reaction to the structure 
determination. Tetrahedron 2006, 62 (6), 1301-1308. 
101. Hay, M. E.; Paul, V. J.; Lewis, S. M.; Gustafson, K.; Tucker, J.; Trindell, R. N., 
Can tropical seaweeds reduce herbivory by growing at night - diel patterns of growth, 
nitrogen-content, herbivory, and chemical versus morphological defenses. Oecologia 
1988, 75 (2), 233-245. 
102. Öztunç, A.; Imre, S.; Lotter, H.; Wagner, H., Ent-13-epiconcinndiol from the red 
alga Chondria tenuissima and its absolute configuration. Phytochemistry 1989, 28 (12), 
3403-3404. 
103. Palermo, J. A.; Flower, P. B.; Seldes, A. M., Chondriamides A and B, new indolic 
metabolites from the red alga Chondria sp. Tetrahedron Lett. 1992, 33 (22), 3097-3100. 
104. Gupta, L.; Talwar, A.; Chauhan, P. M. S., Bis and tris indole alkaloids from 
marine organisms: New leads for drug discovery. Curr. Med. Chem. 2007, 14 (16), 1789-
1803. 
105. Davyt, D.; Entz, W.; Fernandez, R.; Mariezcurrena, R.; Mombrú, A. W.; Saldaña, 
J.; Domínguez, L.; Coll, J.; Manta, E., A New Indole Derivative from the Red Alga 
Chondria atropurpurea. Isolation, Structure Determination, and Anthelmintic Activity1. J. 
Nat. Prod. 1998, 61 (12), 1560-1563. 
106. Kuramochi, K.; Osada, Y.; Kitahara, T., Synthetic study on indolic enamides. 
Tetrahedron 2003, 59 (47), 9447-9454. 
 183
107. N'Diaye, I.; Guella, G.; Chiasera, G.; Mancini, I.; Pietra, F., Almazole A and 
almazole B, unusual marine alkaloids of an unidentified red seaweed of the family 
delesseriaceae from the coasts of Senegal. Tetrahedron Lett. 1994, 35 (27), 4827-4830. 
108. Guella, G.; N'Diaye, I.; Fofana, M.; Mancini, I., Isolation, synthesis and 
photochemical properties of almazolone, a new indole alkaloid from a red alga of 
Senegal. Tetrahedron 2006, 62 (6), 1165-1170. 
109. Gross, H.; Goeger, D. E.; Hills, P.; Mooberry, S. L.; Ballantine, D. L.; Murray, T. 
F.; Valeriote, F. A.; Gerwick, W. H., Lophocladines, Bioactive Alkaloids from the Red 
Alga Lophocladia sp. J. Nat. Prod. 2006, 69 (4), 640-644. 
110. Janot, M. M.; Guilhem, J.; Contz, O.; Wenera, G.; Cionga, E., Ann. Pharm. Fr. 
1979, 37, 413-420. 
111. Sun, Y.; Xu, Y.; Liu, K.; Hua, H.; Zhu, H.; Pei, Y., Gracilarioside and Gracilamides 
from the Red Alga Gracilaria asiatica. J. Nat. Prod. 2006, 69 (10), 1488-1491. 
112. (a) Yotsu-Yamashita, M.; Haddock, R. L.; Yasumoto, T., Polycavernoside A: a 
novel glycosidic macrolide from the red alga Polycavernosa tsudai (Gracilaria edulis). J. 
Am. Chem. Soc. 1993, 115 (3), 1147-1148; (b) Yotsu-Yamashita, M.; Seki, T.; Paul, V. 
J.; Naoki, H.; Yasumoto, T., Four new analogs of polycavernoside A. Tetrahedron Lett. 
1995, 36 (31), 5563-5566; (c) Yotsu-Yamashita, M.; Abe, K.; Seki, T.; Fujiwara, K.; 
Yasumoto, T., Polycavernoside C and C2, the new analogs of the human lethal toxin 
polycavernoside A, from the red alga, Gracilaria edulis. Tetrahedron Lett. 2007, 48 (13), 
2255-2259. 
113. Higa, T.; Kuniyoshi, M., Toxins associated with medicinal and edible seaweeds. 
Journal of Toxicology-Toxin Reviews 2000, 19 (2), 119-137. 
114. Fujiwara, K.; Murai, A.; Yotsu-Yamashita, M.; Yasumoto, T., Total Synthesis and 
Absolute Configuration of Polycavernoside A. J. Am. Chem. Soc. 1998, 120 (41), 10770-
10771. 
 184
115. Williams, D. E.; Sturgeon, C. M.; Roberge, M.; Andersen, R. J., Nigricanosides A 
and B, Antimitotic Glycolipids Isolated from the Green Alga Avrainvillea nigricans 
Collected in Dominica. J. Am. Chem. Soc. 2007, 129 (18), 5822-5823. 
116. Ohtani, I.; Kusumi, T.; Kashman, Y.; Kakisawa, H., High-field FT NMR application 
of Mosher's method. The absolute configurations of marine terpenoids. J. Am. Chem. 
Soc. 1991, 113 (11), 4092-4096. 
117. (a) Frelek, J.; Klimek, A.; Ruskowska, P., Dinuclear transition metal complexes 
as auxiliary chromophores in chiroptical studies on bioactive compounds. Curr. Org. 
Chem. 2003, 7 (11), 1081-1104; (b) Gorecki, M.; Jablonska, E.; Kruszewska, A.; 
Suszczynska, A.; Urbanczyk-Lipkowska, Z.; Gerards, M.; Morzycki, J. W.; Szczepek, W. 
J.; Frelek, J., Practical method for the absolute configuration assignment of tert/tert 1,2-
diols using their complexes with Mo-2(OAc)(4). J. Org. Chem. 2007, 72 (8), 2906-2916. 
118. Tai-Sun, S.; Godber, J. S., Isolation of four tocopherols and four tocotrienols from 
a variety of natural sources by semi-preparative high-performance liquid 
chromatography. J. Chromatogr. A 1994, 678 (1), 49-58. 
119. Amico, V.; Oriente, G.; Piattelli, M.; Ruberto, G.; Tringali, C., A quinone-
hydroquinone couple from the Brown alga Cystoseira stricta. Phytochemistry 1982, 21 
(2), 421-424. 
120. Reddy, P.; Urban, S., Meroditerpenoids from the southern Australian marine 
brown alga Sargassum fallax. Phytochemistry 2009, 70 (2), 250-255. 
121. Munne-Bosch, S.; Alegre, L., The function of tocopherols and tocotrienols in 
plants. Crit. Rev. Plant Sci. 2002, 21 (1), 31-57. 
122. Niki, E., Tocopherylquinone and tocopherylhydroquinone. Redox Rep. 2007, 12 
(5), 204-210. 
123. Littler, D. S. L. a. M. M., South Pacific Reef Plants. Offshore Graphics, Inc.: 
Washington, D.C., 2003. 
 185
124. Saladino, R.; Neri, V.; Farina, A.; Crestini, C.; Nencioni, L.; Palamara, A. T., A 
novel and efficient synthesis of tocopheryl quinones by homogeneous and 
heterogeneous methyltrioxorhenium/hydrogen peroxide catalytic systems. Adv. Synth. 
Catal. 2008, 350 (2), 321-331. 
125. Smilkstein, M.; Sriwilaijaroen, N.; Kelly, J. X.; Wilairat, P.; Riscoe, M., Simple and 
inexpensive fluorescence-based technique for high-throughput antimalarial drug 
screening. Antimicrob. Agents Chemother. 2004, 48 (5), 1803-1806. 
126. Bennett, T. N.; Paguio, M.; Gligorijevic, B.; Seudieu, C.; Kosar, A. D.; Davidson, 
E.; Roepe, P. D., Novel, rapid, and inexpensive cell-based quantification of antimalarial 
drug efficacy. Antimicrob. Agents Chemother. 2004, 48 (5), 1807-1810. 
127. Trager, W.; Jensen, J. B., HUMAN MALARIA PARASITES IN CONTINUOUS 
CULTURE. Science 1976, 193 (4254), 673-675. 
128. Lee, F. Y. F.; Borzilleri, R.; Fairchild, C. R.; Kim, S. H.; Long, B. H.; Reventos-
Suarez, C.; Vite, G. D.; Rose, W. C.; Kramer, R. A., BMS-247550: A novel epothilone 
analog with a mode of action similar to paclitaxel but possessing superior antitumor 
efficacy. Clin. Cancer Res. 2001, 7 (5), 1429-1437. 
129. Collins, L. A.; Franzblau, S. G., Microplate Alamar blue assay versus BACTEC 
460 system for high-throughput screening of compounds against Mycobacterium 
tuberculosis and Mycobacterium avium. Antimicrob. Agents Chemother. 1997, 41 (5), 
1004-1009. 
130. Hyde, J. E., Drug-resistant malaria. Trends Parasitol. 2005, 21 (11), 494-498. 
131. (a) Klayman, D. L.; Lin, A. J.; Acton, N.; Scovill, J. P.; Hoch, J. M.; Milhous, W. 
K.; Theoharides, A. D., Isolation of artemisinin (qinghaosu) from Artemisia annua 
grouping in the United States. J. Nat. Prod. 1984, 47 (4), 715-717; (b) Klayman, D. L., 
Qinghaosu (artemisinin) - an antimalarial drug from China. Science 1985, 228 (4703), 
1049-1055. 
 186
132. (a) Noedl, H.; Se, Y.; Schaecher, K.; Smith, B. L.; Socheat, D.; Fukuda, M. M.; 
Consortium, A. R. C. S., Evidence of Artemisinin-Resistant Malaria in Western 
Cambodia. N. Engl. J. Med. 2008, 359 (24), 2619-2620; (b) Dondorp, A. M.; Nosten, F.; 
Yi, P.; Das, D.; Phyo, A. P.; Tarning, J.; Lwin, K. M.; Ariey, F.; Hanpithakpong, W.; Lee, 
S. J.; Ringwald, P.; Silamut, K.; Imwong, M.; Chotivanich, K.; Lim, P.; Herdman, T.; An, 
S. S.; Yeung, S.; Singhasivanon, P.; Day, N. P. J.; Lindegardh, N.; Socheat, D.; White, 
N. J., Artemisinin Resistance in Plasmodium falciparum Malaria. N. Engl. J. Med. 2009, 
361 (5), 455-467. 
133. Goldberg, D. E.; Slater, A. F. G.; Cerami, A.; Henderson, G. B., Hemoglobin 
degradation in the malaria parasite Plasmodium falciparum - an ordered process in a 
unique organelle. Proc. Natl. Acad. Sci. U. S. A. 1990, 87 (8), 2931-2935. 
134. Rosenthal, P. J.; Meshnick, S. R., Hemoglobin catabolism and iron utilization by 
malaria parasites. Mol. Biochem. Parasitol. 1996, 83 (2), 131-139. 
135. Chou, A. C.; Chevli, R.; Fitch, C. D., Ferriprotoporphyrin-IX fulfulls the criteria for 
identification as the chloroquine receptor of malaria parasites. Biochemistry 1980, 19 (8), 
1543-1549. 
136. Fidock, D. A.; Nomura, T.; Talley, A. K.; Cooper, R. A.; Dzekunov, S. M.; Ferdig, 
M. T.; Ursos, L. M. B.; Sidhu, A. B. S.; Naude, B.; Deitsch, K. W.; Su, X. Z.; Wootton, J. 
C.; Roepe, P. D.; Wellems, T. E., Mutations in the P-falciparum digestive vacuole 
transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol. 
Cell 2000, 6 (4), 861-871. 
137. (a) Robert, A.; Meunier, B., Is alkylation the main mechanism of action of the 
antimalarial drug artemisinin? Chem. Soc. Rev. 1998, 27 (4), 273-279; (b) Hong, Y. L.; 
Yang, Y. Z.; Meshnick, S. R., The interaction of artemisinin with malarial hemozoin Mol. 
Biochem. Parasitol. 1994, 63 (1), 121-128. 
 187
138. Eckstein-Ludwig, U.; Webb, R. J.; van Goethem, I. D. A.; East, J. M.; Lee, A. G.; 
Kimura, M.; O'Neill, P. M.; Bray, P. G.; Ward, S. A.; Krishna, S., Artemisinins target the 
SERCA of Plasmodium falciparum. Nature 2003, 424 (6951), 957-961. 
139. Li, W.; Mo, W. K.; Shen, D.; Sun, L. B.; Wang, J.; Lu, S.; Gitschier, J. M.; Zhou, 
B., Yeast model uncovers dual roles of mitochondria in the action of arternisinin. PLoS 
Genet. 2005, 1 (3), 329-334. 
140. Cervantes, S.; Stout, E. P.; Prudhomme, J.; Engel, S.; Bruton, M.; Cervantes, M.; 
Carter, D.; Tae-Chang, Y.; Hay, M. E.; Aalbersberg, W.; Kubanek, J.; Le Roch, K., High 
content live cell imaging evaluation for the discovery of new antimalarial natural 
products. Submitted to Antimicrobial Agents and Chemotherapy 2010. 
141. Pisciotta, J. M.; Coppens, I.; Tripathi, A. K.; Scholl, P. F.; Shuman, J.; Bajad, S.; 
Shulaev, V.; Sullivan, D. J., The role of neutral lipid nanospheres in Plasmodium 
falciparum haem crystallization. Biochem. J. 2007, 402, 197-204. 
142. Egan, T. J.; Mavuso, W. W.; Ross, D. C.; Marques, H. M., Thermodynamic 
factors controlling the interaction of quinoline antimalarial drugs with ferriprotoporphyrin 
IX. J. Inorg. Biochem. 1997, 68 (2), 137-145. 
143. (a) Vyas, N.; Avery, B. A.; Avery, M. A.; Wyandt, C. M., Carrier-mediated 
partitioning of artemisinin into Plasmodium falciparum-infected erythrocytes. Antimicrob. 
Agents Chemother. 2002, 46 (1), 105-109; (b) Stocks, P. A.; Bray, P. G.; Barton, V. E.; 
Al-Helal, M.; Jones, M.; Araujo, N. C.; Gibbons, P.; Ward, S. A.; Hughes, R. H.; Biagini, 
G. A.; Davies, J.; Amewu, R.; Mercer, A. E.; Ellis, G.; O'Neill, P. M., Evidence for a 
common non-heme chelatable-iron-dependent activation mechanism for semisynthetic 
and synthetic endoperoxide antimalarial drugs. Angewandte Chemie-International 
Edition 2007, 46 (33), 6278-6283. 
 188
144. Ncokazi, K. K.; Egan, T. J., A colorimetric high-throughput beta-hematin inhibition 
screening assay for use in the search for antimalarial compounds. Anal. Biochem. 2005, 
338 (2), 306-319. 
145. Rush, M. A.; Baniecki, M. L.; Mazitschek, R.; Cortese, J. F.; Wiegand, R.; Clardy, 
J.; Wirth, D. F., Colorimetric High-Throughput Screen for Detection of Heme 
Crystallization Inhibitors. Antimicrob. Agents Chemother. 2009, 53 (6), 2564-2568. 
146. Hughes, C. C.; MacMillan, J. B.; Gaudencio, S. P.; Fenical, W.; La Clair, J. J., 
Ammosamides A and B Target Myosin. Angewandte Chemie-International Edition 2009, 
48 (4), 728-732. 
147. Dorn, A.; Stoffel, R.; Matile, H.; Bubendorf, A.; Ridley, R. G., Malarial haemozoin 
beta-hematin supports heme polymerization in the absence of protein. Nature 1995, 374 
(6519), 269-271. 
148. Srivastava, I. K.; Morrisey, J. M.; Darrouzet, E.; Daldal, F.; Vaidya, A. B., 
Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria 
parasites. Mol. Microbiol. 1999, 33 (4), 704-711. 
149. Hawley, S. R.; Bray, P. G.; Mungthin, M.; Atkinson, J. D.; O'Neill, P. M.; Ward, S. 
A., Relationship between antimalarial drug activity, accumulation, and inhibition of heme 
polymerization in Plasmodium falciparum in vitro. Antimicrob. Agents Chemother. 1998, 
42 (3), 682-686. 
150. Janouskovec, J.; Horak, A.; Obornik, M.; Lukes, J.; Keeling, P. J., A common red 
algal origin of the apicomplexan, dinoflagellate, and heterokont plastids. Proc. Natl. 
Acad. Sci. U. S. A. 2010, 107 (24), 10949-10954. 
151. Gerritz, S. W.; Sefler, A. M., 2,5-dimethylfuran (DMFu): An internal standard for 
the "traceless" quantitation of unknown samples via H-1 NMR. J. Comb. Chem. 2000, 2 
(1), 39-41. 
 189
152. Egan, T. J.; Ncokazi, K. K., Effects of solvent composition and ionic strength on 
the interaction of quinoline antimalarials with ferriprotoporphyrin IX. J. Inorg. Biochem. 
2004, 98 (1), 144-152. 
153. McGlacken, G. P.; Fairlamb, I. J. S., 2-Pyrone natural products and mimetics: 
isolation, characterisation and biological activity. Nat. Prod. Rep. 2005, 22 (3), 369-385. 
154. (a) Kazlauskas, R.; Murphy, P. T.; Wells, R. J.; Blackman, A. J., Macrocyclic 
enol-ethers containing an acetylenic group from the red alga Phacelocarpus labillardieri 
Aust. J. Chem. 1982, 35 (1), 113-120; (b) Shin, J.; Paul, V. J.; Fenical, W., New 
macrocyclic alpha-pyrones and gamma-pyrones from the marine red alga 
Phacelocarpus labillardieri. Tetrahedron Lett. 1986, 27 (43), 5189-5192. 
155. Berson, J. A.; Jones, W. M.; Ocallaghan, L. F., Spectra as a guide to structure in 
the hydroxypyrone and hydroxypyridone series. J. Am. Chem. Soc. 1956, 78 (3), 622-
623. 
156. Sato, M.; Uehara, F.; Sato, K.; Yamaguchi, M.; Kabuto, C., Convenient-synthesis 
of chiral cyclophanes that can coordinate to metals. J. Am. Chem. Soc. 1999, 121 (36), 
8270-8276. 
157. (a) Metz, J. G.; Roessler, P.; Facciotti, D.; Levering, C.; Dittrich, F.; Lassner, M.; 
Valentine, R.; Lardizabal, K.; Domergue, F.; Yamada, A.; Yazawa, K.; Knauf, V.; 
Browse, J., Production of polyunsaturated fatty acids by polyketide synthases in both 
prokaryotes and eukaryotes. Science 2001, 293 (5528), 290-293; (b) Kaulmann, U.; 
Hertweck, C., Biosynthesis of polyunsaturated fatty acids by polyketide synthases. 
Angewandte Chemie-International Edition 2002, 41 (11), 1866-1869. 
158. Mizuta, T.; Kubokawa, K., Presence of sex steroids and cytochrome P450 genes 
in amphioxus. Endocrinology 2007, 148 (8), 3554-3565. 
159. Thornton, J. W.; Need, E.; Crews, D., Resurrecting the ancestral steroid receptor: 
Ancient origin of estrogen signaling. Science 2003, 301 (5640), 1714-1717. 
 190
160. Thornton, J. W., Evolution of vertebrate steroid receptors from an ancestral 
estrogen receptor by ligand exploitation and serial genome expansions. Proc. Natl. 
Acad. Sci. U. S. A. 2001, 98 (10), 5671-5676. 
161. Di Cosmo, A.; Di Cristo, C.; Paolucci, M., A estradiol-17 beta receptor in the 
reproductive system of the female of Octopus vulgaris: Characterization and 
immunolocalization. Mol. Reprod. Dev. 2002, 61 (3), 367-375. 
162. Keay, J.; Thornton, J. W., Hormone-Activated Estrogen Receptors in Annelid 
Invertebrates: Implications for Evolution and Endocrine Disruption. Endocrinology 2009, 
150 (4), 1731-1738. 
163. Mimoto, A.; Fujii, M.; Usami, M.; Shimamura, M.; Hirabayashi, N.; Kaneko, T.; 
Sasagawa, N.; Ishiura, S., Identification of an estrogenic hormone receptor in 
Caenorhabditis elegans. Biochem. Biophys. Res. Commun. 2007, 364 (4), 883-888. 
164. Thomas, P., Characteristics of membrane progestin receptor alpha (mPR alpha) 
and progesterone membrane receptor component 1 (PGMRC1) and their roles in 
mediating rapid progestin actions. Front. Neuroendocrinol. 2008, 29 (2), 292-312. 
165. Halanych, K. M., The new view of animal phylogeny. Annu. Rev. Ecol. Evol. Syst. 
2004, 35, 229-256. 
166. Kohler, H. R.; Kloas, W.; Schirling, M.; Lutz, I.; Reye, A. L.; Langen, J. S.; 
Triebskorn, R.; Nagel, R.; Schonfelder, G., Sex steroid receptor evolution and signalling 
in aquatic invertebrates. Ecotoxicology 2007, 16 (1), 131-143. 
167. Snell, T. W.; Kubanek, J., Quorum Sensing in Rotifers. In Chemical 
Communications Among Microbes, Winans, S. C.; Bassler, B. L., Eds. American Society 
of Microbiology: Washington, D.C., 2008; pp 453-463. 
168. Snell, T. W.; Kubanek, J.; Carter, W.; Payne, A. B.; Kim, J.; Hicks, M. K.; Stelzer, 
C. P., A protein signal triggers sexual reproduction in Brachionus plicatilis (Rotifera). 
Marine Biology 2006, 149 (4), 763-773. 
 191
169. Patterson, G. W.; Tsitsatzardis, E.; Wikfors, G. H.; Gladu, P. K.; Chitwood, D. J.; 
Harrison, D., Sterols of Tetraselmis (Prasinophyceae). Comparative Biochemistry and 
Physiology B-Biochemistry & Molecular Biology 1993, 105 (2), 253-256. 
170. Williams, S. P.; Sigler, P. B., Atomic structure of progesterone complexed with its 
receptor. Nature 1998, 393 (6683), 392-396. 
171. Center, N. C. Progesterone Historical Reference Ranges. 
172. Ollevier, F.; Declerck, D.; Diederik, H.; Deloof, A., Identification of nonecdysteriod 
steroids in hemolymph of both male and female Astacus leptodactylus (Crustacea) by 
gas-chromatography mass-spectrometry. Gen. Comp. Endocrinol. 1986, 61 (2), 214-
228. 
173. Gronemeyer, H.; Govindan, M. V., Affinity labeling of steroid-hormone receptors. 
Mol. Cell. Endocrinol. 1986, 46 (1), 1-19. 
174. Zhu, Y.; Hanna, R. N.; Schaaf, M. J. M.; Spaink, H. P.; Thomas, P., Candidates 
for membrane progestin receptors-Past approaches and future challenges. Comparative 
Biochemistry and Physiology C-Toxicology & Pharmacology 2008, 148 (4), 381-389. 
175. (a) Hughes, A. L.; Powell, D. W.; Bard, M.; Eckstein, J.; Barbuch, R.; Link, A. J.; 
Espenshade, P. J., Dap1/PGRMC1 binds and regulates cytochrome P450 enzymes. Cell 
Metab. 2007, 5 (2), 143-149; (b) Losel, R. M.; Besong, D.; Peluso, J. J.; Wehling, M., 
Progesterone receptor membrane component 1 - Many tasks for a versatile protein. 
Steroids 2008, 73 (9-10), 929-934. 
176. (a) Lavery, D. N.; McEwan, I. J., Structure and function of steroid receptor AF1 
transactivation domains: induction of active conformations. Biochem. J. 2005, 391, 449-
464; (b) Gronemeyer, H., Transcription activation by estrogen and progesterone 
receptors. Annu. Rev. Genet. 1991, 25, 89-123. 
 192
177. Fontaneto, D.; Giordani, I.; Melone, G.; Serra, M., Disentangling the 
morphological stasis in two rotifer species of the Brachionus plicatilis species complex. 
Hydrobiologia 2007, 583, 297-307. 
178. Rico-Martinez, R.; Snell, T. W., Comparative binding of antibody to a mate 
recognition pheromone on female Brachionus plicatilis and Brachionus rotundiformis 
(Rotifera). Hydrobiologia 1997, 358, 71-76. 
179. (a) Guillard, R. R.; Ryther, J. H., Studies of marine planktonic diatoms .1. 
Cyclotella nana Hustedt, and Detonula confervacea (cleve) Gran. Can. J. Microbiol. 
1962, 8 (2), 229-239; (b) Berg, C. J., Jr., Culture of Marine Invertebrates. Hutchinson 
Ross: Stroudsburg, PA, 1983. 
180. Snell, T. W.; Shearer, T. L.; Smith, H. A., Exposure to dsRNA elicits RNA 
interference in Brachionus manjavacas (Rotifera). Mar. Biotechnol. 2010, 12. 
181. Snell, T. W.; Shearer, T. L.; Smith, H. A.; Kubanek, J.; Gribble, K. E.; Welch, D. 
B. M., Genetic determinants of mate recognition in Brachionus manjavacas (Rotifera). 
BMC Biol. 2009, 7, 60-72. 
182. Livak, K. J.; Schmittgen, T. D., Analysis of relative gene expression data using 
real-time quantitative PCR and the 2(T)(-Delta Delta C) method. Methods 2001, 25 (4), 
402-408. 
 
 
 
 
